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Abstract 1 
 2 
Adrenocortical carcinoma (ACC) is a rare and in most cases steroid hormone producing 3 
tumor with variable prognosis. The purpose of these guidelines is to provide clinicians with 4 
best possible evidence-based recommendations for clinical management of patients with 5 
ACC based on the GRADE (Grading of Recommendations Assessment, Development and 6 
Evaluation) system. We predefined four main clinical questions, which we judged as 7 
particularly important for the management of ACC patients and performed systematic 8 
literature searches: (A) What is needed to diagnose an ACC by histopathology? (B) Which 9 
are the best prognostic markers in ACC? (C) Is adjuvant therapy able to prevent recurrent 10 
disease or reduce mortality after radical resection? (D) What is the best treatment option for 11 
macroscopically incompletely resected, recurrent or metastatic disease? Other relevant 12 
questions were discussed within the group. SELECTED RECOMMENDATIONS: (i) We 13 
recommend that all patients with suspected and proven ACC are discussed in a 14 
multidisciplinary expert team meeting (ii) We recommend that every patient with (suspected) 15 
ACC should undergo careful clinical assessment, detailed endocrine work-up to identify 16 
autonomous hormone excess, and adrenal-focused imaging. (iii) We recommend that 17 
adrenal surgery for (suspected) ACC should be performed only by surgeons experienced in 18 
adrenal and oncological surgery aiming at a complete en-bloc resection (including resection 19 
of oligo-metastatic disease). (iv) We suggest that all suspected ACC should be reviewed by 20 
an expert adrenal pathologist using the Weiss score and providing Ki67 index. (v) We 21 
suggest adjuvant mitotane treatment in patients after radical surgery that have a perceived 22 
high risk of recurrence (ENSAT stage III, or R1 resection, or Ki67 >10%). (vi) For advanced 23 
ACC not amenable to complete surgical resection, local therapeutic measures (e.g. radiation 24 
therapy, radiofrequency ablation, chemo-embolization) are of particular value. However, we 25 
suggest against the routine use of adrenal surgery in case of widespread metastatic disease. 26 
In these patients we recommend either mitotane monotherapy or mitotane, etoposide, 27 
doxorubicin, and cisplatin depending on prognostic parameters. In selected patients with a 28 
good response, surgery may be subsequently considered. (vii) In patients with recurrent 29 
disease and a disease-free interval of at least 12 months, in whom a complete 30 
resection/ablation seems feasible, we recommend surgery or alternatively other local 31 
therapies. Furthermore, we offer detailed recommendations about the management of 32 
mitotane treatment and other supportive therapies. Finally, we suggest directions for future 33 
research.  34 
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1. Summary of recommendations 35 
 36 
After the review process all Recommendations without Rational will be provided here as 37 
summary.  38 
 39 
 40 
2. Adrenocortical Carcinoma – epidemiology, pathogenesis, clinical 41 
presentation, and general prognosis 42 
 43 
Epidemiology and pathogenesis 44 
The estimated incidence of adult adrenocortical carcinoma (ACC) is between 0.7 – 2.0 per 45 
million per year {Kebebew, 2006 #3;Kerkhofs, 2013 #2}. ACC can occur at any age with a 46 
peak incidence between 40 and 60 years, and with women being more often affected (55-47 
60%). In adults, the vast majority of ACCs are sporadic. Occasionally, however, they occur 48 
as part of hereditary syndromes such as Li-Fraumeni syndrome, Lynch syndrome, multiple 49 
endocrine neoplasia (MEN) 1 and familial adenomatous polyposis {Berruti, 2012 #20;Petr, 50 
2016 #34}. In recent years several multi-center studies have shed light on the pathogenesis 51 
of ACC {de Reynies, 2009 #14;Fragoso, 2012 #18;Ronchi, 2013 #324}{Jouinot, 2017 #17}, 52 
but ‘multi-omic’ studies {Assie, 2014 #12;Juhlin, 2015 #19;Zheng, 2016 #16} reveal that only 53 
a minority of ACC cases have pathogenic driver mutations. For details on this topic we refer 54 
to recent reviews {Assie, 2014 #11;Else, 2014 #135;Faillot, 2016 #277}.  55 
 56 
Clinical presentation (Table 1) 57 
ACC may present with autonomous adrenal hormone excess or with symptoms caused by 58 
an abdominal mass. An increasing number of cases are diagnosed within the group of 59 
incidentally discovered adrenal masses (incidentalomas) (≈ 10-15%). However, the likelihood 60 
of an adrenal incidentaloma being an ACC is low {Terzolo, 1997 #359;Cawood, 2009 61 
#326;Fassnacht, 2016 #46}. About 50-60% of patients with ACC have clinical hormone 62 
excess. Hypercortisolism (Cushing’s syndrome), or mixed Cushing’s and virilizing syndromes 63 
are observed in the majority of these patients. Pure androgen excess is less frequent while 64 
estrogen or mineralocorticoid excess are very rare {Seccia, 2005 #360;Fassnacht, 2011 65 
#61;Else, 2014 #135;Berruti, 2014 #35;Kerkhofs, 2015 #78;Fassnacht, 2013 #60}. Non-66 
specific symptoms from an abdominal mass include abdominal discomfort (nausea, vomiting, 67 
abdominal fullness) or back pain. Classical malignancy-associated symptoms such as weight 68 
loss, night sweats, fatigue or fever are rarely present.  69 
 70 
Table 1: Clinical presentation of ACC# 71 
 72 
Autonomous adrenal hormone excess  50-60 % 
Hypercortisolism (Cushing’s syndrome)* 50-70 % 
Androgen excess (virilization) in female patients* 20-30 % 
Estrogen excess (feminization) in male patients* 5 % 
Mineralocorticoid excess* 2-3 % 
Non-specific symptoms from an abdominal mass 30-40 % 
Incidentally detected by imaging for other purpose 10-15 % 
# number derived from: {Berruti, 2014 #35;Fassnacht, 2009 #56;Johanssen, 2010 #69}, and the 73 
ENSAT ACC registry 74 
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* frequently combined 75 
 76 
General prognosis 77 
The median overall survival of all ACC patients is about 3-4 years. The prognosis is, 78 
however, heterogeneous. Complete surgical resection provides the only means of cure. In 79 
addition to radical surgery, disease stage, proliferative activity/tumor grade, and cortisol 80 
excess are independent prognostic parameters (see also section 4.2. and 5.5.). Five-year 81 
survival is 60-80% for tumors confined to the adrenal space, 35-50% for locally advanced 82 
disease, and much lower in case of metastatic disease with reported percentages ranging 83 
from 0% to 28% {Icard, 2001 #79;Bilimoria, 2008 #80;Sturgeon, 2006 #81;Fassnacht, 2010 84 
#57;Fassnacht, 2009 #58;Fassnacht, 2011 #61;Fassnacht, 2012 #28;Kerkhofs, 2015 #78}. 85 
 86 
 87 
 88 
3. Methods  89 
 90 
3.1. Guideline working group 91 
This guideline was developed by The European Society of Endocrinology (ESE) in 92 
collaboration with the European Network for the Study of Adrenal Tumours (ENSAT). The 93 
chairs of the working group Martin Fassnacht and Massimo Terzolo as well as the 94 
methodological expert Olaf Dekkers were appointed by the ESE Clinical Committee. Tobias 95 
Else served as representative of The Endocrine Society, USA, and Radu Mihai as 96 
representative of the European Society of Endocrine Surgeons. The other members were 97 
suggested by the chairs and approved by the Clinical Committee of ESE. The 98 
multidisciplinary team consisted of the following experts: endocrinologists (Guillaume Assie 99 
(France), Olaf Dekkers (The Netherlands), Tobias Else (USA), Martin Fassnacht (Germany), 100 
Harm Haak (The Netherlands), Massimo Terzolo (Italy), oncologists (Eric Baudin (France), 101 
Alfredo Berruti (Italy), a pathologist Ronald de Krijger (The Netherlands), and an endocrine 102 
surgeon Radu Mihai (UK). The working group had three in-person meetings (November 103 
2016, September 2017, and March 2018) and communicated by phone and email. 104 
Consensus was reached upon discussion; minority positions were taken into account in the 105 
rationale behind recommendations. Prior to the process, all participants completed conflict of 106 
interest forms. 107 
 108 
3.2 Target group  109 
This guideline was developed for healthcare providers involved in the care of patients with 110 
adrenocortical carcinoma i.e., endocrinologists, oncologists, surgeons, radiologists, nuclear 111 
medicine physicians, radio-oncologists, pathologists, specialists in general internal medicine, 112 
and nurse specialists. However, general practitioners or gynecologists or dermatologists 113 
(who are involved in the diagnostic of androgen excess) might also find the guideline useful, 114 
as might our patients. In addition, the guideline document can serve as a source document 115 
for the preparation of patient information leaflets.  116 
 117 
3.3 Aims  118 
The overall purpose of this guideline is to provide clinicians with practical guidance for the 119 
management of patients with adrenocortical carcinoma. In clinical practice, treatment 120 
decisions should take into account the recommendations but also the clinical judgment of the 121 
treating physician. Recommendations are thus never meant to replace clinical judgment. In 122 
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some countries not all recommended tests and treatments, or both, might be available. Thus, 123 
the recommendations have certainly be interpreted in the context of available 124 
resources/treatment in the community, in which the patient is being seen. 125 
 126 
 127 
3.4 Summary of methods used for guideline development  128 
The methods used have been described in more detail previously {Bollerslev, 2015 #1}. In 129 
short, the guideline used GRADE (Grading of Recommendations Assessment, Development 130 
and Evaluation) as a methodological base. The first step was to define clinical question(s) 131 
(see section 3.5), the second being a systematic literature search (see Section 3.6). After 132 
including all relevant articles, we 1), rated the quality of the evidence, and 2) estimated an 133 
average effect for specific outcomes (if possible). The quality of evidence behind the 134 
recommendations is classified as very low (+OOO), low (++OO), moderate (+++O) and 135 
strong (++++).  136 
For the recommendations we took into account: 1) quality of the evidence, 2) balance of 137 
desirable and undesirable outcomes, 3) values and preferences (patient preferences, goals 138 
for health, costs, management inconvenience, feasibility of implementation, etc) {Andrews, 139 
2013 #137;Andrews, 2013 #138}. The recommendations are worded as recommend (strong 140 
recommendation) and suggest (weak recommendation). The meaning of a strong 141 
recommendation can be stated as follows: reasonably informed persons (clinicians, 142 
politicians and patients) would want the management in accordance with the 143 
recommendation. For a weak recommendation, most persons would still act in accordance 144 
with the guideline, but a substantial number would not {Andrews, 2013 #138}. Formal 145 
evidence syntheses were performed and graded only for recommendations addressing our 146 
initial four questions. Recommendations based on good practice and experience of the 147 
panelists were not graded {Guyatt, 2015 #139}. Recommendations were derived from 148 
majority consensus of the guideline development committee, but if at least one member had 149 
substantial disagreements, this is acknowledged in the manuscript. If two or more panelists 150 
did not agree with a recommendation, this was considered as not consensus. For 151 
transparency, all recommendations are accompanied by text explaining why specific 152 
recommendations were made. 153 
 154 
3.5. Clinical question, eligibility criteria and endpoint definition 155 
At the beginning of the guideline development process, the panel agreed on 30 clinical 156 
questions in the management of patients with ACC that should be addressed in the 157 
guidelines. In a next step, we agreed on four most relevant clinical questions (Table 2), for 158 
which a detailed literature search and review was subsequently performed. 159 
 160 
3.6 Description of search and selection of literature  161 
A literature search of electronic medical databases was performed for all four clinical 162 
questions. As we expected that single publications could contribute to different questions (for 163 
example 2 and 4) we decided to perform one overarching search using broad search terms. 164 
The search revealed 5988 papers, of which 615 were duplicates. In summary, we included 165 
18 publications for clinical question 1 (diagnostics for ACC), 35 studies for clinical question 2 166 
(prognosis), 10 publications for clinical question 3 (adjuvant therapy) and 48 publications for 167 
clinical question 4 (recurrent/advanced disease). The review of hormonal overproduction as 168 
prognostic factor was published as stand-alone paper {Vanbrabant, 2018 #140}. For question 169 
3, we included one study after having been provided with baseline characteristics and 170 
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adjusted estimates for mitotane therapy not reported in the original publication {Bertherat, 171 
2007 #82}.  172 
 173 
 174 
3.7. Review process and endorsement of other societies 175 
A draft of the guideline was reviewed by four experts in the field (see “Acknowledgment’ 176 
section) and has been submitted for comments by ESE and ENSAT members. In addition, 177 
the following societies and networks were asked for review and finally endorsed the 178 
guidelines: the European Society of Endocrine Surgeons, the Endocrine Society, USA, the 179 
European Society of Pathology, the American-Australian-Asian Adrenal Alliance (A5), the 180 
European Reference Network on Rare Endocrine Conditions (Endo-ERN), the European 181 
Reference Network on Rare Adult Solid Cancers (ERN EURACAN). Furthermore, patient 182 
groups were approached to review the guidelines. All comments and suggestions were then 183 
discussed and implemented as appropriate by the panel (all comments and responses are 184 
provided in Appendix 8).  185 
    186 
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Table 2: Overview of the key clinical questions and predefined outcome parameters 187 
Clinical Question Predefined selection criteria and key outcome 
parameters 
Metrics of the 
literature search 
Question 1:  
 
Pathology - what is needed to diagnose 
an ACC? 
Sub-question 1A: 
How to make a distinction between 
adrenocortical/non-adrenocortical 
tumor?  
 
Sub-question 1B 
How to make a distinction between 
benign or malignant or indeterminate 
behavior in adrenocortical tumors 
Population 
• Adrenal masses 
Restriction  
• Minimum 25 ACC patients  
• Each marker has to be reported in at least 2 independent cohorts 
Outcome 
• Diagnostic accuracy (Sensitivity/specificity/NPV/PPV)  
Diagnostic marker:  
• (Weiss Score), Ki67, reticulin, Helsinki, SF-1, melan A, inhibin, 
calretinin, chromogranin, SRC1 
Reference standard: 
• Weiss-Score1  
• Recurrence 
Number of papers 
included: 
1a: n=4 
1b: n=15 
(2 papers contributed to 
both) 
Question 2:  
Which are the best prognostic markers 
in ACC?  
 
 
 
 
Population (minimum 100 ACC patients):  
1) Patients after radically resected ACC  
2) Patients with advanced ACC 
Restriction: 
• Prognostic marker has to be reported in at least 2 independent 
cohorts 
Prognostic markers to be considered:  
• Tumor stage (different systems: Sullivan, Lee, UICC, ENSAT, 
etc.), sex, age, Ki67, hormone section, Weiss score, mitotic 
index, R status, molecular/immunohistological markers 
Outcome 
• Overall survival, disease-free and progression-free survival, 
prognostic ability  
Number of papers 
included: 35 
Question 3:  
 
Is adjuvant therapy able to prevent 
recurrent disease or reduce mortality 
after radical resection?  
 
 
 
Population:  
• Diagnosis of ACC with macroscopic radical resection (R0, R1, 
Rx) 
Restriction: 
• Studies with > 10 patients in the intervention group 
• Only studies providing baseline data per treatment group, and 
providing age and stage adjusted estimates  
• In case of >25% overlap only inclusion of the largest study 
Number of papers 
included: 
Mitotane n=6 
Radiation therapy n=4 
 
8 
 
Intervention:  
• Adjuvant treatment with either mitotane, radiation therapy or 
cytotoxic chemotherapy 
Control group: 
• Without therapy or other treatment 
Outcomes:  
• Disease-free survival, overall survival, quality of life, adverse 
events 
Question 4:  
 
What is the best treatment option for 
macroscopically incompletely resected, 
recurrent or metastatic disease? 
 
 
 
Population: 
• Macroscopically incompletely resected, recurrent or metastatic 
ACC 
Restriction: 
• Studies > 10 patients in the intervention group. Only studies 
providing baseline data per treatment group  
Interventions  
• Cytotoxic drugs including mitotane, surgery, radiation therapy, 
radiofrequency ablation, chemoembolization 
Control 
• Not mandatory (single arm cohort studies eligible) 
Outcome 
• Overall survival, progression-free survival, tumor response, 
quality of life, adverse events 
Number of papers 
included: 
cytotoxic drugs 
including mitotane: 
n=27 
surgery: n= 16 
radiation therapy: n=1 
radiofrequency 
ablation: n=1 
radionuclide therapy: 
n=1 
 
 188 
NPV negative predictive value, PPV positive predictive value, SF-1 steroidogenic factor 1, SRC1 steroid receptor coactivator 1, R status Resection status, R0 189 
microscopically complete resection, R1 microscopically incomplete resection, Rx uncertain resection status 190 
1 we are aware that the Weiss score was never properly validated, but we decided that there is no other “gold standard”) 191 
  192 
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4. Summary and conclusions from systematic literature reviews  193 
 194 
4.1. Clinical question 1: Pathology  195 
We included 17 publications {Blanes, 2007 #141;Creemers, 2016 #142;Erickson, 2001 196 
#143;Arola, 2000 #144;Aubert, 2002 #108;Busam, 1998 #146;Kamio, 1990 197 
#148;Komminoth, 1995 #149;Pan, 2005 #150;Rubin, 2016 #151;Sbiera, 2010 198 
#15;Stojadinovic, 2003 #152;Volante, 2006 #153;Wajchenberg, 2000 #154;Wang, 2014 199 
#155;Zhang, 2008 #156;Kovach, 2015 #353} that contributed data to either the diagnosis of 200 
ACC in the context of adrenal vs. non-adrenal distinction (4 studies), or in the context of 201 
benign vs. malignant adrenocortical tumor distinction (15 studies) (two of them contributing to 202 
both subquestions {Arola, 2000 #144;Pan, 2005 #150}). Details of studies are shown in 203 
Appendix 1 (in all samples, diagnosis based on histological examination). Melan-A and 204 
inhibin-alpha were studied in three publications; all other markers were studied in one or 2 205 
publications only. In total data for twenty-seven diagnostic markers were reported. Since 206 
many publications included patients who did not reflect the target population in question for 207 
this guideline (i.e. patients with a suspicion for ACC), positive or negative predictive values 208 
were not provided. A formal meta-analysis was not performed given the low number of 209 
studies per marker. Importantly, no study reported on the combined diagnostic ability of a set 210 
of markers, which actually may reflect the approach in clinical practice.    211 
 212 
4.2. Clinical question 2: Prognostic factors  213 
Thirty-five studies reporting on risk factors for recurrence and/or mortality, and that included 214 
more than 100 patients with histologically proven ACC, were analyzed {Amini, 2016 215 
#157;Asare, 2014 #158;Assie, 2007 #114;Ayala-Ramirez, 2013 #160;Berruti, 2014 216 
#35;Beuschlein, 2015 #50;Bilimoria, 2008 #80;Canter, 2013 #164;Duregon, 2017 217 
#110;Erdogan, 2013 #55;Ettaieb, 2016 #117;Fassnacht, 2009 #58;Freire, 2013 218 
#169;Gicquel, 2001 #170;Glover, 2015 #171;Gonzalez, 2007 #172;Icard, 2001 #79;Jouinot, 219 
2017 #17;Kebebew, 2006 #3;Kendrick, 2002 #176;Kim, 2016 #177;Kim, 2017 #178;Libe, 220 
2015 #29;Livhits, 2014 #180;Lucon, 2002 #181;Margonis, 2016 #182;Margonis, 2016 221 
#183;Millis, 2015 #184;Paton, 2006 #185;Pennanen, 2015 #109;Schulick, 1999 #187;Tran, 222 
2016 #188;Xiao, 2015 #189;Zini, 2009 #190;Ronchi, 2012 #321}(see Appendix 2 for details 223 
of studies included, and Appendix 3 for an overview of all prognostic factors studied). The 224 
threshold of 100 cases was defined upfront as with n=100 and an expected number of 225 
deaths of 50, statistical power was considered sufficient. Almost all studies reported age, sex 226 
and tumor stage as prognostic factors, although several different staging systems were used. 227 
A formal comparison of the studies was difficult due to heterogeneity regarding clinical 228 
characteristics, use of varying definitions of characteristics (e.g. stage) and different cut-offs 229 
(e.g. tumor size, age). Furthermore, the multivariable models presented include adjustment 230 
for different additional variables. We acknowledge a concern over the number of variables 231 
included in models relative to the number of events, and that this may have the potential to 232 
lead to false positive results.  233 
The association between staging and prognosis was robust (+++O), despite different 234 
systems being used {Macfarlane, 1958 #281;Sullivan, 1978 #282;Lee, 1995 #283;DeLellis, 235 
2004 #284;Asare, 2014 #158;Miller, 2010 #90;Lughezzani, 2010 #92;Fassnacht, 2009 236 
#58;Libe, 2015 #29;Lam, 2017 #285}. In a formal comparison, the ENSAT staging 237 
{Fassnacht, 2009 #58} was slightly superior to the UICC staging {Lughezzani, 2010 #92}. 238 
Additionally, the association between hypercortisolism and mortality was consistent, and 239 
remained with a positive hazard ratio after adjustments for tumor stage HR 1.71, 95% CI 240 
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1.18-2.47 {Vanbrabant, 2018 #140}. Ki67 was studied in five publications, showing worse 241 
prognosis with increasing Ki67 in all studies. Other molecular markers have been studied in 242 
single cohorts only (Appendix 2+3). 243 
It is important to mention that relative risks, even if statistically significant, cannot inform 244 
clinical decision making unless translated into predictive values or incorporated in prediction 245 
models. Only one study presented a formal prediction model (including the variables tumor 246 
size, stage, mitotic index, venous invasion, and endocrine activity), showing a sensitivity of 247 
0.91 and a specificity of 0.90 {Freire, 2013 #169} Another study provided nomograms to 248 
facilitate prognosis in individual patients {Kim, 2016 #177}. None of these models, however, 249 
has been validated externally. 250 
 251 
4.3. Clinical question 3: Adjuvant therapy  252 
No randomized clinical trial has been published yet exploring adjuvant therapies; no studies 253 
comparing quality of life after different treatment modalities were found. We included six 254 
studies that assessed the effect of mitotane on recurrence and mortality {Berruti, 2017 255 
#22;Bertherat, 2007 #82;Beuschlein, 2015 #50;Else, 2014 #125;Grubbs, 2010 256 
#191;Postlewait, 2016 #192}. See Appendix 4 for details and Appendix 5 for risk of bias 257 
assessment. Due to an overlap of the study population of >25% between studies {Berruti, 258 
2017 #22;Bertherat, 2007 #82;Beuschlein, 2015 #50} only the German study cohort from 259 
Beuschlein et al. was considered, but not the validation cohort {Beuschlein, 2015 #50}. In 260 
one study, forty-seven patients were enrolled in 4 Italian centers where adjuvant mitotane 261 
was routinely recommended, 55 patients in 4 Italian centers where no adjuvant strategy was 262 
undertaken (control group 1), and 75 German patients left untreated after surgery (control 263 
group 2) {Berruti, 2017 #22;Terzolo, 2007 #33}. However, only the most recent update of 264 
these series was included in the analysis {Berruti, 2017 #22}. In order to avoid counting data 265 
twice only control group 1 was included.  266 
In a meta-analysis the pooled hazard ratio for recurrence was 0.7, 95%CI 0.5-1.1; for 267 
mortality (5 studies) the pooled hazard ratio was 0.7, 95%CI 0.5-0.9 (Figure 1). All six studies 268 
were non-randomized with the potential of a (residual) confounding effect, meaning that 269 
treatment choices are based on prognosis (such as performance status of the patient, tumor 270 
stage etc.), which introduces imbalance in prognostic factors. It is known that when studying 271 
therapeutic effects this confounding effect is difficult to remedy statistically {Bosco, 2010 272 
#193}. One study {Berruti, 2017 #22} circumvented the confounding effect by comparing two 273 
treatment strategies applied in different settings; such comparison relies on other 274 
assumptions {Hernan, 2006 #354}. A further bias in this context is immortal time bias, which 275 
can occur if treatment is initiated after follow-up time starts and this is not accounted for in 276 
the analysis. Such biases tend to overestimate treatment effects {Suissa, 2008 #194}, and 277 
were not explicitly accounted for in most studies. Only one study applied a landmark analysis 278 
to address this bias {Berruti, 2017 #22}. The overall quality rating was very low (+OOO).  279 
Four studies assessed the impact of adjuvant radiation therapy {Fassnacht, 2006 280 
#126;Habra, 2012 #123;Else, 2014 #125;Sabolch, 2015 #127}. See Appendix 4 for details 281 
and Appendix 5 for risk of bias assessment. The study by Sabolch et al. {Sabolch, 2015 282 
#127} was only considered for data on local recurrence, not for recurrence and mortality 283 
given the overlap with another study of the same group {Else, 2014 #125}. All but one study 284 
(59 patients treated with adjuvant radiation therapy {Else, 2014 #125} were small. We found 285 
a pooled hazard ratio of 0.8 (95% CI 0.6-1.1) for recurrence and for mortality of 1.0 (95% CI 286 
0.7-1.5)(Figure 1). The pooled hazard ratio for local recurrence (three studies) after treatment 287 
with radiotherapy was 0.3 (93% CI 0.1-1.9).  288 
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All studies were observational with the potential of (residual) confounding effects, immortal 289 
time bias was not explicitly accounted for in most studies, and the studies were small with 290 
imprecise effect estimates; the overall quality rating was therefore very low (+OOO).  291 
 292 
 293 
 294 
 295 
Figure 1 Meta-analysis of recurrence (A) and mortality (B) of included studies on 296 
adjuvant therapy after radical resection in ACC 297 
 298 
 299 
12 
 
4.4. Question 4: Therapy for advanced or recurrent disease.  300 
A total of twenty-seven publications reported outcomes of 29 different systemic therapies for 301 
advanced or recurrent ACC {Berruti, 2005 #24;Fassnacht, 2015 #27;Fassnacht, 2012 302 
#28;Gonzalez, 2007 #172;Hermsen, 2011 #68;Sperone, 2010 #32;Abraham, 2002 303 
#195;Baudin, 2002 #196;Baudin, 2001 #197;Berruti, 2012 #23;Bonacci, 1998 304 
#199;Bukowski, 1993 #200;Decker, 1991 #201;Haak, 1994 #202;Haluska, 2010 #204;Khan, 305 
2004 #205;Kroiss, 2016 #206;Kroiss, 2012 #207;Naing, 2013 #208;O'Sullivan, 2014 306 
#209;Quinkler, 2008 #74;Schlumberger, 1991 #211;Urup, 2013 #212;Williamson, 2000 307 
#213;Wortmann, 2010 #214;Henning, 2017 #215;Lerario, 2014 #216}; two were randomized 308 
controlled trials ({Fassnacht, 2015 #27;Fassnacht, 2012 #28}; see Appendix 6 for details of 309 
studies included). The first randomized trial compared mitotane plus a combination of 310 
etoposide, doxorubicin, and cisplatin (EDP-M) to mitotane plus streptozocin in 204 patients 311 
with advanced ACC {Fassnacht, 2012 #28}. The trial showed a positive effect of EPD-M on 312 
progression-free survival HR 0.55 (95% CI, 0.43 to 0.69; P<0.001), but failed to show a 313 
significant effect on mortality (HR 0.79; 95% CI, 0.61 to 1.02; p=0.07); (+++O). The second 314 
randomized trial compared linsitinib to placebo (total 139 patients, 2:1 randomization to 315 
therapy) and did not show a clear effect on either progression free (HR 0.83, 95% CI 0.56–316 
1.21; p=0.30) or overall survival (HR 0.94; 95%CI 0.61–1.44; p=0.77){Fassnacht, 2015 #27}; 317 
(+++O).  318 
Many publications reported on single arm studies of different therapeutic regimens. These 319 
single arm studies have an inherent risk of selection bias, and direct comparison is not 320 
possible. Differences in patient characteristics, definition of response criteria and follow-up 321 
duration are a concern (+OOO). Given the uncontrolled design a final conclusion about the 322 
optimal treatment for advanced recurrent ACC cannot be given. Figure 2 shows response 323 
rates from all studies with data for at least one regimen. For most regimens at least some 324 
responses (partial or even complete) were reported; treatment merits in case of stable 325 
disease is more difficult to judge as this depends highly on duration of follow-up and biology 326 
of the disease. Adverse effects from chemotherapy, however, are common and diverse (see 327 
Appendix 6).  328 
 329 
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Henning, 2017 {Henning, 
2017 #215} 
Therapy 
 
 
Gemcitabine and capecitabine 
 
Fassnacht, 2012 A 
{Fassnacht, 2012 #28} 
etoposide, doxorubicin, cisplatin, and mitotane 
Fassnacht, 2012 B 
{Fassnacht, 2012 #28} 
Streptozocin and mitotane 
Hermsen, 2011 {Hermsen, 
2011 #68} 
Mitotane and different cytotoxic drug 
Fassnacht, 2015 {Fassnacht, 
2015 #27} 
Linsitinib 
Berruti, 2005 {Berruti, 2005 
#24} 
Etoposide, doxorubicin, cisplatin, and mitotane  
Gonzalez, 2007 {Gonzalez, 
2007 #172} 
Mitotane 
Williamson, 2000 
{Williamson, 2000 #213} 
Cisplatin and etoposide 
Bukowski, 1993 {Bukowski, 
1993 #200} 
Cisplatin and mitotane  
Decker, 1991 B {Decker, 
1991 #201} 
Mitotane 
Abraham, 2002 {Abraham, 
2002 #195} 
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Sperone, 2010 {Sperone, 
2010 #32} 
Gemictabine and capecitabine/5-fluorouracil 
Kroiss, 2012 {Kroiss, 2012 
#207} 
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Naing, 2013 {Naing, 2013 
#208} 
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Haak, 1994 {Haak, 1994 
#202} 
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Kroiss, 2016 {Kroiss, 2016 
#206} 
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Bonacci, 1998 {Bonacci, 
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Lerario, 2014 {Lerario, 2014 
#216} 
Cixutumumab and mitotane 
Haluska, 2010 {Haluska, 
2010 #204} 
Figitumumab 
Schlumberger, 1991 
{Schlumberger, 1991 #211} 
5-fluorouracil, doxorubicin, and cisplatin 
O’Sullivan, 2014 {O'Sullivan, 
2014 #209} 
Axitinib 
Baudin, 2001 {Baudin, 2001 
#197} 
Mitotane 
Baudin, 2002 {Baudin, 2002 
#196} 
Irinotecan  
Kahn, 2004 {Khan, 2004 
#205} 
Vincristine, teniposide, cisplatin, and cyclophosphamide 
Wortmann, 2010 {Wortmann, 
2010 #214} 
Bevacizumab and capecitabine 
Quinkler, 2008 {Quinkler, 
2008 #74} 
Erlotinib and gemcitabine 
Berruti, 2012 {Berruti, 2012 
#23} 
Sorafenib and metronomic paclitaxel 
  
Figure 2: Overview of the objective response rates in studies with systemic therapies in ACC 330 
The studies are ordered by number of included patients per regimen. This figure has to be interpreted very cautiously, because study protocols, patient cohorts 331 
and characteristics as well as outcome measurements are quite different precluding a direct comparison. CR: complete response; PR: partial response; SD: 332 
stable disease; PD: Progression of the Disease. Some of the older studies did not report stable disease or progression, thus these columns don't sum up to 100% 333 
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Sixteen studies focused on surgery in recurrent and advanced ACC; six publications reported 334 
on oligo-metastasectomy (lung, liver) {Datrice, 2012 #118;Gaujoux, 2012 #218;Kemp, 2011 335 
#219;Kwauk, 1993 #220;op den Winkel, 2011 #221;Ripley, 2011 #222}, whereas 10 336 
publications assessed the effect of surgery in local recurrent and/or metastatic disease 337 
{Bellantone, 1997 #223;Crucitti, 1996 #83;Dy, 2013 #225;Erdogan, 2013 #55;Gonzalez, 338 
2007 #172;Jensen, 1991 #228;Schulick, 1999 #187;Simon, 2017 #136;Tran, 2013 #231;Dy, 339 
2015 #232}. In patients with metastasectomy 5-survival rates up to 40% were reported 340 
{Datrice, 2012 #118;Gaujoux, 2012 #218}, although control groups were lacking (+OOO). 341 
There were large differences regarding extent of disease, indication, and concurrent 342 
treatment in studies comparing a surgical approach to a non-surgical approach for recurrent 343 
or advanced disease. The reported benefit of surgery is confounded by differing indications 344 
for surgery, and this precludes firm conclusions from being drawn (+OOO). Therefore, the 345 
main conclusion is that in patients deemed radically operable by the surgeon/team operation 346 
is a treatment option. However, beside prognostic factors like Ki67 a key influencing factor in 347 
case of recurrence is the disease-free interval prior to recurrence. 348 
For radionuclide therapy {Hahner, 2012 #373}, transcatheter arterial chemoembolization 349 
{Cazejust, 2010 #233}, radiofrequency ablation {Wood, 2003 #235} and radiation {Ho, 2013 350 
#234} only one small study per procedure was found, and no conclusions can be drawn.  351 
 352 
 353 
 354 
5. Recommendations 355 
 356 
5.1. General remarks 357 
The main part of this guideline addresses the management of adult patients with ACC. We 358 
divided the 62 recommendations in 12 sections. In addition, we provide two flow-charts on 359 
the management of patients with ACC amenable to radical resection (Figure 3) and on the 360 
management of patients with advanced ACC not amenable to radical resection (Figure 4) to 361 
give an efficient overview. However, we would like to emphasize once more that none of 362 
these flow-charts nor the entire recommendations can replace clinical judgment of the 363 
treating physician and joint decision-making with the patient.  364 
 365 
 366 
5.1. Overarching recommendations 367 
 368 
R.1.1. We recommend that all patients with suspected and proven adrenocortical 369 
carcinoma (ACC) are discussed in a multidisciplinary expert team meeting 370 
(including health care providers experienced in care of adrenal tumors, 371 
including at least the following disciplines: endocrinology, oncology, 372 
pathology, radiology, surgery) at least at the time of initial diagnosis. In 373 
addition, this team should have access to adrenal-specific expertise in 374 
interventional radiology, radiation therapy, nuclear medicine, and genetics as 375 
well as to palliative care teams. 376 
 377 
Reasoning:  378 
Despite the lack of studies, the panel was convinced that patients with ACC benefit from 379 
multidisciplinary management by a team of experts with experience in care for patients with 380 
this rare disease. Ideally, all patients would be managed by such a team throughout the 381 
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course of their disease, because during the follow-up considerations of multiple diagnostic 382 
and treatment modalities might be required. However, in many health care settings this is yet 383 
an unrealistic expectation. Therefore, we envision that in the future at least one reference 384 
center, that fulfills the above-mentioned criteria, will be established in every country. We 385 
believe that it is crucial that every case of suspected ACC is discussed in detail with a panel 386 
of experts for this disease at the time of the initial diagnosis. Additionally, this expert team 387 
should be ideally requested every time progress is documented (or suspected) and new 388 
treatment options might be required. If there is no accessible center with all the required 389 
expertise in all disciplines, or the patient is not able to travel to such a center, telemedicine 390 
approaches should be encouraged to compensate for these limitations.  391 
 392 
 393 
R.1.2. We suggest that at any time of decision-making regarding therapy, enrollment in 394 
a clinical trial (if available) should be considered. Furthermore, we encourage 395 
patients’ participation in registries and the collection of biological material as 396 
part of structured research programs aimed at defining biomarkers of 397 
diagnosis, prognosis and treatment response.  398 
 399 
Reasoning: 400 
As described above, the evidence for almost all therapeutic strategies for ACC is very low. 401 
Furthermore, the efficacy of systemic therapies is limited, including the most commonly used 402 
treatments - mitotane and platinum-based chemotherapies, with response rates clearly less 403 
than 30% {Baudin, 2001 #197;Berruti, 2012 #20;Else, 2014 #135;Fassnacht, 2012 404 
#28;Hermsen, 2011 #68;Hahner, 2005 #64}. Thus, improved treatment paradigms are 405 
needed urgently. Clinical trials are the best way to improve our knowledge and patient care. 406 
However, the benefits and risk for the individual patient have to be weighed against available 407 
data of agents with known or predicted efficacy in ACC.  408 
Because of the rarity of the disease, it is crucial to include as many patients as possible in 409 
research programs for multicenter therapeutic trials, as well as studies for diagnostic, 410 
prognostic and predictive markers. A list of ongoing trials is accessible on 411 
https://www.clinicaltrials.gov/. Biological material may include tumor samples, ideally frozen 412 
and paraffin-embedded, blood-derived and urine samples. National and international 413 
research networks such as ENSAT (www.ensat.org){Stell, 2012 #91} and the recently 414 
founded A5 (https://adrenal-a5.org/) play instrumental roles in coordinating research 415 
programs. Centers providing care to patients with ACC should register as investigators with 416 
ongoing trials and also facilitate the collection a of biological material and ensure appropriate 417 
consent.  418 
 419 
 420 
 421 
5.2. Diagnostic procedures in suspected ACC 422 
 423 
R.2.1. The diagnosis of ACC is not always obvious. We recommend establishing as 424 
soon as possible whether an adrenal mass is malignant, using all required 425 
diagnostic tools in a timely fashion.  426 
 427 
Reasoning 428 
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Due to the potentially poor prognosis of ACC, it is critical to know as early as possible if an 429 
adrenal mass is malignant or not. Therefore, even if there is only a small likelihood that an 430 
adrenal mass is an ACC, this diagnosis should be rapidly excluded with the highest possible 431 
certainty. A particular suspicion for an ACC might arise from clinical aspects (e.g. rapidly 432 
developed features of adrenocortical hormone excess, see R.2.2), or results from hormonal 433 
work-up (see R.2.3), or indeterminate or suspicious imaging (see R.2.4). An adrenal biopsy 434 
should only be considered in those selected cases in which an adrenal metastasis of an 435 
extra-adrenal malignancy is suspected or when the tumor is considered as inoperable 436 
{Fassnacht, 2016 #46} (for details and explanation see R.2.7). The proposed diagnostic 437 
work-up is summarized in Table 3.  438 
  439 
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Table 3: Diagnostic work-up in patients with suspected or proven ACC  440 
 441 
Hormonal work up  
• Glucocorticoid excess  - 1mg dexamethasone suppression test or free 
cortisol in 24-h urine1 
- basal ACTH (plasma)2 
• Sex steroids and steroid precursors3 - DHEA-S 
- 17-OH-progesterone 
- androstenedione 
- testosterone (only in women) 
- 17-beta-estradiol (only in men and 
postmenopausal women) 
- 11-deoxycortisol 
• Mineralocorticoid excess - potassium 
- aldosterone/renin ratio (only in patients with 
arterial hypertension and/or hypokalemia) 
• Exclusion of a pheochromocytoma - Fractionated metanephrines in 24h urine or 
free plasma-metanephrines  
Imaging - CT or MRI of abdomen and pelvis,  
- Chest CT 
- FDG-PET/CT4 
- Bone or brain imaging (when skeletal or 
cerebral metastases are suspected) 
 442 
1 The 1-mg dexamethasone test is the preferred method to exclude relevant hypercortisolism. 443 
However, if overt Cushing syndrome is evident, then cortisol in 24-h urine might be at least as good to 444 
quantify the cortisol excess. Alternatively, salivary or serum bedtime cortisol can be used. 445 
2 ACTH can be skipped if hypercortisolism is excluded. 446 
3 The most suitable set of precursors and sex hormones has not yet been established and local 447 
availability might be taken into account.  448 
4 The panel did not agree on the systematic use of FDG-PET/CT (see R.2.4). 449 
 450 
 451 
R.2.2. We recommend that every patient with (suspected) ACC should undergo careful 452 
assessment including case history, clinical examination for symptoms and 453 
signs of adrenal hormone excess.  454 
 455 
Reasoning 456 
All patients should undergo a careful evaluation with detailed history and physical 457 
examination. In particular, patients should be evaluated for rapidly developing Cushing’s 458 
syndrome (which frequently presents not as 'full blown' Cushing, but rather predominantly 459 
with muscle weakness, hypokalemia, wasting and constitutional symptoms), and symptoms 460 
and signs of a large abdominal mass. Clinical evaluation should additionally focus on 461 
symptoms and signs of androgen excess, hirsutism or virilization in women or recent onset of 462 
gynecomastia in men, because these might be clinical indicators for an androgen- or 463 
estrogen-producing ACC, respectively {Fassnacht, 2004 #59;Allolio, 2006 #236;Else, 2014 464 
#135;Fassnacht, 2009 #56;Nieman, 2008 #134;Libe, 2007 #237}. Any evidence of co-465 
secretion of different steroids raises the suspicion of an ACC (especially if sex-hormones are 466 
involved). In contrast, mild, long standing hirsutism is usually not caused by an ACC, but 467 
rather due to (among other diagnoses) polycystic ovary syndrome and non-classical 468 
congenital adrenal hyperplasia {Legro, 2013 #238}. Primary aldosteronism is rare in ACC 469 
and usually accompanied by severe hypokalemia {Funder, 2016 #239}. However, 470 
hypokalemia in ACC is more frequently caused by massive cortisol excess overwhelming the 471 
renal 11-β hydroxysteroid dehydrogenase type 2 system. 472 
 473 
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 474 
R.2.3. We recommend that all patients with suspected ACC undergo a detailed 475 
hormonal work-up to identify potential autonomous excess of glucocorticoids, 476 
sex-hormones, mineralocorticoids and adrenocortical steroid hormone 477 
precursors (see Table 3). In addition, a pheochromocytoma must be excluded.  478 
 479 
Reasoning 480 
A comprehensive endocrine work-up is helpful for various reasons. (i) The diagnosis of 481 
steroid excess is frequently able to establish the adrenocortical origin of the tumor. (ii) The 482 
steroid pattern may indicate whether an adrenal lesion is an ACC. For example, autonomous 483 
co-secretion of androgens and cortisol in any patient and secretion of steroid precursors or 484 
estradiol in males are highly suspicious for ACC {Fassnacht, 2004 #59}. Furthermore, 485 
hormonal evaluation is of prognostic value as cortisol-secreting tumors generally have a 486 
worse prognosis {Vanbrabant, 2018 #140}. (iii) If undiagnosed, autonomous cortisol 487 
secretion may be followed by life-threatening adrenal insufficiency after complete resection of 488 
the primary tumor. The best test to diagnose autonomous cortisol secretion is the 1-mg 489 
overnight dexamethasone suppression test {Nieman, 2008 #134}. If hypercortisolism is 490 
present, it is crucial to prove ACTH-independency, because an adrenal metastasis of an 491 
ectopic ACTH-secreting tumor (e.g. lung cancer) can mimic an ACC. (iv) Elevated hormones 492 
prior to surgery may serve as tumor markers during follow-up. Finally, conventional imaging 493 
cannot discriminate an ACC from a pheochromocytoma. However, undiagnosed 494 
pheochromocytoma may lead to dangerous hypertensive crises (especially during invasive 495 
procedures). Therefore, a pheochromocytoma has to be ruled out in any case of an adrenal 496 
tumor whenever no obvious autonomous steroid excess is present {Fassnacht, 2016 #46}. It 497 
is important to note, however, that slightly elevated metanephrines levels (< 2-fold), 498 
particularly when inconsistent with a large tumor size, might be non-specific and can be 499 
observed in ACC. 500 
 501 
 502 
R.2.4. We recommend adrenal-focused imaging in all patients with suspected ACC.  503 
 504 
Reasoning 505 
Imaging tools for adrenal tumors were carefully reviewed during the development of the ESE-506 
ENSAT guidelines for adrenal incidentalomas {Dinnes, 2016 #54;Fassnacht, 2016 #46}. 507 
Thus, we refer to these documents for details. Briefly, there are currently three main imaging 508 
techniques available for the differentiation of malignant and benign adrenal tumors: 509 
computed tomography (CT), magnetic resonance imaging (MRI), and positron emission 510 
tomography with 18F-2-deoxy-D-glucose (mostly combined with CT; FDG-PET/CT). CT and 511 
MRI are techniques mainly optimised to identify benign lesions, providing a tool for the 512 
exclusion of adrenal malignancy {Peppercorn, 1998 #244;Caoili, 2002 #243;Blake, 2006 513 
#242;Ilias, 2007 #245}. Conversely, FDG-PET/CT is mainly used for the detection of 514 
malignant disease {Mackie, 2006 #121;Groussin, 2009 #247;Deandreis, 2011 #246}. A 515 
recently performed meta-analysis indicated that the level of evidence is low to very low for all 516 
these imaging methods {Dinnes, 2016 #54}. In the last 2 years some additional studies have 517 
been published {Cistaro, 2015 #362;Altinmakas, 2017 #254;Ciftci, 2017 #255;Bluemel, 2017 518 
#250;Werner, 2016 #248;Wu, 2016 #249;Nakajo, 2017 #257;Guerin, 2017 #256;Marty, 2018 519 
#251;Kim, 2018 #252;Delivanis, 2018 #253;Romeo, 2018 #258;Thomas, 2018 #259;Ng, 520 
2018 #260;Kim, 2018 #252}. However, the panel still considers that of the available imaging 521 
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modalities, only non-contrast CT is sufficiently reliable to rule-out an ACC when the adrenal 522 
lesion is homogenous and has low CT density ≤ 10 HU. In contrast, ACCs are usually large 523 
and of inhomogeneous appearance, and characterized by low fat content (and hence higher 524 
HU density){Petersenn, 2015 #323}. Recently, FDG-PET has been proposed as possibly the 525 
best second-line test to assess indeterminate masses by unenhanced CT {Cistaro, 2015 526 
#362;Guerin, 2017 #256;Nakajo, 2017 #257}. However, the experience shows that sensitivity 527 
and negative predictive value are much better than specificity or positive predictive value. 528 
Therefore, no consensus could be reached for a general recommendation on FDG-PET in all 529 
patients. Additional reasons in favor of systematic FDG-PET are: whole body imaging 530 
(beyond thorax and abdomen, particularly for distant bone metastasis) and in advanced 531 
disease, a reference uptake value for all metastases can be established, which can help 532 
judging the future evolution of disease. Evidence against FDG-PET includes cost, additional 533 
radiation exposure, false-positive findings, and difficult access in some countries. 534 
If adrenal imaging indicates an indeterminate mass, other parameters should be considered: 535 
For instance, in such a situation a tumor size > 4 cm, combined adrenocortical hormone 536 
excess (see also R.2.3), rapidly developing symptoms or young age (e.g. < 40 years) might 537 
point to an ACC. However, it is important to note that no single imaging method can 538 
definitively prove the diagnosis of ACC. 539 
 540 
 541 
R.2.5. We recommend in any case where there is high suspicion for ACC performing a 542 
chest CT, in addition to an abdominal-pelvic cross-sectional imaging (CT or 543 
MRI), because the results might influence therapeutic decision-making.  544 
 545 
Reasoning: 546 
Since decisions for treatment strategy, particularly decisions for surgery, and prognostication 547 
rely on tumor stage, it is mandatory to systematically and rapidly evaluate for metastases, 548 
before initiation of any anti-tumor treatment. Thoraco-abdomino-pelvic imaging will cover the 549 
vast majority of metastatic locations, which most often are lung and liver, and will assess 550 
locoregional tumor extent. Imaging should include contrast-enhanced imaging. For 551 
abdominal imaging there are advantages and disadvantages for both CT and MRI, but for 552 
thoracic imaging CT is the method of choice, because it outperforms all other methods in 553 
detecting small pulmonary lesions.  554 
Additional imaging may be required to better characterize tumor vascularization, or specific 555 
tumor extent such as a vena cava thrombus. 556 
 557 
 558 
R.2.6. We suggest performing additional imaging (e.g. bone and brain imaging) only in 559 
case of clinical suspicion of metastatic lesions. 560 
 561 
Reasoning: 562 
Bone and brain metastases are rare events (especially in patients without other metastatic 563 
lesions). Therefore, additional imaging focusing on these sites is only warranted when there 564 
is increased clinical suspicion or other imaging is suggestive for bone metastases. It should 565 
be noted, however, that the basis for this advice has never been studied systematically.  566 
 567 
 568 
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R.2.7. We recommend against the use of an adrenal biopsy in the diagnostic work-up 569 
of patients with suspected ACC unless there is evidence of metastatic disease 570 
that precludes surgery and histopathologic proof is required to inform 571 
oncological management.  572 
 573 
Reasoning: 574 
Differentiating benign from malignant adrenocortical tumors is very challenging on a biopsy 575 
only and may lead to misdiagnosis {Bancos, 2016 #49;Fassnacht, 2016 #46}. Furthermore, 576 
the biopsy comes with significant risks such as hemorrhage {Williams, 2014 #262}. The risk 577 
of tumor dissemination precluding a R0 resection is very low {Williams, 2014 #262}. 578 
However, a biopsy might be indicated in an adrenal mass without any hormone excess in 579 
patients with a history of extra-adrenal cancers to exclude or prove an adrenal metastasis of 580 
an extra-adrenal malignancy. For details see the adrenal incidentaloma guidelines 581 
{Fassnacht, 2016 #46}. 582 
 583 
 584 
 585 
5.3. Surgery for suspected localized ACC 586 
 587 
R.3.1. We recommend that adrenal surgery for suspected/confirmed ACC should be 588 
performed only by surgeons experienced in adrenal and oncological surgery. 589 
 590 
Reasoning 591 
ACC surgery requires expertise in both adrenal and oncological surgery due to the specific 592 
anatomy, the malignant character of the disease and the potential need for multi-organ en-593 
bloc resection to optimize the probability of a R0 resection and minimize the risk of 594 
complications.  595 
Data comparing outcome between 'high-volume' and 'low-volume' centers for ACC are 596 
limited. Published reports from the UK, USA and Spain show an unacceptable low annual 597 
workload for the majority of surgeons involved in any adrenal surgery, with a median 1 598 
case/year {Palazzo, 2016 #7;Park, 2009 #9;Lindeman, 2018 #264;Villar, 2010 #263}. This 599 
situation is likely to have a negative impact on patient care and contrasts significantly with 600 
the current status in other surgical specialties. 601 
Based on the upper quartile distribution of workload of surgeons in the USA, a volume of 4 602 
adrenalectomies/year was used to define a ‘high-volume’ surgeon {Park, 2009 #9} but this 603 
threshold might be too low to inspire confidence. Several studies showed that those doing 604 
more than 6-7 cases per year have shorter length of stay and fewer complications {Palazzo, 605 
2016 #7;Park, 2009 #9;Gallagher, 2007 #265}. Despite the perceived benefit of being 606 
operated in a high-volume center, published data from Italy and the USA showed no 607 
significant association between overall survival / disease-free survival and workload even 608 
though patients operated in high-volume centers had more radical surgery, more lymph node 609 
assessment and more use of chemotherapy {Lombardi, 2012 #266;Gratian, 2014 #268}. In 610 
contrast, the creation of national centers for adrenal surgery in The Netherlands led to 611 
significantly improved disease-free survival (1y: 93% vs. 78%, 5y: 63% vs. 42 %) {Hermsen, 612 
2012 #36;Kerkhofs, 2013 #41}. Therefore, the panel believes that a minimal annual workload 613 
of 6 adrenalectomies/year seems to be required to ensure sufficient experience in adrenal 614 
surgery, but > 20 adrenalectomies/year are desirable for those involved in surgery for ACC. 615 
Furthermore, due to the complexity of some operations, it is essential to involve surgeons 616 
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with different expertise (e.g. vascular, liver, and cardiac surgeons) for pre-surgical planning 617 
and during these complex operations. 618 
Protocols ensuring referral to regional or national centers should be established and patients 619 
should feel empowered to ask about the previous experience of individual surgeons. 620 
 621 
 622 
R.3.2. We recommend complete en bloc resection of all adrenal tumors suspected to 623 
be ACC including the peritumoral/periadrenal retroperitoneal fat. We 624 
recommend against enucleation and partial adrenal resection for suspected 625 
ACC. If adjacent organs are suspected to be invaded, we recommend en bloc 626 
resection. However, we suggest against the routine resection of the ipsilateral 627 
kidney in the absence of direct renal invasion.  628 
 629 
Reasoning 630 
Complete resection is of utmost importance for all ACCs and successful surgery is a 631 
prerequisite for cure. As the diagnosis of ACC might only become apparent after histological 632 
analysis, it remains imperative for all adrenalectomies (laparoscopic or open) in patients with 633 
a reasonable suspicion for ACC to respect the principles of oncological surgery in order to 634 
ensure complete resection (R0 status) {Gaujoux, 2017 #87;Gaujoux, 2012 #86}. 635 
To ensure that the pathologist can judge the completeness of surgery, any fragmentation of 636 
the tumor has to be avoided. Intraoperative tumour rupture or spillage and R2 resection are 637 
associated with very high recurrence rates and poor overall survival {Bilimoria, 2008 #80} 638 
{Crucitti, 1996 #83}.  639 
Although there are no specific studies comparing outcome of surgery with and without 640 
resection of invaded adjacent organs, it is deemed to be ‘good surgical practice’ to resect 641 
adjacent tissues that are/could be invaded by tumor. This holds true for involvement of 642 
spleen, distal pancreas, stomach, kidney, right liver, colon, diaphragm, the wall of the IVC or 643 
left renal vein. A cohort study compared the oncological results of patients with stage II ACC 644 
treated by radical adrenalectomy alone or by en-bloc resection with kidney. The results did 645 
not support the hypothesis that nephrectomy improves the oncological outcome {Porpiglia, 646 
2016 #31}. Combined nephrectomy, however, offers a lower risk of capsular rupture and can 647 
include complete lymphadenectomy of the renal hilum, but impairs kidney function and this 648 
may limit further access to chemotherapy. Thus, in case of possible invasion in the kidney, 649 
partial nephrectomy should be considered on an individual basis. 650 
 651 
 652 
R.3.3. Open surgery is the standard surgical approach for confirmed or highly 653 
suspected ACC. Therefore, we recommend open surgery for all tumors with 654 
radiological findings suspicious of malignancy and evidence for local invasion. 655 
However, for tumors < 6 cm without any evidence of local invasion, 656 
laparoscopic adrenalectomy (respecting the principles of oncological surgery) 657 
is reasonable if the surgeon has sufficient experience in these types of surgery.  658 
 659 
Reasoning 660 
There is an ongoing debate if laparoscopic adrenalectomy is an acceptable alternative for 661 
adrenal tumors with suspicion of ACC. Based on the systematic review on this topic until July 662 
2014 {Fassnacht, 2016 #46} and an additional literature search until December 2017 663 
{Donatini, 2014 #274;Sgourakis, 2015 #273;Autorino, 2016 #272;Langenhuijsen, 2016 664 
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#271;Lee, 2017 #6;Zheng, 2018 #269;Mpaili, 2018 #270;Huynh, 2016 #333}, we conclude 665 
that the quality of evidence from these observational studies is still very low. The main 666 
concerns with all these studies are differences of baseline characteristics between groups, 667 
and between important prognostic factors, such as tumor stage or size. The lack of any 668 
randomized trial prevents any final conclusions. However, in order to provide guidance for 669 
clinicians the panel concurs with two other recent European guidelines {Fassnacht, 2016 670 
#46;Gaujoux, 2017 #87} and agrees that all tumors with some radiological evidence of local 671 
invasion (including enlarged lymph nodes) should undergo surgery with an open approach. 672 
The likelihood of a benign adrenal tumor is higher in the group of adrenal incidentalomas ≤ 6 673 
cm, for whom a laparoscopic approach is reasonable. However, this cut-off is arbitrary and 674 
the experience of the surgeon is the single most important factor. Furthermore, it is advised 675 
to convert to an open procedure when obvious signs of invasion are encountered during 676 
laparoscopic surgery that would prevent complete resection. For detailed discussion we refer 677 
to the recent recommendations for the surgical management of ACC by ESES and ENSAT 678 
{Gaujoux, 2017 #87} and the guidelines on adrenal incidentaloma {Fassnacht, 2016 #46}.  679 
Although retroperitoneoscopic adrenalectomy is gaining popularity, only a small number of 680 
surgeons are likely to have completed the learning curve to reach sufficient expertise, which 681 
is estimated to be at least 20 cases {Barczynski, 2007 #275;Schreinemakers, 2010 #276}. 682 
This is a very significant issue in the context of the overall minimal experience of most 683 
surgeons offering adrenalectomy (see above). Outside specialized centers with large volume 684 
practice, retroperitoneoscopic adrenalectomy should only be considered for benign tumors 685 
<4 cm. 686 
 687 
 688 
R.3.4. We suggest that routine locoregional lymphadenectomy should be performed 689 
with adrenalectomy for highly suspected or proven ACC. It should include (as a 690 
minimum) the periadrenal and renal hilum nodes. All suspicious or enlarged 691 
lymph nodes identified on preoperative imaging or intraoperatively should be 692 
removed. 693 
 694 
Reasoning 695 
Reports from several databases indicated that patients with stage III tumors and positive 696 
lymph nodes can have a 10-year overall survival rate of up to 40% after resection 697 
{Fassnacht, 2009 #58;Lughezzani, 2010 #92;Libe, 2015 #29;Nilubol, 2016 #8;Saade, 2015 698 
#93}. However, the wide range of reported lymph node involvement in ACC (from 4 to 73%) 699 
{Icard, 2001 #79;Bilimoria, 2008 #80;Harrison, 1999 #88} demonstrates that regional 700 
lymphadenectomy is neither formally performed by all surgeons nor accurately assessed or 701 
reported by all pathologists. According to large American and French series, approximately 702 
10-30% of patients with ACC had formal lymphadenectomy as part of the tumor resection, 703 
reflecting the heterogeneity of operative management {Icard, 2001 #79;Nilubol, 2016 #8}. A 704 
minimum of four lymph nodes should be retrieved in order to declare lymph node negative 705 
cases {Panjwani,  #89} Furthermore, in an analysis of 120 cases identified from a multi-706 
institutional database, the benefit of lymphadenectomy on overall survival persisted on 707 
multivariable analysis controlling for adverse preoperative and intraoperative factors 708 
associated with lymphadenectomy, such as tumor size, palpable mass, irregular tumor 709 
edges, suspicious nodes on imaging, and multivisceral resection {Gerry, 2016 #94}. The 710 
largest series so far included 283 patients and the resection of more than five lymph nodes 711 
reduced also the risk of local recurrence and disease-related death in a multivariate analysis 712 
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{Reibetanz, 2012 #75}. 713 
However, the panel is not in favor of a repeat surgery if complete adrenalectomy was 714 
performed without lymphadenectomy (e.g. due to perceived benign tumor). The clinical 715 
benefit is uncertain and probably lower than the harm (e.g. delayed adjuvant therapy). 716 
 717 
 718 
R.3.5. We recommend that individualized treatment decisions are made in cases of 719 
tumors with extension into large vessels based on multidisciplinary surgical 720 
team. Such tumors should not be regarded ‘unresectable’ until reviewed in an 721 
expert center. 722 
 723 
Reasoning 724 
Extension of ACC into the adrenal vein, renal vein or inferior vena cava occurs in 725 
approximately 15-25% {Chiche, 2006 #96;Turbendian, 2010 #95;Fassnacht, 2009 #58}. 726 
Venous involvement consists mostly of intravenous tumor thrombus. Thrombectomy might 727 
require vena cava cross-clamping above or below the hepatic vein confluence or 728 
cardiopulmonary bypass, depending on the upper level of extent of the thrombus. The 729 
resection might include a complete thrombectomy, a flush manoeuvre and, occasionally, 730 
vascular cuff or prosthetic IVC replacement. A 3-year overall survival rate of about 25% in a 731 
large series {Mihai, 2012 #97} encourages the performance of a venous resection in the 732 
presence of vena cava or renal vein invasion but without distant metastases. 733 
 734 
 735 
R.3.6. If the first surgery was suboptimal and macroscopically incomplete (R2 736 
resection), we suggest to discuss repeat surgery in a multidisciplinary expert 737 
team. 738 
 739 
Reasoning 740 
There has been no prospective study assessing the benefits (or the lack thereof) of early 741 
reoperation in patients whose initial adrenalectomy was incomplete (R2 status). It is the 742 
panel’s view that such patients should have intensive postoperative monitoring and if local 743 
recurrence is detected radiologically, in the absence of other metastases, they should 744 
undergo surgery with a curative intent at an expert center, if it is deemed likely to lead to an 745 
R0 resection.   746 
 747 
 748 
R.3.7. We recommend perioperative hydrocortisone replacement in all patients with 749 
hypercortisolism that undergo surgery for ACC.  750 
 751 
Reasoning:  752 
Overt ACTH-independent Cushing's syndrome or biochemical autonomous cortisol secretion 753 
might lead to adrenal insufficiency after removal of the adrenal source of cortisol (even in 754 
patients with incompletely suppressed ACTH) {Eller-Vainicher, 2010 #4}. Therefore, the 755 
group unanimously sees a clear indication of intra- and postoperative glucocorticoid 756 
replacement, preferably with hydrocortisone, in all patients with evidence for ‘(possible) 757 
autonomous cortisol secretion’ (post-dexamethasone cortisol >50 nmol/L (>1.8 μg/dL)). This 758 
should follow the suggestions for major stress dose replacement as per recent international 759 
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guidelines {Bornstein, 2016 #314}. Postoperatively, the dose of glucocorticoid should be 760 
tapered on an individualized basis by a physician experienced with this clinical scenario.  761 
 762 
 763 
 764 
5.4. Pathological work-up  765 
 766 
R.4.1. We recommend that the diagnosis of ACC should be confirmed by 767 
histopathology (+++0).  768 
 769 
Reasoning:  770 
Histopathology is the gold-standard of diagnosing ACC and should in principle be obtained in 771 
all patients. For patients deemed operable this will be done on the basis of the resection 772 
specimen and for those patients who are inoperable, a biopsy will be taken in accordance 773 
with good oncological practice. However, the majority of panelists argued that in selected 774 
cases biopsy might be omitted when there is advanced disease with unequivocal ACTH-775 
independent cortisol excess, androgen excess (testosterone, DHEAS) or estradiol excess. 776 
There is no role for biopsy in a patient who is considered suitable for surgery of the adrenal 777 
mass.  778 
 779 
 780 
R.4.2.  We suggest that all adrenal tumors, which cannot be readily classified, and all 781 
suspected ACC, should be reviewed by an expert adrenal pathologist (++OO).  782 
 783 
Reasoning:  784 
Diagnosing ACC can be challenging and misdiagnoses are relatively frequent events. In 21 785 
of 161 of the patients (13%) registered with the German ACC Registry between 2006 and 786 
2009, the diagnosis of ACC had to be revised by the reference pathologist {Johanssen, 2010 787 
#69}. Similar results were found in a large series from Italy with a rate of misdiagnosis in 26 788 
out of 300 cases (9%) {Duregon, 2015 #98}.  789 
 790 
 791 
R.4.3. We suggest the use of immunohistochemistry for steroidogenic factor-1 (SF1) 792 
for the distinction of primary adrenocortical tumors and non-adrenocortical 793 
tumors (+OOO). 794 
 795 
Reasoning:  796 
Generally, the distinction between adrenocortical and non-adrenocortical tumors is clear and 797 
can be made on the basis of hematoxylin and eosin-stained slides. In case of doubt, on the 798 
basis of histology only, whether a tumor originates from the adrenal cortex or not, 799 
immunohistochemistry with SF1 is the most sensitive and specific marker currently available 800 
to establish if the tumor in question is of adrenocortical origin, with a sensitivity of 98% and a 801 
specificity of 100% {Sbiera, 2010 #15}. If this marker is not available, we advise a 802 
combination of markers, which should include inhibin-alpha, melan-A, and calretinin {Sangoi, 803 
2011 #99;Weissferdt, 2014 #100}. Depending on the differential diagnosis, other 804 
immunohistochemistry markers used to make alternative diagnoses may be considered 805 
following local standard procedures. 806 
 807 
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 808 
R.4.4. We recommend the use of the Weiss system, based on a combination of 9 809 
histological criteria that can be applied on hematoxylin and eosin-stained 810 
slides, for the distinction of benign and malignant adrenocortical tumors 811 
(++OO). 812 
 813 
Reasoning:  814 
There are many classification systems based on histology and/or a limited number of 815 
additional markers for the distinction of benign and malignant adrenocortical tumors. The 816 
Weiss system is the most widely used, and although it is not fully standardized {Tissier, 2010 817 
#102;Tissier, 2012 #101} the panel favors use of this score. It should be noted that all 818 
scoring systems have similar inherent problems. Using the Weiss system, a score of 3 or 819 
higher (on a total of 9 criteria, see Table 4) indicates ACC {Weiss, 1984 #104;Weiss, 1989 820 
#103}. A score of 2 and 3 may be considered as borderline between benign and malignant 821 
tumors (tumors of uncertain malignant potential). In such instance, one of several other 822 
classification systems, including the van Slooten index {van Slooten, 1985 #107}, the 823 
modified Weiss score {Aubert, 2002 #108}, the Helsinki classification {Pennanen, 2015 824 
#109;Duregon, 2017 #110}, and the addition of reticulin stain assessment {Duregon, 2013 825 
#26} may be used.  826 
 827 
Special attention should be paid to histological variants of adrenocortical tumors, mainly 828 
oncocytic tumors, which, because of their specific characteristics, will always have a Weiss 829 
score of least 3, whether they are benign or malignant. For these tumors, an adapted scoring 830 
system should be used, the Lin-Weiss-Bisceglia system {Bisceglia, 2004 #111;Duregon, 831 
2011 #112;Wong, 2011 #113}.   832 
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Table 4 Histopathologic criteria by Weiss {Weiss, 1984 #104;Weiss, 1989 #103} 833 
The presence of three or more of the following criteria highly 
correlated with subsequent malignant behavior: 
• High nuclear grade (Fuhrman criteria {Fuhrman, 1982 
#357}) 
• > 5 mitoses per 50 high-power field 
• Atypical mitotic figures 
• < 25% of tumor cells are clear cells 
• Diffuse architecture (> 33% of tumor) 
• Necrosis  
• Venous invasion (smooth muscle in wall) 
• Sinusoidal invasion (no smooth muscle in wall) 
• Capsular invasion 
 834 
 835 
 836 
R.4.5. We recommend the use of Ki67 immunohistochemistry for every resection 837 
specimen of an adrenocortical tumor (++OO). 838 
Ki67 immunohistochemistry has been proposed for prognostic purposes. Higher Ki67 levels 839 
are consistently associated with poor prognosis. Threshold levels of 10% and 20% have 840 
been considered for discriminating low from high Ki67 labeling index {Beuschlein, 2015 841 
#50;Libe, 2015 #29}. However it is not clear whether any single significant threshold can be 842 
determined (see R.5.2.).  843 
Ki67 labeling has been shown to be unevenly distributed in tumors. Therefore, determination 844 
of the labeling index should be done on whole tumors, with specific attention to the area of 845 
highest Ki67 labeling, preferably by use of an image analysis system {Lu, 2014 846 
#115;Papathomas, 2016 #116}. If only a biopsy is available a low Ki67 labeling may not be 847 
representative and therefore can be misleading.  848 
If Ki67 immunohistochemistry is not available, mitotic count may help in prognostic 849 
stratification of ACC. Mitotic count has been proposed for grading of ACC, using >20 mitoses 850 
per 50 high-power field to define high-grade tumors {Weiss, 1989 #103;Assie, 2007 851 
#114;Miller, 2010 #90}. However, the precise correlation between mitotic count and Ki67 852 
labeling is undetermined.  853 
 854 
 855 
R.4.6.  We recommend that the pathology report of a suspected ACC should at least 856 
contain the following information: Weiss score (including the exact mitotic 857 
count), exact Ki67 index, resection status, and pathological tumor stage 858 
(indicating invasion or not of the capsule and/or surrounding tissue and 859 
organs) and nodal status (+OOO).  860 
 861 
Reasoning 862 
The importance of Weiss score and Ki67 index has been discussed in R4.4 and R4.5, 863 
respectively. It is important that the exact values are given, because this is of prognostic 864 
relevance. Resection status is a major prognostic factor (see R 5.2.). Tumor stage, including 865 
nodal involvement, is discussed below (see R.5.1). 866 
 867 
28 
 
 868 
 869 
 870 
5.5. Staging classification and prognostic factors  871 
 872 
R.5.1. At initial diagnosis, we recommend using the ENSAT staging classification 873 
(Table 5) (+++O).  874 
 875 
Reasoning 876 
Tumor staging is the most important prognostic factor. Specifically, the presence of 877 
metastases is by far the strongest indicator of poor prognosis. Several staging classifications 878 
have been proposed {Macfarlane, 1958 #281;Sullivan, 1978 #282;Lee, 1995 #283;DeLellis, 879 
2004 #284;Asare, 2014 #158;Miller, 2010 #90;Lughezzani, 2010 #92;Fassnacht, 2009 880 
#58;Libe, 2015 #29;Lam, 2017 #285}. Among these, the ENSAT staging classification 881 
appears to be the most discriminant, but the differences between staging systems are minor 882 
{Fassnacht, 2016 #46}(see also section 4.2.). The panel felt strongly that a one unique 883 
staging classification should be adopted across centers in order to improve standardization 884 
and documentation of clinical data, and so improve patient care and enhance clinical 885 
research. 886 
The ENSAT classification requires extensive imaging prior to surgery (see R.2.4.), 887 
systematic lymph node resection, a complete surgical report (see R.3.3 and R.3.4.), and a 888 
complete pathological report (see R.4.6.).  889 
 890 
Table 5: ENSAT staging classification {Fassnacht, 2016 #46} 891 
 892 
ENSAT stage Definition 
I T1, N0, M0 
II T2, N0, M0 
III T1-T2, N1, M0 
T3-T4, N0-N1, M0 
IV T1-T4, N0-N1, M1 
 893 
T1: tumor ≤ 5cm; T2: tumor > 5cm; T3: infiltration into surrounding tissue; T4: tumor invasion into 894 
adjacent organs or venous tumor thrombus in vena cava or renal vein; N0: no positive lymph node; 895 
N1: positive lymph node; M0: no distant metastases; M1: presence of distant metastases. 896 
 897 
 898 
R.5.2. At initial diagnosis, we recommend taking the following factors into account 899 
when assessing the prognosis and treatment options: tumor stage, resection 900 
status, Ki67 index (or mitotic count), autonomous cortisol secretion and the 901 
patient's general condition (++OO).  902 
 903 
Reasoning 904 
Of the many reported prognostic factors tumor stage is the most important, because it 905 
reflects tumor extent. Especially the presence of metastases is strongly pejorative (see 906 
R.5.1.). Resection status is also a strong prognostic factor {Bilimoria, 2008 #80;Johanssen, 907 
2010 #69;Libe, 2015 #29}, and should be carefully documented in the surgical and pathology 908 
reports. Furthermore, several studies have identified Ki67 immunostaining (or mitotic index) 909 
as major prognostic factors {Morimoto, 2008 #278;Weiss, 1989 #103;Miller, 2010 910 
#90;Beuschlein, 2015 #50;Libe, 2015 #29}. As revealed by our systemic literature search, 911 
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hypercortisolism was also one of the most consistent prognostic factors (see section 4.2; 912 
{Abiven, 2006 #279;Berruti, 2014 #35;Vanbrabant, 2018 #140}. 913 
Finally, the patient’s general condition is an obvious prognostic factor, especially at advanced 914 
age {Asare, 2014 #158}. It is, however, noticeable that ACC patients often do not show 915 
altered general condition despite advanced disease.  916 
From a patient perspective, the panel felt it important to consider two distinct scenarios. First, 917 
the risk of recurrence of patients with a localized (stage I-III) disease. For these patients, 918 
tumor stage, resection status and Ki67 labeling index are currently the main prognostic 919 
factors. This panel proposes to define two classes of localized ACC: low/moderate risk ACC 920 
includes stage I-II and R0 and Ki67 ≤10%, whereas high risk ACC includes stage III, R1, or 921 
Ki67 >10%. However, the panel is aware that the dichotomy is arbitrary.  922 
The second scenario to consider deals with the prognosis of patients with advanced disease 923 
(stage IV or recurrent disease not amenable to complete resection or R2 resection). In this 924 
situation, high tumor burden, high tumor grade, high Ki67 index, and uncontrolled symptoms 925 
are major factors associated with worse prognosis {Assie, 2007 #114;Libe, 2015 #29}. 926 
However, there is consensus that the kinetics of tumor growth might be also relevant, 927 
particularly when making the decision for initiation of cytotoxic chemotherapy. However, this 928 
parameter has not been formally assessed. Although a correlation of tumor growth and tumor 929 
grade exists, it is not true for all tumors.  930 
 931 
 932 
R.5.3. During follow-up, we recommend re-assessing prognosis at each evaluation, to 933 
guide treatment strategy (++OO).  934 
 935 
Reasoning 936 
After complete surgery, the major prognostic factor is whether there is any tumor recurrence. 937 
At the time of recurrence the main prognostic factors are time between initial surgery and 938 
recurrence, tumor burden and resectability {Datrice, 2012 #118;Erdogan, 2013 #55;Ettaieb, 939 
2016 #117;Simon, 2017 #136}.  940 
For patients with advanced disease, prognostic factors include Ki67 index, tumor burden, 941 
general patient condition, and kinetics of tumor growth, as well as response to treatment. 942 
Limited evidence is available, but these factors make clinical sense and are corroborated by 943 
this panel’s experience.  944 
 945 
 946 
5.6. Methods and time interval for imaging and hormonal assessment during 947 
follow-up  948 
 949 
R.6.1. We recommend following patients with regular cross-sectional imaging of the 950 
abdomen, pelvis and chest for disease recurrence or progression.  951 
 952 
Reasoning 953 
A majority of disease recurrence and progression occurs either loco-regionally, or with 954 
metastases to lung or liver and therefore should be identified by thoraco-abdomino-pelvic 955 
imaging. Bone metastases are infrequent and brain involvement is exceptional {Fassnacht, 956 
2009 #56;Libe, 2015 #29;Burotto, 2015 #119}. In general, 18-FDG-PET/CT might provide 957 
additional information (see R.2.4.) particularly prior to any surgical intervention {Leboulleux, 958 
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2006 #120;Mackie, 2006 #121;Ardito, 2015 #122}. In addition, change in tracer uptake might 959 
inform about disease evolution. 960 
 961 
 962 
R.6.2. After complete resection, we suggest radiological imaging every 3 months for 2 963 
years, then every 3-6 months for a further 3 years. The majority of the panel 964 
suggests continuation of follow-up imaging beyond 5 years, but surveillance 965 
should then be adapted. 966 
 967 
Reasoning 968 
There are no published studies that address specifically this issue. Therefore, the suggested 969 
imaging interval is in accordance with the practice at many expert centers, and with 970 
standards for other malignant tumors. In the experience of the panel few tumors with initial 971 
curative surgery will recur after more than five years and therefore a 5-yr surveillance is likely 972 
to include >90% of the ACC population that will experience disease recurrence. However, the 973 
majority of the panel felt uncomfortable with the notion of complete cessation of imaging after 974 
5 years and preferred for instance an annual imaging for another 5 years. After stopping 975 
regular imaging, patients and primary care physicians should remain vigilant in terms of 976 
potential symptoms or signs of late recurrences (see also R.6.4.). 977 
 978 
 979 
R.6.3. For advanced ACC, we recommend surveillance based on prognostic factors, 980 
expected treatment efficacy and treatment-related toxicity, as well as the 981 
available alternative treatment options. 982 
 983 
Reasoning 984 
The imaging interval in advanced ACC depends on the ongoing treatment and the overall 985 
prognosis, but will usually be in 2-3 monthly intervals. For patients receiving mitotane alone, 986 
imaging intervals might be even more individualized (e.g. 2-5 months) based on tolerability 987 
and tumor kinetics. For patients undergoing loco-regional treatments, specific surveillance 988 
following procedures must be determined by the team performing these procedures, both to 989 
assess efficacy and adverse effects. For patients opting for entirely palliative management, 990 
without any anti-neoplastic therapy, no systematic imaging is advised. 991 
 992 
 993 
R.6.4. In all patients, we recommend regular screening for hormone secretion.  994 
 995 
Reasoning 996 
Biochemical evaluation together with clinical evaluation fulfills two purposes: (i) it allows in a 997 
few patients the early detection of recurrences and (ii) it also identifies patients that might 998 
benefit from early anti-hormonal therapy. Biochemical evaluation should focus on steroid 999 
hormones or metabolites that were present at the time of diagnosis of the initial tumor. 1000 
However, some panelists favored a more complete hormonal evaluation, because some 1001 
tumors might change their steroid secretion pattern over time.  1002 
 1003 
 1004 
 1005 
5.7. Adjuvant therapy 1006 
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 1007 
R.7.1. For adrenal tumors with uncertain malignant potential, we recommend against 1008 
adjuvant therapy (+OOO).  1009 
Reasoning: 1010 
In certain tumors it is difficult to define if the tumor is truly malignant (see R.4.4.). Since all 1011 
adjuvant therapies are associated with potential toxicity, only patients with a definitive 1012 
diagnosis of ACC should be considered for adjuvant treatment. 1013 
 1014 
R.7.2. We suggest adjuvant mitotane treatment in those patients without macroscopic 1015 
residual tumor after surgery but who have a perceived high risk of recurrence 1016 
(+OOO). However, we cannot suggest for or against adjuvant therapy for 1017 
patients at low/moderate risk of recurrence (stage I-II, R0 resection and Ki67 ≤ 1018 
10%) and adjuvant therapy options should be discussed on an individual basis. 1019 
 1020 
Reasoning: 1021 
The panel is in favor of offering mitotane to patients with high risk of recurrence (stage III, or 1022 
R1 resection, or Ki67 >10%; see R.5.2.) despite the absence of completely convincing 1023 
evidence (see section 4.3). The panel decided on the use of mitotane in the adjuvant setting 1024 
based on three arguments: (i) the perceived effects {Terzolo, 2007 #33;Berruti, 2010 1025 
#21;Berruti, 2017 #22;Bertherat, 2007 #82;Else, 2014 #125;Fassnacht, 2010 #57;Grubbs, 1026 
2010 #191;Postlewait, 2016 #192} (acknowledging this is based on low quality evidence), 1027 
see Figures 1A + B; (ii) published data showing a tumor response in ~20% of patients with 1028 
advanced disease treated with mitotane {Baudin, 2001 #197;Else, 2014 #135;Hahner, 2005 1029 
#64;Megerle, 2018 #294}; (iii) clinical experience of the panelists. For details on mitotane 1030 
management see section 5.9. 1031 
Ki67 has emerged as the most powerful predictor of recurrence, and tumors with Ki67 ≤10% 1032 
might represent a subset of patients with a good prognosis. For these patients mitotane 1033 
might be considered overtreatment. For this subset of patients (<30% of all localized ACCs) 1034 
the ongoing ADIUVO trial, a prospective study where patients are randomized to adjuvant 1035 
mitotane vs. observation, will provide guidance in a few years.   1036 
There is no clinical, histopathological, or molecular marker that reliably predicts response to 1037 
mitotane although several markers have been proposed {Volante, 2012 #327;Ronchi, 2014 1038 
#322}. A study showed that mitotane levels may influence patient outcome in adjuvant 1039 
setting {Terzolo, 2013 #313} as it has been reported in advanced ACC. The secretory status 1040 
of the tumor has a negative prognostic value but does not seem to influence response to 1041 
treatment {Berruti, 2014 #35;Berruti, 2017 #22;Megerle, 2018 #294}.  1042 
In patients who undergo surgery for recurrence of ACC but who have not previously had 1043 
medical therapy, the decision on adjuvant mitotane should follow the same lines of 1044 
reasoning.  1045 
 1046 
 1047 
R.7.3. Once the decision for mitotane treatment is established, we recommend 1048 
starting mitotane as soon as clinically possible after surgery (+OOO).  1049 
Reasoning: 1050 
The ideal timing to start adjuvant mitotane is unknown; however, by analogy with other 1051 
oncological adjuvant treatments we are convinced that starting mitotane within six weeks is 1052 
ideal, and would not initiate the treatment later than 3 months. This reasoning is sound with 1053 
the biological concept of adjuvant therapy in general, and with the latency of mitotane to 1054 
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reach effective levels and anti-tumor activity. However, no published data are available to 1055 
demonstrate the superiority of an early start of treatment or the lack of efficacy when started 1056 
later than 3 months.  1057 
 1058 
 1059 
R.7.4. In patients without recurrence who tolerate mitotane in an acceptable manner, 1060 
we suggest to administer adjuvant mitotane for at least 2 years, but not longer 1061 
than 5 years (+OOO).  1062 
 1063 
Reasoning: 1064 
The optimal duration of mitotane treatment is unknown and practice varies among different 1065 
centers. Some members of the panel continue treatment for 3 to 5 years if tolerated {Terzolo, 1066 
2014 #363}, while others discontinue after 2 to 3 years {Fassnacht, 2011 #61;Berruti, 2012 1067 
#20;Else, 2014 #135}. Prognostic factors at diagnosis, patient compliance with treatment and 1068 
plasma mitotane levels reached during treatment are factors that influence duration of 1069 
treatment. Mitotane may possibly act as an oncostatic measure in those patients {Huang, 1070 
2008 #350;Terzolo, 2009 #328}. However, the rate of recurrence 5 years after surgery is 1071 
potentially too low to advise continuation of therapy treatment beyond this time point. 1072 
Treatment-related toxicity, lack of experience in long-term administration are additional 1073 
factors portending against indefinite treatment.  1074 
 1075 
 1076 
R.7.5. The panel did not come to a definitive consensus on adjuvant radiation therapy. 1077 
However, we suggest against the routine use of radiation therapy in patients 1078 
with stage I-II and R0 resection (+OOO). The panel suggests considering 1079 
radiation in addition to mitotane therapy on an individualized basis therapy in 1080 
patients with R1 or Rx resection or in stage III. 1081 
 1082 
Reasoning: 1083 
The systematic literature search indicated that radiation therapy is able to prevent local 1084 
recurrence but does not significantly affect distant recurrences or overall survival {Else, 2014 1085 
#125;Fassnacht, 2006 #126;Habra, 2012 #123;Polat, 2009 #73;Sabolch, 2015 1086 
#127;Sabolch, 2013 #124} (see section 4.3. and Figure 1). However, distant metastases 1087 
account for about 40-60% of tumor relapses {Berruti, 2017 #22;Amini, 2016 #157;Erdogan, 1088 
2013 #55} and have large impact on the patient prognosis, and are more difficult to treat 1089 
effectively. Conversely, prevention of the complications due to local recurrence argues in 1090 
favor of radiation therapy. Adjuvant radiation therapy might be particularly reasonable in 1091 
patients with R1 resection. This was already suggested by earlier studies, but also by a very 1092 
recent study that was published after the meta-analysis associated with this report {Nelson, 1093 
2018 #358}. 1094 
 1095 
Radiation therapy is not advised for patients who experienced widespread tumor spillage 1096 
during surgery. The combination of radiation therapy and mitotane is biologically sound 1097 
{Cerquetti, 2008 #330;Cerquetti, 2010 #329} and possible but at the cost of greater toxicity 1098 
(e.g. constitutional, gastrointestinal and liver toxicity). In addition, there is concern that 1099 
radiation therapy may delay systemic therapy or prevent effective mitotane administration 1100 
resulting in lower drug levels.  1101 
 1102 
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 1103 
R.7.6. If adjuvant radiation therapy is administered, we recommend starting 1104 
treatment as soon as clinically possible after surgery and to deliver radiation 1105 
therapy at the dose of 50-60 Gy to the previous tumor bed in fractionated 1106 
doses of approximately 2 Gy each (+OOO). 1107 
Reasoning: 1108 
Radiation therapy was delivered following this scheme in previous observational studies 1109 
{Fassnacht, 2006 #126;Habra, 2012 #123;Sabolch, 2013 #124;Else, 2014 #125;Sabolch, 1110 
2015 #127} and lower dosage seems to be less effective {Polat, 2009 #73}.  1111 
 1112 
 1113 
R.7.7. The panel did not come to a definitive consensus on adjuvant use of cytotoxic 1114 
drugs. We suggest against the routine use of cytotoxic drugs in the adjuvant 1115 
setting. However, the panel suggests considering adjuvant chemotherapy in 1116 
selected patients with very high risk for recurrence. 1117 
 1118 
Reasoning: 1119 
Scant data are available on the use of cytotoxic drugs in an adjuvant setting and the studies 1120 
did not control the results of treatment with a matched control group of untreated patients, or 1121 
patients treated undergoing mitotane therapy {Khan, 2000 #296}. However, the majority of 1122 
panelists favors discussion of this option with patients with high risk of recurrence (ideally in 1123 
the setting of clinical trials). Despite the lack of published data, some members of the panel 1124 
are currently using cisplatin, with or without etoposide, in patients at perceived very high risk 1125 
of recurrence (e.g. Ki67 >30%. large tumor thrombus in the vena cava, stage IV, or R1 1126 
resection).  1127 
In patients with R2 resection or tumor spillage, the same considerations for treatment of 1128 
(locally) advanced disease should apply (see section 5.8.). 1129 
 1130 
 1131 
Figure 3: Treatment for ACC amenable to complete resection 1132 
 1133 
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 1134 
 1135 
 1136 
DFI disease-free interval between complete resection and recurrence 1137 
1 All patients with stage I+II and most patients with stage III should be amenable to radical resection. If complete 1138 
resection is not feasible, consider neo-adjuvant treatment (e.g. cisplatin or EDP). In selected patients with stage 1139 
IV and oligo-metastatic disease complete resection might be possible as well and should be aimed at. 1140 
2 In patients with R2 resection, consider re-surgery by an expert surgeon (see R.3.6) or see Figure 1B  1141 
3 If Ki67 staining is not available, a low (<20 mitoses / 50 high power fields) or a high mitotic rate (> 20 mitoses / 1142 
50 high power fields) may be used for risk stratification.  1143 
4 Individual decision (see R.7.2.). If possible enroll in clinical trial like ADIUVO (www.adiuvo-trial.org).  1144 
5 In some patients (e.g. Ki67 >30%. large tumor thrombus in the vena cava, stage IV, or R1 resection) consider 1145 
additional cytotoxic therapy (e.g. 3-4 cycle of cisplatin + etoposide).  1146 
6 After two years the time intervals are gradually extended.  1147 
7 If the disease-free interval is between 6 and 12 months or in patients with DFI > 12, in whom complete resection 1148 
is not possible, an individual approach is required (see R.8.7.)   1149 
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5.8. Treatment of recurrent and/or advanced ACC 1150 
 1151 
Clinical scenarios of patients with recurrent and/or advanced ACC are highly variable. 1152 
Therefore, we try to provide recommendations for at least the most frequent presentations 1153 
(see also Figure 4). Although a (small) proportion of patients experience a relatively long 1154 
survival {Hermsen, 2008 #128;Fassnacht, 2009 #58;Libe, 2015 #29;Else, 2014 #135}, the 1155 
prognosis of advanced/metastatic ACC is generally limited. The goal of any therapy is to 1156 
palliate symptoms and prolong survival. In this situation it is even more important than in 1157 
other scenarios to tailor treatment on an individual basis taking into account the disease 1158 
extent, the patient performance status and particularly the preference of the patient. 1159 
 1160 
 1161 
R.8.1. For patients presenting at time of initial diagnosis with limited intra-abdominal 1162 
metastases we suggest surgical therapy if complete resection of all lesions 1163 
seems feasible (+OOO). In case of limited extra-abdominal lesions, we suggest 1164 
adrenal tumor resection in conjunction with therapy aiming at long-term tumor 1165 
control of the other lesions (+OOO). In all patients, we recommend to start 1166 
mitotane therapy as soon as clinically possible (+OOO). 1167 
 1168 
Reasoning:  1169 
Complete surgery is the best chance to reach long-term disease control although the 1170 
likelihood of complete tumor removal in advanced ACC is low. If clinically possible, a single 1171 
surgical approach should be planned. If a one-time surgical approach is impossible (e.g. due 1172 
to extra-abdominal metastases), other loco-regional approaches (see R.8.2) should be 1173 
discussed within a multidisciplinary expert team and the patient on an individual basis. Local 1174 
expertise and preference of the patient should be taken into account. Any initial treatment 1175 
(surgery, local and/or medical therapy) should be initiated in a timely fashion (≤ 4-6 weeks 1176 
following initial diagnosis).  1177 
In general, prognostic parameters (see R.5.2 + 5.3) should influence the overall treatment 1178 
strategy. If the disease has an aggressive behavior (i.e. increase in tumor burden [e.g. 1179 
increasing size of existing tumors or new metastasis] observed in subsequent imaging 1180 
performed within a few weeks) systemic options (chemotherapy plus mitotane) may be 1181 
favored. If partial responses or prolonged stabilization are then observed, surgery and/or 1182 
additional loco-regional options might be particularly useful (“neo-adjuvant approach", see 1183 
also R.8.3). This strategy could also be potentially advantageous in patients for whom tumor 1184 
shrinkage might allow a more conservative surgical approach (i.e. patients in whom radical 1185 
surgery would imply the complete or partial removal of neighboring organs such as kidney, 1186 
spleen and part of the pancreas){Bednarski, 2014 #334}.  1187 
These patients are at high risk for recurrence and therefore adjuvant mitotane seems to be 1188 
justified {Wangberg, 2010 #361}. Addition of cytotoxic drugs might be a possible option 1189 
(although data are lacking; see also R.7.7.).  1190 
 1191 
 1192 
R.8.2. The panel is convinced that in addition to surgery other local therapeutic 1193 
measures (e.g. radiation therapy, radiofrequency ablation, cryoablation, 1194 
microwave ablation, chemo-embolization) are of value for therapy of advanced 1195 
ACC. We suggest individualization of the decision on the method of choice 1196 
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based on the localization of the tumor lesion(s), local expertise, prognostic 1197 
factors, and patient's preference (+OOO).  1198 
 1199 
Reasoning:  1200 
Published data on local therapies in advanced ACC are very limited {Cazejust, 2010 1201 
#233;Ho, 2013 #234;Polat, 2009 #73;Wood, 2003 #235} and summarized in Appendix 6. 1202 
However, the experience of many panelists provides additional support of efficacy of these 1203 
local measures. Nevertheless, it is impossible to indicate which method is superior. Most 1204 
important, the expertise of the local team in applying these methods should be taken into 1205 
account when discussing this issue with patients in a shared decision-making process.  1206 
 1207 
 1208 
R.8.3. We suggest against the routine use of adrenal surgery in case of widespread 1209 
metastatic disease at the time of first diagnosis (+OOO).  1210 
 1211 
Reasoning: Despite the lack of large studies addressing this particular question, a majority of 1212 
the panel agreed that patients with widespread and unresectable disease will usually not 1213 
benefit from surgery. However, a few panelists suggested that adrenalectomy could be an 1214 
option if technically possible.  1215 
In patients who respond very well to systemic therapy, surgery should be considered at an 1216 
appropriate time point; especially if complete resection becomes feasible ("neo-adjuvant 1217 
approach"). However, the published evidence for such an approach is scant {Rangel, 2013 1218 
#331;Bednarski, 2014 #334}.  1219 
In selected cases (e.g. patients with severe hormone excess) debulking surgery might be an 1220 
option, although anti-hormonal drugs (see R.10.1) should be considered here. In these 1221 
cases, surgery might be especially reasonable if > 80% of the tumor burden can be removed 1222 
safely. In patients with a poor clinical condition and significant localized metastatic burden, 1223 
additional localized therapies (see R.8.2) may be considered as an alternative.  1224 
 1225 
 1226 
R.8.4. In patients with advanced ACC at the time of diagnosis not qualifying for local 1227 
treatment, we recommend either mitotane monotherapy or mitotane + EDP 1228 
depending on prognostic parameters (+++O).  1229 
 1230 
Reasoning:  1231 
Mitotane is the treatment of choice for patients with advanced ACC (for details about the 1232 
management of mitotane see section 5.9). However, a very recent cohort study suggests that 1233 
patients with metastastic disease at the time of primary diagnosis might not be the ideal 1234 
candidates for mitotane monotherapy {Megerle, 2018 #294}. Furthermore, unfavorable 1235 
prognostic parameters (e.g. high tumor burden, uncontrolled symptoms, high proliferative 1236 
index, clinical evidence of a fast growing tumor) are important factors favoring a more 1237 
aggressive/more rapidly active therapeutic approach. If more aggressive therapy is indicated, 1238 
then the combination of EDP in addition to mitotane (EDP-M) is the most validated regimen 1239 
{Fassnacht, 2012 #28}. EDP-M is the only treatment approach in ACC that is successfully 1240 
evaluated in a randomized trial, the FIRM-ACT study. It has to be highlighted, however, that 1241 
only progression-free survival was significantly improved in comparison to the alternative 1242 
therapy (in this case streptozotocin plus mitotane; 5.0 vs. 2.1 months; HR 0.55; 95% CI 0.43 1243 
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to 0.69; P<0.001)), whereas for overall survival the crossover design might have diluted the 1244 
results (14.8 vs 12.0 months, HR 0.79; 95% CI, 0.61 to 1.02; P=0.07).  1245 
The administration of EDP-M comes with risk of adverse events and it is important that the 1246 
treatment will be administered by physicians with sufficient experience in oncology 1247 
treatments. All cytotoxic drugs induce asthenia, nausea, vomiting and reversible 1248 
myelotoxicity. In addition, etoposide might lead (among other adverse effects) to liver toxicity 1249 
and reversible alopecia, doxorubicin to congestive heart failure and reversible alopecia; 1250 
cisplatin to renal toxicity, otoxicity, peripheral neuropathy. In some patients, the risks might 1251 
even outweigh the benefits (especially in patients with reduced performance status). If there 1252 
are concerns about the use of doxorubicin, cisplatin/carboplatin with or without etoposide 1253 
(EP or P) might be an alternative option. Carboplatin may be an alternative to cisplatin, 1254 
particularly when cardiac or renal function is compromised. Again, in this cohort, loco-1255 
regional treatment options may be particularly applicable. 1256 
Several studies have tried to find biomarkers that predict response to cytotoxic therapy in 1257 
ACC {Ronchi, 2009 #320;Malandrino, 2010 #335;Roca, 2017 #319;Laufs, 2018 #336}. 1258 
However, no reliable marker could be identified yet.  1259 
A few centers prefer the combination of etoposide and cisplatin (EP), because there is no 1260 
single study proving that EDP is truly superior to EP. In patients with poor overall health 1261 
cisplatin with mitotane may be an option. However, the evidence for etoposide + cisplatin or 1262 
cisplatin alone is based only on small phase II studies {Bonacci, 1998 #199;Bukowski, 1993 1263 
#200;Williamson, 2000 #213}.  1264 
There is limited evidence that standard chemotherapeutic agents may be more active in the 1265 
presence of elevated mitotane concentrations {Bates, 1991 #295; Fassnacht, 2012 1266 
#28;Sperone, 2010 #32}, but the panel is not in favor in delaying cytotoxic therapy for this 1267 
reason for more than 14 days. Several centers start mitotane and cytotoxic therapy in 1268 
parallel.  1269 
 1270 
Figure 4: Treatment of advanced ACC 1271 
 1272 
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 1273 
 1274 
EDP Etoposide, Doxorubicin, cisPlatin  1275 
1 only in selected patients (e.g. with severe hormone excess)  1276 
2 The following factors might guide the decision: site of disease involvement, tumor burden, symptoms, tumor 1277 
grade/Ki67 index 1278 
3 The following factors might guide the decision:  site of disease involvement, tumor burden, symptoms, tumor 1279 
grade/Ki67 index, and importantly kinetics of tumor growth  1280 
4 radiotherapy, radiofrequency ablation, cryo ablation, microwave ablation, (chemo-)embolization  1281 
5 Few panelist favored cisplatin + etoposide  1282 
6 For the currently available cytotoxic regimens see Table 6 and contact specialized center.  1283 
 1284 
 1285 
 1286 
R.8.5. In patients with recurrent disease and a disease-free interval of at least 12 1287 
months, in whom a complete resection/ablation seems feasible, we recommend 1288 
surgery or alternatively other local therapies (+OOO). We recommend starting 1289 
mitotane as soon as possible after the intervention.  1290 
R.8.6. We recommend EDP-M as first line treatment if the time interval between last 1291 
surgery/loco-regional therapy and recurrence is less than 6 months (++OO), 1292 
rather than repeat loco-regional measures.  1293 
R.8.7. For all other patients with recurrent disease an individualized approach is 1294 
needed.  1295 
 1296 
Reasoning:  1297 
It has been suggested that patients with a disease-free interval of 12 months or more have a 1298 
significantly better prognosis and long-term disease control is achievable, if loco-regional 1299 
measures are successful {Datrice, 2012 #118;Erdogan, 2013 #55}. The choice of different 1300 
loco-regional therapies depends again on benefit/risk ratio, local availability and expertise, 1301 
and the clinical scenario in a given individual patient. Most panelists favor surgery (if 1302 
complete resection is feasible) followed by mitotane therapy.  1303 
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If the recurrence occurs during adjuvant mitotane therapy, additional measures could be 1304 
considered. In patients with local recurrence, adjuvant radiation therapy after surgery should 1305 
be discussed. In other scenarios, additional administration of cytotoxic drugs should be 1306 
discussed with the patient, particularly when mitotane blood levels were in the recommended 1307 
range > 14 mg/l. 1308 
Patients with early recurrence usually suffer from a very aggressive tumor, which most likely 1309 
cannot be controlled by surgery or localized therapies. Decision-making should incorporate 1310 
the concern that any local measure will only delay the administration of systemic therapy. 1311 
Similar to the discussion to R.9.3, the FIRM-ACT data indicate EDP-M as the most effective 1312 
form of therapy. An exception might be patients in whom incomplete initial surgery is the 1313 
most likely cause for early progression. In these selected patients repeat surgery at an expert 1314 
center might be an appropriate alternative (see R.3.6).  1315 
Patients with recurrence between 6 and 12 months after primary surgery usually have a poor 1316 
prognosis and would, therefore, benefit from a more aggressive therapeutic approach (e.g. 1317 
EDP-M). However, this decision should be discussed with the patient taking into account 1318 
prognostic parameters (see section 5.5.), the feasibility of a R0 resection and patient’s 1319 
general condition. Patients with a disease-free interval > 12 months, in whom complete 1320 
resection or loco-regional therapy is not feasible and who are currently not treated with 1321 
mitotane, might be good candidates for mitotane monotherapy {Megerle, 2018 #294}.  1322 
 1323 
 1324 
R.8.8. In patients who progress under mitotane monotherapy, we recommend to add 1325 
EDP (+++O).  1326 
 1327 
Reasoning:  1328 
Mitotane is a slow-acting drug and in patients with rapidly progressing tumor, it might be too 1329 
slow or not effective enough. In these patients, based on the FIRM-ACT data {Fassnacht, 1330 
2012 #28}, additional administration of EDP is the first choice (for alternatives see Reasoning 1331 
R.8.4.). However, if the tumor burden is limited despite obvious progression, another 2-3 1332 
months mitotane monotherapy could also be justified, particularly if adequate mitotane levels 1333 
have not been achieved. In these cases, additional loco-regional options should be 1334 
considered.  1335 
 1336 
 1337 
R.8.9. In patients who respond to medical therapy (including achievement of long-1338 
term stable disease), we suggest re-considering local measures aiming at long-1339 
term tumor control. Such an approach could be also considered in patients 1340 
attaining a generally good control of the disease, in which a limited number of 1341 
lesions are progressing.  1342 
 1343 
Reasoning:  1344 
In some patients, in whom long-term disease control could be achieved, loco-regional 1345 
measures (in addition to ongoing medical therapy) might be able to reach complete 1346 
remission or at least significantly reduce tumor burden {Berruti, 2005 #24}. In patients with 1347 
"mixed responses"; e.g. progressive disease limited to few lesions, loco-regional options 1348 
might be reasonable to add to the ongoing medical therapy.  1349 
 1350 
 1351 
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R.8.10. In patients who progress under EDP-M we suggest considering additional 1352 
therapies including clinical trials on an individual basis (+OOO). 1353 
 1354 
Reasoning:  1355 
Several drugs and drug combinations have been tested in advanced ACC. However, except 1356 
EDP-M none of them has been successfully evaluated in large randomized trials. Figure 2 1357 
outlines the outcomes of the different approaches. However, this figure has to be interpreted 1358 
with great caution, because differences in the characteristics of the patients included in the 1359 
different cohorts preclude direct comparison between studies. Therefore, it is not possible to 1360 
draw definitive conclusions. Due to the limited treatment options, the panel clearly favors 1361 
enrollment of patients with progressing tumors in clinical trials investigating experimental 1362 
therapies including phase I trials. However, the panel felt that despite the lack of convincing 1363 
data, some guidance might be helpful for patients that cannot be enrolled in clinical trials 1364 
(Table 6). Beyond cisplatin-based therapies, the two reasonably well-studied second-line 1365 
cytotoxic regimens are gemcitabine + capecitabine (+/- mitotane) {Henning, 2017 1366 
#215;Sperone, 2010 #32} and streptozotocin + mitotane {Khan, 2000 #296;Fassnacht, 2012 1367 
#28}. However, objective response rates are clearly below 10% and median progression-free 1368 
survival (PFS) is generally <4 months, but a few patients with long-term disease control and 1369 
even complete responses in single patients are described. Nevertheless, a few panelists 1370 
argued against the use of streptozotocin, because median PFS in the FIRM-ACT trial was 1371 
only two months {Fassnacht, 2012 #28}. As for EDP, these cytotoxic drugs should be 1372 
administered only by physicians experienced with chemotherapy. Typical adverse effects of 1373 
streptozotocin are nausea, vomiting, diarrhea, renal and liver toxicity and of the association 1374 
gemcitabine and capecitabine nausea, vomiting and reversible myelotoxicity. 1375 
Loco-regional measures can be particularly useful when progression is limited, or only 1376 
affects limited areas (e.g. single organs). In these cases, such localized therapies (see 1377 
R.8.2) might be able to provide higher response rates for these specific organ/tissue areas 1378 
than second line systemic options. 1379 
Several tyrosine kinase inhibitors have been investigated in advanced ACC {Berruti, 2012 1380 
#23;Fassnacht, 2015 #27;Kroiss, 2012 #207;O'Sullivan, 2014 #209}, but the results were 1381 
largely disappointing. However, in retrospect, drug efficacy could have been hampered by 1382 
increased metabolism of the TKI due to mitotane-induced CYP3A4 activity. Nevertheless, 1383 
currently no specific TKI can be suggested for the treatment of advanced ACC. Targeting the 1384 
IGF2/IGF receptor signaling pathway was pathophysiologically a very promising approach 1385 
and initial small studies suggested some efficacy {Almeida, 2008 #303;Boulle, 1998 1386 
#304;Gicquel, 1994 #305;Giordano, 2003 #306;Weber, 2000 #307;Haluska, 2010 1387 
#204;Jones, 2015 #299;Lerario, 2014 #216;Naing, 2011 #301;Naing, 2013 #208}. However, 1388 
the large placebo-controlled phase III GALACCTIC trial demonstrated that the IGF1R 1389 
inhibitor linsitinib did not improve progression-free or overall survival {Fassnacht, 2015 #27}. 1390 
Therefore, monotherapy with drugs targeting this pathway are not reasonable for therapy in 1391 
an unselected patient population.  1392 
 1393 
 1394 
Table 6: Systemic therapies for recurrent / advanced ACC  1395 
 
First-line therapies (see text for details) 
 
• Surgery +/- other local measures (see R.8.1 and R.8.4) 
 
41 
 
• Mitotane monotherapy  
- details on the management see section 5.9. 
 
• Etoposide, Doxorubicin and Cisplatin (EDP) plus Mitotane (EDP/M) {Fassnacht, 2012 #28} 
every 28 days: 
day 1  40mg/m2 doxorubicin (D) 
day 2  100mg/m2 etoposide (E) 
day 3+4 100mg/m2 etoposide (E) + 40mg/m2 cisplatin (P) 
plus oral mitotane aiming at a blood level between 14-20mg/l.  
 
In patients unfit for the EDP-M regimen, (E)P-M may constitute a reasonable alternative.  
Every 28 days 
day 1  100mg/m2 etoposide (E) 
day 2+3 100mg/m2 etoposide (E) + 40mg/m2 cisplatin (P) 
 
 
Additional therapeutic options 
 
• Consider enrollment of patients in clinical trials (www.clinicaltrial.gov) 
 
• Consider loco-regional therapies 
 
• Gemcitabine plus capecitabine {Henning, 2017 #215;Sperone, 2010 #32}  
800 mg/m2 gemcitabine on day 1 and 8 (repeated every 3 weeks) 
1,500 mg capecitabine orally per day in a continuous fashion 
Mitotane can be continued (individualized decision) 
 
• Streptozotocin plus Mitotane (Sz/M) {Fassnacht, 2012 #28} 
induction: day 1-5: 1g Sz/d 
afterwards 2g/d Sz every 21 days 
plus oral mitotane aiming at a blood level between 14-20mg/l 
 
 1396 
 1397 
R.8.11. The optimal timing of mitotane discontinuation is currently unknown and the 1398 
panel could not come to a specific recommendation on this issue. 1399 
 1400 
Reasoning:  1401 
A recent cohort study reported that discontinuation of mitotane should be considered in 1402 
patients who experienced progressive disease after one year of mitotane therapy {Vezzosi, 1403 
2018 #308}. Part of the panel considers mitotane discontinuation when there is progressive 1404 
disease despite mitotane blood levels above 14 mg/L while others often continue mitotane 1405 
indefinitely in their practice. Tolerability of treatment is an important issue to consider in this 1406 
decision. Moreover, it has to be considered that CYP3A4 induction by mitotane can greatly 1407 
enhance metabolism of many drugs {Kroiss, 2011 #72}, including a number of experimental 1408 
anti-ACC compounds, and so potentially limit their effectiveness.   1409 
42 
 
5.9. Special considerations on mitotane 1410 
 1411 
If mitotane therapy is started (independent of the clinical scenario) the following issues have 1412 
to be considered. 1413 
 1414 
R.9.1. We recommend starting therapy with mitotane in an escalating regimen 1415 
depending on the performance status of the patient as well as the tolerability in 1416 
the first weeks.  1417 
 1418 
Reasoning 1419 
There are different regimens to administer mitotane, but none of them has been proven to be 1420 
superior. In patients with good performance status some panelists use a high starting dose 1421 
approach: mitotane is administered at a starting dose of 1.5 g/day and if well-tolerated from a 1422 
gastrointestinal perspective the dose is increased on day two to 3 g/day, on day three to 4.5 1423 
g/day, and on day four to 6 g/day {Faggiano, 2006 #309;Mauclere-Denost, 2011 #310}. This 1424 
dosage will be administered until first mitotane blood level is assessed. In this high dose 1425 
regimen, it is strongly recommended to measure mitotane blood levels 2-3 weeks after 1426 
initiation of therapy. Afterwards dosage will be adjusted according to blood concentrations 1427 
and tolerability. Other panelists prefer a low starting dose approach. With this approach, 1428 
mitotane is administered at a starting dose of 1 g/day and increased when there is good 1429 
gastrointestinal tolerance every 3 days by 0.5 g up to a total dose of 3.0 - 4.0 g/day and then 1430 
adjusted according to blood concentrations and tolerability {Terzolo, 2000 #311;Terzolo, 1431 
2008 #364;Terzolo, 2014 #363}.  1432 
In a formal comparative pharmacokinetic study, the high-dose starting regimen led to slightly 1433 
higher mitotane plasma levels within 12 weeks of treatment, and more patients reached the 1434 
target level of 14 mg/L {Kerkhofs, 2013 #38}. However, these results were not statistically 1435 
significant due to lack of power. Beyond these two regimens, there is a variety of other 1436 
possibilities and choice depends on personal practice, clinical scenario and patient 1437 
conditions.  1438 
Mitotane is a lipophilic drug and is supposed to be better absorbed from the gut with a high 1439 
fat content of the diet, e.g. with milk or chocolate. {Moolenaar, 1981 #374}. In case of limited 1440 
gastrointestinal tolerance, symptomatic treatments of nausea and or diarrhea may be 1441 
proposed. 1442 
 1443 
R.9.2. We recommend monitoring of blood concentration of mitotane. The general aim 1444 
is to reach a mitotane blood level above 14 mg/L (+OOO). 1445 
 1446 
Reasoning 1447 
As long as mitotane plasma levels are increasing and have not yet reached a plateau at 1448 
>14mg/L, mitotane plasma levels will be assessed every 3-4 weeks. Mitotane plasma level 1449 
determination is best done as morning trough sampling, at least 12 hours after the last dose, 1450 
preventing false high levels {Kerkhofs, 2014 #351}. When mitotane plasma levels have 1451 
reached a plateau, it is usually sufficient to measure blood levels every 6-12 weeks.  1452 
Usually it takes several weeks (sometimes months) to reach mitotane levels > 14 mg/L. As 1453 
long as the concentration is < 14 mg/L it is reasonable to continue to increase the dosage if 1454 
this is tolerated by the patient. Due to slow pharmacokinetic characteristics, the dose of 1455 
mitotane can be reduced in most patients as soon as a plasma level of > 14mg/L is reached. 1456 
Over time, mitotane dosage will be titrated to the best tolerable dose while maintaining a 1457 
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plasma level >14mg/L. Most patients experience adverse effects to a certain extent and 1458 
these usually correlate with the plasma mitotane level (although there is major inter-individual 1459 
variability) (see Table 7). However, some gastrointestinal adverse effects (like diarrhea) 1460 
seem to correlate more with the oral dosage than with the plasma level and occur more 1461 
frequently in the first phase of treatment {Terzolo, 2000 #311;Allolio, 2006 #236;Daffara, 1462 
2008 #25;Terzolo, 2008 #364;Terzolo, 2014 #363}. Several studies {van Slooten, 1984 1463 
#312;Baudin, 2001 #197;Haak, 1994 #202} have shown that CNS-related adverse events in 1464 
particular occur more frequently when the plasma mitotane is > 20 mg/L. Therefore, many 1465 
experts recommend aiming to keep plasma concentrations below 20 mg/L. However, it can 1466 
be speculated that higher plasma levels may also be associated with better clinical efficacy. 1467 
Furthermore, some patients do not experience relevant adverse events even at plasma 1468 
levels well above 20 mg/L. Regarding the lower limit it has to be acknowledged that in at 1469 
least a few patients objective responses are seen even though plasma levels of >14 mg/l 1470 
were not achieved {Megerle, 2018 #294}. Therefore, some panelists favored a target range 1471 
of plasma mitotane of 8-30 mg/L, whereas others aim at an individualized target level of 1472 
mitotane.  1473 
 1474 
Most studies addressing plasma mitotane levels analyze patients with advanced disease. 1475 
However, there is one study suggesting that the same target level is also reasonable for the 1476 
adjuvant setting {Terzolo, 2013 #313}. Therefore, the panel is in favor to use the same 1477 
approach for both patient groups.  1478 
 1479 
 1480 
R.9.3. We recommend glucocorticoid replacement in all patients treated with mitotane 1481 
(except those with ongoing cortisol excess). We suggest to using 1482 
hydrocortisone/cortisone acetate for this purpose. Due to increased steroid 1483 
clearance and increase cortisol-binding globulin at least twice the standard 1484 
replacement dose is usually required. 1485 
 1486 
Reasoning 1487 
A possible strategy is to start concomitant treatment on day one of mitotane treatment with 1488 
hydrocortisone 20 mg/d. Alternatively, patients can be instructed to start hydrocortisone later 1489 
(e.g. after 2-3 weeks or in case they experience adrenal insufficiency), because impairment 1490 
of glucocorticoid effectiveness is rarely observed within the first few weeks. Due to the 1491 
increased clearance and increased cortisol-binding globulin {Daffara, 2008 #25;Chortis, 2013 1492 
#52;Reimondo, 2017 #349;Kerkhofs, 2015 #39} with increasing mitotane plasma levels and 1493 
based on clinical symptoms, the total hydrocortisone replacement dose will usually increased 1494 
to a typical total daily dose of 50 mg in two or three divided doses. However, some patients 1495 
require daily dosages up to 100 mg. There is no reliable laboratory marker to guide the 1496 
optimal dosage of hydrocortisone {Reimondo, 2017 #349}, which has to be based on clinical 1497 
judgment similar to the management of patients with adrenal insufficiency {Bornstein, 2016 1498 
#314}. Mitotane-induced increase in cortisol-binding globulin may confound interpretation of 1499 
serum cortisol measurement. The measurement of free cortisol may offer additional 1500 
information, but more studies are required to clarify the value of this method {Alexandraki, 1501 
2010 #325}. Some panelists measure plasma ACTH and use ACTH levels more than 2-fold 1502 
of the upper limit of normal as evidence for insufficient glucocorticoid replacement. Other 1503 
centers prefer a combined measurement of plasma ACTH and 24-hour urine free cortisol 1504 
levels to assess adequacy of and optimize glucocorticoid replacement for patients receiving 1505 
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mitotane. However, when urinary cortisol is measured by immunoassays, interference by 1506 
cortisol metabolites induced by mitotane might occur.  1507 
In case of acute adverse events and/or hospital admission, patients should be treated 1508 
intravenously with high-dose hydrocortisone (e.g. 100 mg TID) until resolution of symptoms.  1509 
Some patients experience symptoms and signs of insufficient mineralocorticoid activity 1510 
(hyperkalemia, hyponatremia, hypotension, decreased wellbeing) despite full-dose 1511 
substitution with hydrocortisone. In these patients, addition of fludrocortisone should be 1512 
considered. Clinical judgment, electrolytes, and plasma renin concentration can be used for 1513 
decision making whether to start fludrocortisone {Allolio, 2006 #236;Daffara, 2008 1514 
#25;Terzolo, 2008 #364;Terzolo, 2014 #363}.  1515 
 1516 
 1517 
R.9.4. We recommend regular monitoring of mitotane-induced adverse effects (Table 1518 
7) and to treat them appropriately (Table 8). To increase tolerability of mitotane, 1519 
we suggest starting supportive therapy ideally before severe toxicity occurs. 1520 
 1521 
Reasoning 1522 
In addition to adrenal insufficiency (see R.9.3.) mitotane treatment comes with a plethora of 1523 
potential adverse events {Daffara, 2008 #25}(Table 2). Therefore, it is important to evaluate 1524 
the patients regularly (e.g. in the first 6 months every 3-4 weeks, thereafter every 6-12 1525 
weeks).  1526 
Gastrointestinal adverse effects are frequent, particularly in the first months of therapy. 1527 
Supportive therapy should include antiemetic and anti-diarrheal medication, as needed. 1528 
Some centers even start supportive therapy at initiation of mitotane therapy. However, one 1529 
has to be aware that nausea may also be a sign of adrenal insufficiency that needs 1530 
recognition and appropriate treatment. Nevertheless, it should be emphasized that despite 1531 
optimization of dosing schedules, the key factor influencing build-up of appropriate mitotane 1532 
plasma levels is patient tolerability, so efforts should be made in order to optimize this. 1533 
In case of central nervous system (CNS) adverse effects grade 2 (moderate) and/or gastro-1534 
intestinal adverse effects grade 3 (severe, but not life-threatening), mitotane dose should be 1535 
reduced by 1-1.5 gram/day. In case of CNS severe, but not life-threatening (grade 3) adverse 1536 
effects or any relevant grade 4 toxicity (life-threatening), and/or increase of liver enzymes >5 1537 
times baseline (except GGT), mitotane should be interrupted until significant improvement of 1538 
symptoms occurs and be restarted at 50–75% of the last dose. 1539 
Assessment of thyroid hormone status (TSH, FT4, every 3 months) is advised as mitotane 1540 
may induce a clinical picture similar to central hypothyroidism {Daffara, 2008 #25;Russo, 1541 
2016 #365}, possibly through a direct effect on the pituitary gland or induction of thyroid 1542 
hormone metabolism. Replacement therapy with levothyroxine can be considered for these 1543 
patients. 1544 
In men with signs of hypogonadism, assessment of testosterone and sex hormone-binding 1545 
globulin levels is warranted, as hypogonadism is common {Daffara, 2008 #25}. Mitotane-1546 
induced increase in SHBG may confound interpretation of testosterone measurement. 1547 
Testosterone supplementation may be considered in patients with low testosterone and 1548 
symptoms of hypogonadism, but inhibition of 5-α reductase might prevent full activity of 1549 
testosterone {Chortis, 2013 #52}.  1550 
Ovarian steroid synthesis is less affected but women in childbearing age treated with 1551 
mitotane may develop multiple, and sometimes huge, ovarian cysts that may be painful and 1552 
sometimes require treatment. 1553 
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Cholesterol levels very frequently increase during mitotane treatment {Tada, 2014 #332}. 1554 
Hypercholesterolemia can be treated with statin therapy using agents not metabolized by 1555 
CYP3A4 (e.g. rosuvastatine or pravastatine). However, HDL cholesterol is usually also 1556 
elevated significantly and this should be taken in consideration. Thus, statin therapy might 1557 
only be beneficial in selected patients (e.g. with good prognosis in an adjuvant setting, high 1558 
LDL cholesterol and additional high cardiovascular risk factors). Therefore, an indivdual 1559 
decision making regarding the benefits of any lipid lowering therapy is necessary. 1560 
Psychological and social aspects of treatment should not be neglected, i.e., professional 1561 
counseling may be warranted. Follow-up on patient’s well-being may be performed by 1562 
questionnaire-based assessment of toxicity upon the start of the treatment and by repeating 1563 
this assessment every 3 months. 1564 
 1565 
 1566 
R.9.5. We recommend being aware of significant drug interactions of mitotane (e.g. 1567 
due to strong induction of CYP3A4). All concomitant medication should be 1568 
checked for CYP3A4 interactions and substituted for an alternative if necessary 1569 
and available. Other care-providers should be advised not to initiate other drug 1570 
therapies without consultation. 1571 
 1572 
Reasoning 1573 
A comprehensive (but not exhaustive) summary of relevant drug interactions with mitotane is 1574 
provided in Kroiss et al. {Kroiss, 2011 #72} and in the Appendix 7.  1575 
 1576 
 1577 
 1578 
Table 7: Adverse effects during mitotane treatment*   1579 
 1580 
Adverse Effect Frequency 
• Gastrointestinal: nausea, vomiting, diarrhea, anorexia very common  
• Adrenal insufficiency very common  
• CNS: lethargy, somnolence, vertigo, ataxia  
Confusion, depression, dizziness, decreased memory 
common  
common 
• Increase of hepatic enzymes (in particular gamma-GT) very common  
• Liver failure rare 
• Hepatic microsomal enzyme induction with 
increased metabolism of glucocorticoids and other steroids  
and barbiturates, phenytoin, warfarin, and many other drugs (see Appendix 7) 
 
very common  
common 
• Increase in hormone-binding globulins (CBG, SHBG, TBG, etc.) very common  
• Disturbance of thyroid parameters (interference with binding of T4 to TBG, total 
T4↓, free T4↓, TSH↓) 
very common  
• Hypercholesterolemia, hypertriglyceridemia  very common  
• Gynecomastia very common 
• Skin rash common 
• Primary hypogonadism in men common 
• Prolonged bleeding time common 
• Leucopenia common 
• Thrombocytopenia, anemia rare 
• Autoimmune hepatitis rare 
• Cardiovascular: hypertension  not known 
• Ocular: blurred or double vision, toxic retinopathy, cataract, macular edema not known 
• Hemorrhagic cystitis not known 
  
*modified by the authors based on information published by the European Medicine Agency 1581 
(EMA): 1582 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000521/human1583 
_med_000895.jsp&mid=WC0b01ac058001d124 and clinical experience 1584 
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Frequency is defined according to the following convention: very common (≥1/10), common 1585 
(≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare 1586 
(<1/10,000), Not known (cannot be estimated from the available data) 1587 
 1588 
 1589 
  1590 
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Table 8: Monitoring during mitotane treatment  1591 
 1592 
Parameter Interval Comment 
Recommended monitoring  
Mitotane blood 
level 
Every 3-4 weeks, as soon 
as plateau of blood level is 
reached every 2-3 months 
Target blood level > 14 mg/L (details see R.9.2) 
GOT, GPT, 
bilirubin, (gGT) 
Initially every 3-4 weeks, 
after 6 months every 2-3 
months 
GGT is invariably elevated without clinical consequences. If other 
liver enzymes are rapidly increasing (> 5-fold of baseline), there is 
risk of liver failure: interrupt mitotane 
Blood count Initially after 3-4 weeks, then 
every 3-4 months 
Check for rare and in most cases not significant leucopenia, 
thrombocytopenia, and anemia  
Suggested monitoring  
ACTH Suspected glucocorticoid 
deficiency or excess  
Glucocorticoid status is difficult to determine 
Target: ACTH in the normal range or slightly above 
TSH, fT4 Every 3 – 4 months Disturbance of thyroid hormones is frequent. 
Thyroid hormone replacement is only recommended in patients 
with clinical symptoms of hypothyroidism  
Renin Every 6 months If renin ↑ and clinical symptoms of hypoaldosteronism are present, 
add fludrocortisone 
 
Cholesterol (HDL, 
LDL) 
Every 3-4 months (in 
adjuvant setting) 
If LDL / HDL cholesterol ↑↑ consider treatment with statins in 
selected cases. 
Testosterone and 
SHBG in men 
Every 3-4 months (in 
adjuvant setting) 
If testosterone is low and clinical symptoms of hypogonadism are 
present add testosterone 
 1593 
 1594 
 1595 
5.10. Other supportive therapies 1596 
 1597 
R.10.1. We recommend medical therapy to control hormone excess in all patients with 1598 
clinically relevant hormone-producing ACC.  1599 
 1600 
Reasoning 1601 
Overt glucocorticoid excess causes significant morbidity, such as diabetes, osteoporosis, 1602 
muscle weakness and immunosuppression, conditions that can impact quality of life and 1603 
increase mortality. Mitotane is effective in controlling adrenocortical hormone excess 1604 
syndromes, but its efficacy is delayed by several weeks. In general, mild hormone secretion 1605 
can be effectively managed by mitotane alone. However, severe Cushing syndrome needs a 1606 
more rapid control. Furthermore, these patients should receive appropriate anticoagulation 1607 
and also pneumocystis directed antibiotic prophylaxis until cortisol levels are safely controlled 1608 
{Nieman, 2015 #133}. In selected patients, surgery might even be postponed for few weeks 1609 
until Cushing's syndrome is partly under control with the use of rapid agents inhibiting 1610 
steroidogenesis (i.e. metyrapone). However, some panelists argued that surgery might be 1611 
the fastest way to control severe hypercortisolism.  1612 
Available steroidogenic enzyme inhibitors and steroid receptor antagonists are able to attain 1613 
quick reduction of cortisol effects. Anti-hormonal agents can be initiated together with 1614 
mitotane. Once therapeutic mitotane levels are established, anti-steroidogenic action is also 1615 
maximized, and other anti-hormonal drugs can be reduced guided by tolerability, symptoms 1616 
and biochemical measurements. If possible doses should be titrated to normalization of 1617 
hormone levels, or in the case of receptor antagonists to improved well-being, accepting that 1618 
assessment of this can be challenging in cancer patients. 1619 
Despite the lack of comparative studies, the majority of panel members considers that 1620 
metyrapone is the first therapeutic choice for the management advanced ACC patients with 1621 
severe Cushing syndrome. The drug is well tolerated and can be safely administered in 1622 
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association with mitotane and cytotoxic chemotherapy {Claps, 2017 #131}. Moreover, its 1623 
metabolism and elimination are not altered by concomitant mitotane. Ketoconazole an 1624 
inhibitor of several key cytochrome P450 (CYP) enzymes involved in multiple steps of 1625 
steroidogenesis in the adrenal cortex, is another alternative, but often less effective than 1626 
metyrapone and requires regular monitoring of liver function tests. Its advantage is that it 1627 
also inhibits androgen production. Ketoconazole should be avoided at initiation of mitotane 1628 
therapy because both substances are potentially hepatotoxic and it will be difficult to attribute 1629 
the hepatotoxicity to one or the other drug. Hypercortisolemia can also be treated with 1630 
mifepristone, a glucocorticoid antagonist, but dosing is based on clinical judgement as 1631 
cortisol levels remain elevated or rise further on therapy {Castinetti, 2009 #132}. Moreover, 1632 
the high circulating cortisol levels when on mifepristone may cause mineralocorticoid effects, 1633 
including hypertension and hypokalemia that necessitate treatment with high doses of 1634 
spironolactone. Patients treated with enzyme inhibitors or receptor antagonists need to be 1635 
educated about symptoms and signs of adrenal insufficiency. All patients at risk for adrenal 1636 
insufficiency need to be supplied with emergency medication and instructions. Intravenous 1637 
etomidate can be used for seriously ill patients with severe hypercortisolemia who cannot 1638 
take oral medication.  1639 
In the management of severe Cushing's syndrome, locoregional options (see R.8.2.) should 1640 
also be discussed, in selected cases.  1641 
Androgen excess in women can impact quality of life due to hirsutism and virilization. It can 1642 
be treated with androgen receptor antagonists, such as bicalutamide, flutamide, or 1643 
spironolactone. 1644 
Only a small fraction of all tumors produce aldosterone, leading to hypertension and 1645 
hypokalemia. Mineralocorticoid excess is best treated with mineralocorticoid receptor 1646 
antagonists, such as spironolactone or eplerenone. However, patients with severe Cushing's 1647 
syndrome may also experience hypokalemia, related to mineralocorticoid receptor activation. 1648 
In case of severe hypokalemia, spironolactone and epithelial sodium channel inhibitors such 1649 
as amiloride can be used, potentially at high doses, along with potassium supplementation. 1650 
In such cases, frequent serum electrolyte measurement, initially several times a week, are 1651 
mandatory, as there is a risk of rapid occurrences of hyperkalemia and hyponatremia. 1652 
In the rare situation of estradiol production by tumors in male patients, therapy with estrogen 1653 
receptor antagonists or aromatase inhibitors could be considered. 1654 
 1655 
 1656 
R.10.2. We recommend therapy with anti-resorptive treatment in patients with bone 1657 
metastasis. 1658 
 1659 
Reasoning 1660 
Bone metastasis in cancer patients are associated with poor quality of life due to bone pain 1661 
and increased risk of adverse skeletal-related events (SREs) such as pathological fractures, 1662 
spinal cord compression and hypercalcemia. Several randomized phase III trials have 1663 
demonstrated that bone resorption inhibitors such as bisphosphonates and denosumab are 1664 
efficacious in the prevention of skeletal-related events in patients with bone metastasis from 1665 
breast, prostate, lung and others primary malignancies. No data are available for ACC 1666 
patients. However, based on these results, it has become general practice to treat patients 1667 
with any kind of bone metastasis with anti-resorptive therapies. The administration of 1668 
denosumab or bisphosphonates in 'oncological doses' in association with calcium intake and 1669 
vitamin D supplementation are therefore advisable in ACC patients with metastatic bone 1670 
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disease, with the aim to prevent adverse skeletal-related events and improve control of bone 1671 
pain.  1672 
In patients with ACC with Cushing's syndrome that cannot be otherwise controlled anti-1673 
resorptive treatment, using ‘anti-osteoporotic doses’, should be considered, because it is well 1674 
established that glucocorticoid-excess increases the risk of osteoporotic fractures. Since 1675 
fracture risk declines rapidly after lowering excess cortisol, or antagonizing its effects, anti-1676 
osteoporotic therapies are usually not required once cortisol secretion is controlled (either by 1677 
surgery or medical therapy). 1678 
 1679 
 1680 
R.10.3. We recommend palliative radiation for symptom palliation in 1681 
advanced/metastatic ACC patients  1682 
 1683 
Reasoning 1684 
Palliative radiation therapy is a commonly utilized intervention for symptom relief among 1685 
patients with metastatic cancer. Two schedules of irradiation are commonly used, which 1686 
include 8 Gy in a single fraction or 30 Gy in ten fractions. This treatment modality is highly 1687 
effective in achieving relief of symptoms arising from bone metastases, with positive 1688 
responses in up to 50% - 90% of cancer patients {Chow, 2012 #355;Pin, 2018 #356}. Painful 1689 
bone metastases are, therefore, the main indication of palliative radiation in metastatic ACC 1690 
patients {Polat, 2009 #73}. Other indications are symptomatic recurrences, severe mass 1691 
effect and the rare case of brain metastases. 1692 
 1693 
 1694 
R.10.4. We recommend integrating palliative care into standard oncology care for all 1695 
patients with advanced ACC 1696 
 1697 
Reasoning 1698 
According to the WHO palliative care is defined as ‘an approach that improves the quality of 1699 
life of patients and their families facing the problems associated with life-threatening illness, 1700 
through the prevention and relief of suffering by means of early identification and impeccable 1701 
assessment and treatment of pain and other problems, physical, psychosocial and spiritual’ 1702 
(WHO: WHO definition of palliative care. http://www.who.int/cancer/palliative/definition/en/). 1703 
As previously stated, the goal of care for metastasized ACC is to obtain long-term disease 1704 
control and prolong patient survival. Although prognosis of patients with advanced ACC is 1705 
often poor, there is a patient subset destined to obtain a relatively long survival, while treated 1706 
with antineoplastic therapies. The needs of patients with cancer and their families have 1707 
changed over time. According to the ASCO guidelines the best model to manage metastatic 1708 
patients is to integrate palliative care early in the course of the disease and throughout the 1709 
trajectory of care, extending to long-term survivorship as well as end-of-life (hospice) care. In 1710 
this integrated approach the primary endocrinologists and oncologists focus on the primary 1711 
oncologic disease, and the palliative care team addresses the majority of the patient’s 1712 
physical and psychological concerns. The team plans all therapy aiming to integrate patient 1713 
wishes and employ treatment options balancing quality of life and increased survival with 1714 
therapy associated risks and complications {Ferrell, 2017 #316}.  1715 
 1716 
 1717 
 1718 
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R.10.5. We suggest counseling for fertility protection in female patients in 1719 
reproductive age. Fertility counseling should not only be restricted to patients 1720 
undergoing cytotoxic chemotherapy, but also given to patients who plan to 1721 
embark on mitotane therapy.  1722 
 1723 
Reasoning 1724 
A considerable proportion of patients are diagnosed with ACC during their reproductive 1725 
years. Several drugs used to treat ACC harbor significant risk for impairment of fertility or the 1726 
exact risks are unknown (e.g. mitotane). On the other hand, in recent years several treatment 1727 
options for preservation of fertility have been introduced. However, none of them has gained 1728 
general acceptance. Therefore, we just advise to discuss this topic with every patient. This 1729 
discussion should include the consideration given in section 5.12. on pregnancy and ACC in 1730 
general.  1731 
 1732 
 1733 
 1734 
5.11. Genetic counseling 1735 
 1736 
R.11.1. For adults with ACC, we recommend at least a basic clinical genetic 1737 
evaluation, exploring personal and family history for evidence of a hereditary 1738 
predisposition syndrome.  1739 
 1740 
Reasoning 1741 
The detection of germline mutations impacts on the clinical care and surveillance of index 1742 
patients and offers the possibility to identify at risk family members. Probably, up to 5% of 1743 
adult ACC arise in patients with germline TP53 mutations {Herrmann, 2012 #287;Raymond, 1744 
2013 #289;Waldmann, 2012 #77} and about 3% of all ACC patients have an underlying 1745 
diagnosis of Lynch syndrome {Raymond, 2013 #288;Zheng, 2016 #16}. Special attention 1746 
should be given to these two hereditary syndromes, because for them there are well-1747 
established screening guidelines available {Stoffel, 2015 #367;Daly, 2017 #368;Kratz, 2017 1748 
#370;Ballinger, 2017 #369;Gupta, 2017 #366}. Up to 13% of all adrenal lesions in patients 1749 
with MEN1 represent adrenal cancer (22084155). Cases of ACC have been reported in 1750 
patients with Beckwith-Wiedemann syndrome (children), Familial Adenomatous Polyposis 1751 
(APC) and Carney Complex {Petr, 2016 #34}. 1752 
Germline genetic testing for ACC patients should primarily be considered for the genes 1753 
related to Li-Fraumeni syndrome and Lynch syndrome. ACC is an integral part of Li-1754 
Fraumeni syndrome and when considering germline genetic testing, it is important to keep in 1755 
mind that at least 20% of germline TP53 pathogenic variants occur as de novo mutations in 1756 
the absence of any family history. Lynch syndrome is present in the same fraction of ACC 1757 
patients as in colorectal cancer patients (3-5%), where general screening for Lynch 1758 
syndrome is recommended {Stoffel, 2015 #367;Stoffel, 2015 #372}. Both, Li-Fraumeni 1759 
syndrome and Lynch syndrome have well established surveillance guidelines for carriers of 1760 
pathogenic variants {Stoffel, 2015 #367;Daly, 2017 #368;Kratz, 2017 #370;Ballinger, 2017 1761 
#369;Gupta, 2017 #366}. Evaluation for Lynch syndrome can be initiated by 1762 
immunohistochemistry for MSH2, MLH1, PMS2, MSH6 and microsatellite instability testing, 1763 
or direct genetic germline analysis of MSH2, MLH1, PMS2, MSH6 and EPCAM. Genetic 1764 
diagnosis of Li-Fraumeni syndrome is usually done by germline analysis for variants in TP53. 1765 
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For other syndromes (depending on family history and clinical suspicion) we refer to other 1766 
sources {Petr, 2016 #34;Else, 2012 #290}.  1767 
Although not the topic of this guideline, all children with a diagnosis of ACC should undergo a 1768 
systematic search of germline TP53 pathogenic variants, because 50-90% of ACC in 1769 
children are related to germline pathogenic TP53 variants {McDonnell, 2003 #291;Custodio, 1770 
2013 #293;Wasserman, 2015 #292} 1771 
 1772 
 1773 
R.11.2. The panel does not recommend for or against genetic tumor testing for 1774 
somatic alterations. 1775 
 1776 
Reasoning 1777 
While the panel recognizes that there is great hope that testing for somatic mutations and 1778 
other markers in cancers general may allow tailoring of therapy and personalized 1779 
approaches for therapy, for ACCs this approach is not yet established in routine clinical 1780 
practice. Therefore, molecular testing should be offered within the framework of structured 1781 
and systematic research projects.  1782 
 1783 
 1784 
 1785 
5.12. Pregnancy and ACC 1786 
 1787 
 1788 
R.12.1. When an adrenal mass suspected to be an ACC is diagnosed during 1789 
pregnancy, we recommend prompt surgical resection regardless of pregnancy 1790 
trimester.  1791 
  1792 
Reasoning 1793 
Considering the poor prognosis of ACC and the importance of a prompt and complete 1794 
surgical removal for prognosis, adrenal surgery should be pursued independent of the term 1795 
of the pregnancy {Eschler, 2015 #129}. Preterm delivery (especially in the third trimester) 1796 
and pregnancy loss are obvious risks when surgery is performed. Therefore, the patient and 1797 
their family, obstetric providers and the ACC care team must engage in an informed 1798 
discussion considering disease prognosis and the risk to the mother and fetus as related to 1799 
the underlying disease and interventional procedures. A shared decision-making after 1800 
discussion of all options is imperative.  1801 
 1802 
 1803 
R.12.2. Patients should be informed on pregnancy-related concerns specific to the 1804 
current or past diagnosis of ACC. 1805 
 1806 
Reasoning 1807 
No evidence is available regarding how long patients should wait after the treatment of an 1808 
ACC before they can safely consider pregnancy.  1809 
Importantly, the main concern is the poor prognosis of the malignant tumor and the potential 1810 
that pregnancy could be a negative prognostic factor, possibly increasing the risk of 1811 
recurrence. There is limited evidence that ACC occurring during pregnancy or in the 1812 
postpartum period is associated with a worse prognosis than in non-pregnant women 1813 
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{Abiven-Lepage, 2010 #315}. The hypothesis that pregnancy could favor the development of 1814 
a more aggressive variant of ACC was raised.  1815 
Due to the extreme paucity of information about this issue, it seems prudent to relay the 1816 
information to the patient that there is a substantial risk of disease recurrence in the first 1817 
years following the diagnosis of ACC.  1818 
Since ACC may express estrogen receptors and there are preclinical data showing that 1819 
estrogen may facilitate tumor development and progression through cross-talk with the IGF 1820 
pathway {Sirianni, 2012 #317}, contraceptive measures other than estrogen-containing 1821 
preparations are preferred.  1822 
 1823 
 1824 
R.12.3. We recommend avoiding pregnancy while being on mitotane treatment.  1825 
 1826 
Reasoning 1827 
The main concern with mitotane therapy is the potential of teratogenic effects, due to the 1828 
suspicion that the drug may cross the placenta and cause adrenolytic activity on the human 1829 
fetus. However, there are only few case reports of pregnancies when on mitotane therapy 1830 
{Tripto-Shkolnik, 2013 #130}. Therefore, it is impossible to draw definitive conclusions about 1831 
the safety of mitotane treatment or its associated risks. Woman treated with mitotane should 1832 
be informed about these risks, and ensure effective contraception to avoid pregnancy. 1833 
Moreover, when mitotane treatment is discontinued, it seems wise to ensure undetectable 1834 
mitotane plasma levels before considering pregnancy {de Corbiere, 2015 #318}, which might 1835 
take 3-12 months. In case a patient becomes pregnant while on mitotane therapy, the 1836 
uncertainty regarding risks of mitotane for the fetus should be discussed. In case the patient 1837 
wishes to continue pregnancy mitotane therapy should be withheld.  1838 
 1839 
 1840 
 1841 
 1842 
6. Future directions and recommended research 1843 
 1844 
Due to the fact that the evidence for most of the recommendations provided in these 1845 
guidelines is weak or even very weak, there are no doubts that major efforts are needed to 1846 
improve diagnosis, treatment, and quality of life for patients with ACC.  1847 
Among many important research questions, we selected ten topics as particularly important. 1848 
All of them can only be addressed in an international collaborative interdisciplinary manner.  1849 
1) Clinical response to the best available therapy (i.e. EDP + mitotane) for advanced ACC is 1850 
very limited with an objective response rate of less than 25%. Therefore, we undeniably 1851 
lack efficient drugs for treating this disease. Thus, identifying new therapeutic targets and 1852 
options is a high priority. Here is a comprehensive but by far not complete list of 1853 
emerging therapies: internal radionuclide therapy, such as metomidate-based therapies; 1854 
drugs targeting the following pathways or targets: Wnt/beta-catenin; CDKN2A / TP53 / 1855 
RB; IGF2 / mTOR; telomeres; drugs targeting histone modifications. In general, a 1856 
combined approach seems to be reasonable. There is a growing notion that individual 1857 
patients and individual tumors might respond better to certain therapies, depending on 1858 
their molecular landscape. Therefore, studies focusing on subgroup classification and 1859 
identification are important. Due to the mitotane-associated pharmacological issues (e.g. 1860 
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CYP3A4 induction), it might be reasonable to test experimental drugs in mitotane-naïve 1861 
patients within clinical studies. 1862 
2) Immunotherapy is the latest revolution in cancer therapy, however preliminary data with 1863 
single immune check point inhibitors showed a modest activity in ACC patients. Molecular 1864 
and oncogenic pathways either in tumor cells or tumor microenvironment that can impair 1865 
induction or execution of a local antitumor immune response should be carefully studied in 1866 
ACC. 1867 
3) Since currently available systemic therapies have limited efficacy, but a subgroup of 1868 
patient is destined to obtain a consistent benefit from them, the identification of predictive 1869 
markers of efficacy (either clinical or molecular) of standard treatments is of paramount 1870 
importance in order to spare toxic regimens to patients not destined to obtain a disease 1871 
response. 1872 
4) With regards to improvement of surgery for ACC, standardization of procedures (e.g. 1873 
laparoscopic vs. open surgery, lymph node dissection) should be promoted and tested in 1874 
clinical trials.  1875 
5) The high recurrence rate in the majority of patients even after complete resection calls for 1876 
improvement of adjuvant therapy. There are significant gaps in our understanding, which 1877 
patients might truly benefit from the different adjuvant therapies and prospective trials are 1878 
urgently needed. The ongoing ADIUVO trial will hopefully provide important information for 1879 
low/intermediate risk patients, but a trial in high-risk patients (e.g. mitotane vs. mitotane + 1880 
cisplatin + etoposide) is equally important.  1881 
6) Despite extensive efforts, the mechanism of action and pharmacodynamics of mitotane 1882 
remain poorly understood {Hescot, 2015 #338;Hescot, 2013 #339;Sbiera, 2015 1883 
#337;Hescot, 2017 #340}. In addition, mitotane is a strong inducer of xenobiotics 1884 
metabolism, probably negatively impacting subsequent and parallel therapies. Therefore, 1885 
further understanding and improving the pharmacology and mechanism of action of 1886 
mitotane with the goal of development of mitotane related drugs that do not share the 1887 
negative adverse-effects would be a significant goal. 1888 
7) Translational research with the goal of rational treatment stratification should be promoted. 1889 
Recent molecular classifications, identifying distinct molecular subtypes with different 1890 
outcomes, should be tested prospectively. These markers could provide a cornerstone for 1891 
stratifying treatment strategies. This would mean that some patients of the ‘better 1892 
outcome’ molecular group might benefit from forgoing any adjuvant therapy. Reversely, 1893 
patients in the “poor outcome” molecular group could be included in a randomized trial 1894 
testing mitotane + cytotoxic drugs as an adjuvant therapy. In addition, it will be important 1895 
to define differences in pharmacogenomics or tumor genomics that define exceptional 1896 
responders to mitotane and/or EDP. This data can fuel further sub-stratification of ACC 1897 
patients for certain therapies. 1898 
8) In addition to improving treatment, other future research directions may include the use of 1899 
artificial intelligence in diagnostic work-up of adrenal tumors and the improvement of 1900 
screening and follow-up procedures using non-invasive techniques such as urine or 1901 
serum steroid metabolomics {Arlt, 2011 #48;Kerkhofs, 2015 #40;Taylor, 2017 #341;Hines, 1902 
2017 #342} or ‘liquid biopsies’ with circulating tumor cells {Pinzani, 2013 #343}, circulating 1903 
miRNAs {Chabre, 2013 #344;Szabo, 2014 #345;Perge, 2017 #346}, or circulating cell-free 1904 
tumor DNA {Creemers, 2017 #347;Garinet, 2018 #348} for early diagnosis or detection of 1905 
recurrence.  1906 
9) In the long term, a better understanding of the pathogenesis of ACC is needed to pave the 1907 
way for future progress. Therefore, basic research efforts have to continue. Preclinical 1908 
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models are needed, to test new treatments, including additional new cell lines, tumor 1909 
organoids, and new animal models. Mechanisms of tumorigenesis, tumor evolution 1910 
(genetic heterogeneity, clonal evolution) and further definition of known and future 1911 
therapeutic targets should be encouraged.  1912 
10) No studies so far have revealed the wishes and experiences of patients. Given the poor 1913 
prognosis and the toxic therapies, there is a definite need for ‘Patient Related Outcomes’. 1914 
PRO’s should be measured (PROM’s) and incorporated in our strategy for value based 1915 
cure and care. 1916 
 1917 
In general, it is our common task to overcome the major limitation in ACC research – the 1918 
rarity of this disease. Therefore, beyond proofs of concept requiring few patients, clinical 1919 
trials can only be performed if a large number of centers gather multicenter studies. This 1920 
underscores the critical role of adrenal research networks, such as ENSAT or A5, to 1921 
coordinate these efforts. Ideally a limited number of large prospective trials should 1922 
continuously be ongoing, in order to allow for sufficient patient recruitment. In the same 1923 
context we envision that at least one reference center in every country will be established to 1924 
provide multidisciplinary expertise for this rare disease to all patients.  1925 
 1926 
Altogether, owing to its rarity and its severity, ACC should continue to mobilize researchers, 1927 
physicians and patients in a coordinated engaged effort. 1928 
 1929 
 1930 
 1931 
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Appendices 1933 
• Appendix 1: Question 1: Pathology - what is needed to diagnose an ACC? Summary 1934 
of included studies (1a: distinguishing adrenal from non-adrenal tumors; 1b: 1935 
distinguishing benign from malignant behavior in adrenal tumors) 1936 
• Appendix 2: Question 2: Which are the best prognostic markers in ACC? Summary of 1937 
included studies  1938 
• Appendix 3: Question 2: Prognostic factors in ACC - overview of studies markers 1939 
• Appendix 4: Question 3: Is adjuvant therapy able to prevent recurrent disease or 1940 
reduce mortality after radical resection? Summary of included studies (3a: Adjuvant 1941 
mitotane after surgery; 3b: Adjuvant radiotherapy after surgical resection) 1942 
• Appendix 5: Evidence tables Question 3 (adjuvant therapy) 1943 
• Appendix 6: Question 4: What is the best treatment option for macroscopically 1944 
incompletely resected, recurrent or metastatic disease? Summary of included studies 1945 
• Appendix 7: Summary of relevant drug interactions with mitotane 1946 
• Appendix 8: Comments to this Guidelines by invited reviewers and members of the 1947 
European Society of Endocrinology (ESE) and the European Network for the Study of 1948 
Adrenal Tumors (ENSAT), representatives of associated societies of ESE, and 1949 
patient representatives 1950 
 1951 
 1952 
Funding 1953 
This guideline was sponsored by the European Society of Endocrinology with support by the 1954 
European Network for the Study of Adrenal Tumors. 1955 
 1956 
Acknowledgements 1957 
The authors of the guideline would like to thank and acknowledge Mouhammed Habra, 1958 
Electron Kebebev, and Britt Skogseid for their expert review and additional members of the 1959 
European Society of Endocrinology, the European Network for the Study of Adrenal Tumors 1960 
55 
 
or representatives of national endocrine societies for valuable and critical comments. In 1961 
addition, we thank 3 patient representatives who provided valuable feedback for the 1962 
guideline. The comments of the reviewers as well as the authors’ responses are available as 1963 
Appendix 8. Furthermore, we thank John Newell-Price for very helpful English proof-reading.  1964 
Finally we would like to thank Annemarie Venemans for her support in the systematic 1965 
literature search.  1966 
 1967 
 1968 
Declaration of potential conflict of interests (in the last 5 years) 1969 
 1970 
Guillaume Assié  1971 
• Speakers fee / travel support for congresses from: HRA Pharma (2016); Ipsen 1972 
Pharma (2013, 2014); Novartis (2012, 2013, 2014, 2015, 2016) 1973 
 1974 
Eric Baudin  1975 
• Speakers fee: HRA Pharma 1976 
• Research support by HRA Pharma 1977 
 1978 
Alfredo Berruti 1979 
• Member to remunerated Advisory Boards of Astellas, Sanofi, Janssen, Merck Sharp 1980 
and Dome, Novartis, Ipsen  1981 
• Speakers fee / travel support for congresses from: Astellas, Sanofi, Janssen, 1982 
Novartis, Ipsen  1983 
• Research support by Janssen (Phase II trial of Abiraterone in the management of 1984 
Cushing Syndrome induced by Adrennocortical Carcinoma; 2016); Sanofi: Phase II 1985 
trial of Cabazitaxel as second line treatment in the treatment of patients with 1986 
advanced Adrenocortical Carcinoma; 2014)  1987 
 1988 
Martin Fassnacht  1989 
• Advisory board member: of HRA Pharma (2015; not remunerated); Atterocor (2013); 1990 
Astellas Pharma (2012) 1991 
• Speakers fee / travel support for congresses from: HRA Pharma (2013); Ipsen 1992 
Pharma (2011, 2012) 1993 
 1994 
Harm Haak  1995 
• Research support by HRA Pharma (2016) 1996 
 1997 
Massimo Terzolo -  1998 
• Advisory Board member of HRA Pharma (2013; not remunerated), Atterocor-Millendo 1999 
(2013-2015) 2000 
• Research support by HRA Pharma (2016) 2001 
• Speaker fee/travel support from HRA Pharma (2014, 2015) 2002 
 2003 
The other authors declare no conflict of interest.  2004 
 2005 
  2006 
56 
 
References 2007 
1 Kebebew E, Reiff E, Duh QY, Clark OH & McMillan A. Extent of disease at 2008 
presentation and outcome for adrenocortical carcinoma: have we made progress? World 2009 
Journal of Surgery 2006 30 872–878. (https://doi.org/10.1007/s00268-005-0329-x) 2010 
2 Kerkhofs TM, Verhoeven RH, Van der Zwan JM, Dieleman J, Kerstens MN, Links TP, 2011 
Van de Poll-Franse LV & Haak HR. Adrenocortical carcinoma: a population-based study on 2012 
incidence and survival in the Netherlands since 1993. European Journal of Cancer 2013 49 2013 
2579–2586. (https://doi.org/10.1016/j.ejca.2013.02.034) 2014 
3 Berruti A, Baudin E, Gelderblom H, Haak HR, Porpiglia F, Fassnacht M & 2015 
Pentheroudakis G. Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, 2016 
treatment and follow-up. Annals of Oncology 2012 23 131–138. 2017 
4 Petr EJ & Else T. Genetic predisposition to endocrine tumors: diagnosis, surveillance 2018 
and challenges in care. Seminars in Oncology 2016 43 582–590. (https://doi.org/10.1053/j. 2019 
seminoncol.2016.08.007) 2020 
5 de Reynies A, Assie G, Rickman DS, Tissier F, Groussin L, Rene- Corail F, Dousset 2021 
B, Bertagna X, Clauser E & Bertherat J. Gene expression profiling reveals a new 2022 
classification of adrenocortical tumors and identifies molecular predictors of malignancy and 2023 
survival. Journal of Clinical Oncology 2009 27 1108–1115. (https://doi. 2024 
org/10.1200/JCO.2008.18.5678) 2025 
6 Fragoso MC, Almeida MQ, Mazzuco TL, Mariani BM, Brito LP, Goncalves TC, 2026 
Alencar GA, Lima L de O, Faria AM, Bourdeau I et al. Combined expression of BUB1B, 2027 
DLGAP5, and PINK1 as predictors of poor outcome in adrenocortical tumors: validation in  a 2028 
Brazilian cohort of adult and pediatric patients. European Journal of Endocrinology 2012 166 2029 
61–67. (https://doi.org/10.1530/EJE-11-0806)  2030 
7 Ronchi CL, Sbiera S, Leich E, Henzel K, Rosenwald A, Allolio B & Fassnacht M. Single 2031 
nucleotide polymorphism array profiling of adrenocortical tumors – evidence for an adenoma 2032 
carcinoma sequence? PLoS ONE 2013 8 e73959. (https://doi.org/10.1371/ 2033 
journal.pone.0073959) 2034 
8 Jouinot A, Assie G, Libe R, Fassnacht M, Papathomas T, Barreau O, de la Villeon B, 2035 
Faillot S, Hamzaoui N, Neou M et al. DNA methylation is an independent prognostic marker 2036 
of survival in adrenocortical cancer. Journal of Clinical Endocrinology and Metabolism 2017 2037 
102 923–932. 2038 
9 Assie G, Letouze E, Fassnacht M, Jouinot A, Luscap W, Barreau O, Omeiri H, 2039 
Rodriguez S, Perlemoine K, Rene-Corail F et al. Integrated genomic characterization of 2040 
adrenocortical carcinoma. Nature Genetics 2014 46 607–612. 2041 
(https://doi.org/10.1038/ng.2953) 2042 
10 Juhlin CC, Goh G, Healy JM, Fonseca AL, Scholl UI, Stenman A, Kunstman JW, 2043 
Brown TC, Overton JD, Mane SM et al. Whole-exome sequencing characterizes the 2044 
landscape of somatic mutations and copy number alterations in adrenocortical carcinoma. 2045 
Journal of Clinical Endocrinology and Metabolism 2015 100 E493–E502. (https:// 2046 
doi.org/10.1210/jc.2014-3282) 2047 
11 Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, Lerario AM, 2048 
Else T, Knijnenburg TA, Ciriello G et al. Comprehensive pan-genomic characterization of 2049 
adrenocortical carcinoma. Cancer Cell 2016 29 723–736. 2050 
(https://doi.org/10.1016/j.ccell.2016.04.002) 2051 
57 
 
12 Assie G, Jouinot A & Bertherat J. The ‘omics’ of adrenocortical tumours for 2052 
personalized medicine. Nature Reviews Endocrinology 2014 10 215–228. 2053 
(https://doi.org/10.1038/nrendo.2013.272) 2054 
13 Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM, Jolly S, Miller BS, 2055 
Giordano TJ & Hammer GD. Adrenocortical carcinoma. Endocrine Reviews 2014 35 282–2056 
326. (https://doi. org/10.1210/er.2013-1029) 2057 
14 Faillot S & Assie G. ENDOCRINE TUMOURS: The genomics of adrenocortical 2058 
tumors. European Journal of Endocrinology 2016 174 R249–R265. 2059 
(https://doi.org/10.1530/EJE-15-1118) 2060 
15 Terzolo M, Ali A, Osella G & Mazza E. Prevalence of adrenal carcinoma among 2061 
incidentally discovered adrenal masses. A retrospective study from 1989 to 1994. Gruppo 2062 
Piemontese Incidentalomi Surrenalici. Archives of Surgery 1997 132 914–919. 2063 
(https://doi.org/10.1001/archsurg.1997.01430320116020) 2064 
16 Cawood TJ, Hunt PJ, O’Shea D, Cole D & Soule S. Recommended evaluation of 2065 
adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal 2066 
cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? 2067 
European Journal of Endocrinology 2009 161 513–527. (https://doi.org/10.1530/ EJE-09-2068 
0234) 2069 
17 Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, Tabarin A, 2070 
Terzolo M, Tsagarakis S & Dekkers OM. Management of adrenal incidentalomas: European 2071 
Society of Endocrinology Clinical Practice Guideline in collaboration with the European 2072 
Network for the Study of Adrenal Tumors. European Journal of Endocrinology 2016 175 G1–2073 
G34. (https://doi.org/10.1530/EJE-16-0467) 2074 
18 Seccia TM, Fassina A, Nussdorfer GG, Pessina AC & Rossi GP. Aldosterone-2075 
producing adrenocortical carcinoma: an unusual cause of Conn’s syndrome with an ominous 2076 
clinical course. Endocrine-Related Cancer 2005 12 149–159. 2077 
(https://doi.org/10.1677/erc.1.00867) 2078 
19 Fassnacht M, Libe R, Kroiss M & Allolio B. Adrenocortical carcinoma: a clinician’s 2079 
update. Nature Reviews Endocrinology 2011 7 323–335. 2080 
(https://doi.org/10.1038/nrendo.2010.235) 2081 
20 Berruti A, Fassnacht M, Haak H, Else T, Baudin E, Sperone P, Kroiss M, Kerkhofs T, 2082 
Williams AR, Ardito A et al. Prognostic role of overt hypercortisolism in completely operated 2083 
patients with adrenocortical cancer. European Urology 2014 65 832–838. 2084 
(https://doi.org/10.1016/j. eururo.2013.11.006) 2085 
21 Kerkhofs TM, Ettaieb MH, Hermsen IG & Haak HR. Developing treatment for 2086 
adrenocortical carcinoma. Endocrine-Related Cancer 2015 22 R325–R338. 2087 
(https://doi.org/10.1530/ERC-15-0318) 2088 
22 Fassnacht M, Kroiss M & Allolio B. Update in adrenocortical carcinoma. Journal of 2089 
Clinical Endocrinology and Metabolism 2013 98 4551–4564. (https://doi.org/10.1210/jc.2013-2090 
3020) 2091 
23 Fassnacht M & Allolio B. Clinical management of adrenocortical carcinoma. Best 2092 
Practice and Research Clinical Endocrinology and Metabolism 2009 23 273–289. 2093 
24 Johanssen S, Hahner S, Saeger W, Quinkler M, Beuschlein F, Dralle H, Haaf M, 2094 
Kroiss M, Jurowich C, Langer P et al. Deficits in the management of patients with 2095 
58 
 
adrenocortical carcinoma in germany. Deutsches Arzteblatt International 2010 107 U885–2096 
U889. 2097 
25 Icard P, Goudet P, Charpenay C, Andreassian B, Carnaille B, Chapuis Y, Cougard P, 2098 
Henry JF & Proye C. Adrenocortical carcinomas: surgical trends and results of a 253-patient 2099 
series from the French Association of Endocrine Surgeons study group. World Journal of 2100 
Surgery 2001 25 891–897. (https://doi.org/10.1007/s00268- 001-0047-y) 2101 
26 Bilimoria KY, Shen WT, Elaraj D, Bentrem DJ, Winchester DJ, Kebebew E & 2102 
Sturgeon C. Adrenocortical carcinoma in the United States: treatment utilization and 2103 
prognostic factors. Cancer 2008 113 3130–3136. (https://doi.org/10.1002/cncr.23886) 2104 
27 Sturgeon C, Shen WT, Clark OH, Duh QY & Kebebew E. Risk assessment in 457 2105 
adrenal cortical carcinomas: how much does tumor size predict the likelihood of malignancy? 2106 
Journal of the American College of Surgeons 2006 202 423–430. (https://doi. 2107 
org/10.1016/j.jamcollsurg.2005.11.005) 2108 
28 Fassnacht M, Johanssen S, Fenske W, Weismann D, Agha A, Beuschlein F, Fuhrer 2109 
D, Jurowich C, Quinkler M, Petersenn S et al. Improved survival in patients with stage II 2110 
adrenocortical carcinoma followed up prospectively by specialized centers. Journal of Clinical 2111 
Endocrinology and Metabolism 2010 95 4925–4932. 2112 
29 Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, 2113 
Terzolo M, Mueller HH, Hahner S & Allolio B. Limited prognostic value of the 2004 2114 
International Union Against Cancer staging classification for adrenocortical carcinoma: 2115 
proposal for a Revised TNM Classification. Cancer 2009 115 243–250. (https://doi. 2116 
org/10.1002/cncr.24030) 2117 
30 Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-2118 
Brittinger C, Lacroix A, Jarzab B et al. Combination chemotherapy in advanced 2119 
adrenocortical carcinoma. New England Journal of Medicine 2012 366 2189–2197. 2120 
(https://doi.org/10.1056/ NEJMoa1200966) 2121 
31 Bollerslev J, Rejnmark L, Marcocci C, Shoback DM, Sitges-Serra A, van Biesen W & 2122 
Dekkers OM. European Society of Endocrinology Clinical Guideline: treatment of chronic 2123 
hypoparathyroidism in adults. European Journal of Endocrinology 2015 173 G1–G20. 2124 
(https:// doi.org/10.1530/EJE-15-0628) 2125 
32 Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, Nasser M, 2126 
Meerpohl J, Post PN, Kunz R et al. GRADE guidelines: 14. Going from evidence to 2127 
recommendations: the significance and presentation of recommendations. Journal of Clinical 2128 
Epidemiology 2013 66 719–725. (https://doi.org/10.1016/j.jclinepi.2012.03.013) 2129 
33 Andrews JC, Schunemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, Rind D, 2130 
Montori VM, Brito JP, Norris S et al. GRADE guidelines: 15. Going from evidence to 2131 
recommendation- determinants of a recommendation’s direction and strength. Journal of 2132 
Clinical Epidemiology 2013 66 726–735. (https://doi.org/10.1016/j. jclinepi.2013.02.003) 2133 
34 Guyatt GH, Schunemann HJ, Djulbegovic B & Akl EA. Guideline panels should not 2134 
GRADE good practice statements. Journal of Clinical Epidemiology 2015 68 597–600. 2135 
(https://doi.org/10.1016/j. jclinepi.2014.12.011) 2136 
35 Vanbrabant T, Fassnacht M, Assie G & Dekkers OM. Influence of hormonal functional 2137 
status on survival in adrenocortical carcinoma: systematic review and meta-analysis. 2138 
European Journal of Endocrinology 2018. 2139 
59 
 
36 Bertherat J, Coste J & Bertagna X. Adjuvant mitotane in adrenocortical carcinoma. 2140 
New England Journal of Medicine 2007 357 1256–1257; author reply 1259. 2141 
(https://doi.org/10.1056/ NEJMc076267) 2142 
37 Blanes A & Diaz-Cano SJ. Histologic criteria for adrenocortical proliferative lesions – 2143 
value of mitotic figure variability. American Journal of Clinical Pathology 2007 127 398–408. 2144 
(https://doi. org/10.1309/MCGUQ3R4A4WWN3LB) 2145 
38 Creemers SG, van Koetsveld PM, van Kemenade FJ, Papathomas TG, Franssen GJ, 2146 
Dogan F, Eekhoff EM, van der Valk P, de Herder WW, Janssen JA et al. Methylation of IGF2 2147 
regulatory regions to diagnose adrenocortical carcinomas. Endocrine-Related Cancer 2016 2148 
23 727–737. (https://doi.org/10.1530/ERC-16-0266) 2149 
39 Erickson LA, Jin L, Sebo TJ, Lohse C, Pankratz VS, Kendrick ML, van Heerden JA, 2150 
Thompson GB, Grant CS & Lloyd RV. Pathologic features and expression of insulin-like 2151 
growth factor-2 in adrenocortical neoplasms. Endocrine Pathology 2001 12 429–435. 2152 
(https://doi. org/10.1385/EP:12:4:429) 2153 
40 Arola J, Liu J, Heikkila P, Ilvesmaki V, Salmenkivi K, Voutilainen R & Kahri AI. 2154 
Expression of inhibin alpha in adrenocortical tumours reflects the hormonal status of the 2155 
neoplasm. Journal of Endocrinology 2156 
2000 165 223–229.  (https://doi.org/10.1677/joe.0.1650223)  2157 
41 Aubert S, Wacrenier A, Leroy X, Devos P, Carnaille B, Proye C, Wemeau JL, Lecomte-2158 
Houcke M & Leteurtre E. Weiss system revisited: a clinicopathologic and 2159 
immunohistochemical study of 49 adrenocortical tumors. American Journal of Surgical 2160 
Pathology 2002 26 1612–1619. (https://doi.org/10.1097/00000478-200212000-00009) 2161 
42 Busam KJ, Iversen K, Coplan KA, Old LJ, Stockert E, Chen YT, McGregor D & 2162 
Jungbluth A. Immunoreactivity for A103, an antibody to melan-A (Mart-1), in adrenocortical 2163 
and other steroid tumors. American Journal of Surgical Pathology 1998 22 57–63. 2164 
(https://doi. org/10.1097/00000478-199801000-00007) 2165 
43 Kamio T, Shigematsu K, Sou H, Kawai K & Tsuchiyama H. Immunohistochemical 2166 
expression of epidermal growth factor receptors in human adrenocortical carcinoma. Human 2167 
Pathology 1990 21 277–282. (https://doi.org/10.1016/0046-8177(90)90227-V) 2168 
44 Komminoth P, Roth J, Schroder S, Saremaslani P & Heitz PU. Overlapping 2169 
expression of immunohistochemical markers and synaptophysin mRNA in 2170 
pheochromocytomas and adrenocortical carcinomas. Implications for the differential 2171 
diagnosis of adrenal gland tumors. Laboratory Investigation 1995 72 424–431. 2172 
45 Pan CC, Chen PCH, Tsay SH & Ho DMT. Differential immunoprofiles of 2173 
hepatocellular carcinoma, renal cell carcinoma, and adrenocortical carcinoma: a systemic 2174 
immunohistochemical survey using tissue array technique. Applied Immunohistochemistry 2175 
and Molecular Morphology 2005 13 347–352. (https://doi.org/10.1097/01. 2176 
pai.0000146525.72531.19) 2177 
46 Rubin B, Regazzo D, Redaelli M, Mucignat C, Citton M, Iacobone M, Scaroni C, 2178 
Betterle C, Mantero F, Fassina A et al. Investigation of N-cadherin/beta-catenin expression in 2179 
adrenocortical tumors. Tumour Biology 2016 37 13545–13555. (https://doi.org/10.1007/ 2180 
s13277-016-5257-x) 2181 
47 Sbiera S, Schmull S, Assie G, Voelker HU, Kraus L, Beyer M, Ragazzon B, 2182 
Beuschlein F, Willenberg HS, Hahner S et al. High diagnostic and prognostic value of 2183 
60 
 
steroidogenic factor-1 expression in adrenal tumors. Journal of Clinical Endocrinology and 2184 
Metabolism 2010 95 E161–E171. 2185 
48 Stojadinovic A, Brennan MF, Hoos A, Omeroglu A, Leung DH, Dudas ME, Nissan A, 2186 
Cordon-Cardo C & Ghossein RA. Adrenocortical adenoma and carcinoma: histopathological 2187 
and molecular comparative analysis. Modern Pathology 2003 16 742–751. 2188 
(https://doi.org/10.1097/01.MP.0000081730.72305.81) 2189 
49 Volante M, Sperone P, Bollito E, Frangipane E, Rosas R, Daffara F, Terzolo M, 2190 
Berruti A & Papotti M. Matrix metalloproteinase type 2 expression in malignant adrenocortical 2191 
tumors: Diagnostic and prognostic significance in a series of 50 adrenocortical carcinomas. 2192 
Modern Pathology 2006 19 1563–1569. (https://doi.org/10.1038/ modpathol.3800683) 2193 
50 Wajchenberg BL, Albergaria Pereira MA, Medonca BB, Latronico AC, Campos 2194 
Carneiro P, Alves VA, Zerbini MC, Liberman B, Carlos Gomes G & Kirschner MA. 2195 
Adrenocortical carcinoma: clinical and laboratory observations. Cancer 2000 88 711–736. 2196 
(https:// doi.org/10.1002/(SICI)1097-0142(20000215)88:4<711::AID- CNCR1>3.0.CO;2-W) 2197 
51 Wang C, Sun Y, Wu H, Zhao D & Chen J. Distinguishing adrenal cortical carcinomas 2198 
and adenomas: a study of clinicopathological features and biomarkers. Histopathology 2014 2199 
64 567–576. (https:// doi.org/10.1111/his.12283) 2200 
52 Zhang HY, Bu H, Chen HJ, Wei B, Liu WP, Guo J, Li FY, Liao DY, Tang Y & Zhang Z. 2201 
Comparison of immunohistochemical markers in the differential diagnosis of adrenocortical 2202 
tumors –  immunohistochemical analysis of adrenocortical tumors. Applied 2203 
Immunohistochemistry and Molecular Morphology 2008 16 32–39. 2204 
53 Kovach AE, Nucera C, Lam QT, Nguyen A, Dias-Santagata D & Sadow PM. Genomic 2205 
and immunohistochemical analysis in human adrenal cortical neoplasia reveal beta-catenin 2206 
mutations as potential prognostic biomarker. Discoveries 2015 3 e40. 2207 
54 Amini N, Margonis GA, Kim Y, Tran TB, Postlewait LM, Maithel SK, Wang TS, Evans 2208 
DB, Hatzaras I, Shenoy R et al. Curative resection of adrenocortical carcinoma: rates and 2209 
patterns of postoperative recurrence. Annals of Surgical Oncology 2016 23 126–133. 2210 
(https://doi. org/10.1245/s10434-015-4810-y) 2211 
55 Asare EA, Wang TS, Winchester DP, Mallin K, Kebebew E & Sturgeon C. A novel 2212 
staging system for adrenocortical carcinoma better predicts survival in patients with stage I/II 2213 
disease. Surgery 2014 156 1378–1386. (https://doi.org/10.1016/j. surg.2014.08.018) 2214 
56 Assie G, Antoni G, Tissier F, Caillou B, Abiven G, Gicquel C, Leboulleux S, Travagli 2215 
JP, Dromain C, Bertagna X et al. Prognostic parameters of metastatic adrenocortical 2216 
carcinoma. Journal of Clinical Endocrinology and Metabolism 2007 92 148–154. 2217 
57 Ayala-Ramirez M, Jasim S, Feng L, Ejaz S, Deniz F, Busaidy N, Waguespack SG, 2218 
Naing A, Sircar K, Wood CG et al. Adrenocortical carcinoma: clinical outcomes and 2219 
prognosis of 330 patients at a tertiary care center. European Journal of Endocrinology 2013 2220 
169 891–899. (https://doi.org/10.1530/EJE-13-0519) 2221 
58 Beuschlein F, Weigel J, Saeger W, Kroiss M, Wild V, Daffara F, Libe R, Ardito A, 2222 
Ghuzlan AA, Quinkler M et al. Major prognostic role of Ki67 in localized adrenocortical 2223 
carcinoma after complete resection. Journal of Clinical Endocrinology and Metabolism 2015 2224 
100 841–849. (https://doi.org/10.1210/jc.2014-3182) 2225 
59 Canter DJ, Mallin K, Uzzo RG, Egleston BL, Simhan J, Walton J, Smaldone MC, 2226 
Master VA, Bratslaysky G & Kutikov A. Association of tumor size with metastatic potential 2227 
61 
 
and survival in patients with adrenocortical carcinoma: an analysis of the National Cancer 2228 
Database. Canadian Journal of Urology 2013 20 6915–6921. 2229 
60 Duregon E, Cappellesso R, Maffeis V, Zaggia B, Ventura L, Berruti A, Terzolo M, 2230 
Fassina A, Volante M & Papotti M. Validation of the prognostic role of the ‘Helsinki Score’ in 2231 
225 cases of adrenocortical carcinoma. Human Pathology 2017 62 1–7. 2232 
(https://doi.org/10.1016/j. humpath.2016.09.035) 2233 
61 Erdogan I, Deutschbein T, Jurowich C, Kroiss M, Ronchi C, Quinkler M, Waldmann J, 2234 
Willenberg HS, Beuschlein F, Fottner C et al. The role of surgery in the management of 2235 
recurrent adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism 2013 2236 
98 181–191. 2237 
62 Ettaieb MH, Duker JC, Feelders RA, Corssmit EP, Menke-van der Houven van Oordt 2238 
CW, Timmers HJ, Kerstens MN, Wilmink JW, Zelissen PM, Havekes B et al. Synchronous vs 2239 
metachronous metastases in adrenocortical carcinoma: an analysis of the dutch adrenal 2240 
network. Hormones and Cancer 2016 7 336–344. (https://doi. org/10.1007/s12672-016-0270-2241 
5) 2242 
63 Freire DS, Siqueira SAC, Zerbini MCN, Wajchenberg BL, Correa- Giannella ML, 2243 
Lucon AM & Pereira MAA. Development and internal validation of an adrenal cortical 2244 
carcinoma prognostic score for predicting the risk of metastasis and local recurrence. Clinical 2245 
Endocrinology 2013 79 468–475. (https://doi.org/10.1111/ cen.12174) 2246 
64 Gicquel C, Bertagna X, Gaston V, Coste J, Louvel A, Baudin E, Bertherat J, Chapuis 2247 
Y, Duclos JM, Schlumberger M et al. Molecular markers and long-term recurrences in a large 2248 
cohort of patients  with sporadic adrenocortical tumors. Cancer Research 2001 61 6762–2249 
6767. 2250 
65 Glover AR, Zhao JT, Ip JC, Lee JC, Robinson BG, Gill AJ, Soon PS & Sidhu SB. 2251 
Long noncoding RNA profiles of adrenocortical cancer can be used to predict recurrence. 2252 
Endocrine-Related Cancer 2015 22 99–109. (https://doi.org/10.1530/ERC-14-0457) 2253 
66 Gonzalez RJ, Tamm EP, Ng C, Phan AT, Vassilopoulou-Sellin R, Perrier ND, Evans 2254 
DB & Lee JE. Response to mitotane predicts outcome in patients with recurrent adrenal 2255 
cortical carcinoma. Surgery 2007 142 867–874. (https://doi.org/10.1016/j. surg.2007.09.006) 2256 
67 Kendrick ML, Curlee K, Lloyd R, Farley DR, Grant CS, Thompson GB, Rowland C, 2257 
Young WF Jr, Van Heerden JA, Duh QY et al. Aldosterone-secreting adrenocortical 2258 
carcinomas are associated with unique operative risks and outcomes. Surgery 2002 132 2259 
1008–1012. (https://doi.org/10.1067/msy.2002.128476) 2260 
68 Kim Y, Margonis GA, Prescott JD, Tran TB, Postlewait LM, Maithel SK, Wang TS, 2261 
Evans DB, Hatzaras I, Shenoy R et al. Nomograms to predict recurrence-free and overall 2262 
survival after curative resection of adrenocortical carcinoma. JAMA Surgery 2016 151 365–2263 
373. (https:// doi.org/10.1001/jamasurg.2015.4516) 2264 
69 Kim Y, Margonis GA, Prescott JD, Tran TB, Postlewait LM, Maithel SK, Wang TS, 2265 
Glenn JA, Hatzaras I, Shenoy R et al. Curative surgical resection of adrenocortical 2266 
carcinoma: determining long-term outcome based on conditional disease-free probability. 2267 
Annals of Surgery 2017 265 197–204. (https://doi.org/10.1097/ SLA.0000000000001527) 2268 
70 Libe R, Borget I, Ronchi CL, Zaggia B, Kroiss M, Kerkhofs T, Bertherat J, Volante M, 2269 
Quinkler M, Chabre O et al. Prognostic factors in stage III-IV adrenocortical carcinomas 2270 
(ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. Annals of 2271 
Oncology 2015 26 2119–2125. (https://doi.org/10.1093/annonc/ mdv329) 2272 
62 
 
71 Livhits M, Li N, Yeh MW & Harari A. Surgery is associated with improved survival for 2273 
adrenocortical cancer, even in metastatic disease. Surgery 2014 156 1531–1540; discussion 2274 
1540–1531. (https:// doi.org/10.1016/j.surg.2014.08.047) 2275 
72 Lucon AM, Pereira MA, Mendonca BB, Zerbini MC, Saldanha LB & Arap S. 2276 
Adrenocortical tumors: results of treatment and study of Weiss’s score as a prognostic factor. 2277 
Revista do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo 2278 
2002 57 251–256. (https://doi.org/10.1590/S0041-87812002000600002) 2279 
73 Margonis GA, Kim Y, Prescott JD, Tran TB, Postlewait LM, Maithel SK, Wang TS, 2280 
Evans DB, Hatzaras I, Shenoy R et al. Adrenocortical carcinoma: impact of surgical margin 2281 
status on long-term outcomes. Annals of Surgical Oncology 2016 23 134–141. (https://doi. 2282 
org/10.1245/s10434-015-4803-x) 2283 
74 Margonis GA, Kim Y, Tran TB, Postlewait LM, Maithel SK, Wang TS, Glenn JA, 2284 
Hatzaras I, Shenoy R, Phay JE et al. Outcomes after resection of cortisol-secreting 2285 
adrenocortical carcinoma. American Journal of Surgery 2016 211 1106–1113. 2286 
(https://doi.org/10.1016/j. amjsurg.2015.09.020) 2287 
75 Millis SZ, Ejadi S & Demeure MJ. Molecular profiling of refractory adrenocortical 2288 
cancers and predictive biomarkers to therapy. Biomarkers in Cancer 2015 7 69–76. 2289 
(https://doi.org/10.4137/BIC.S34292) 2290 
76 Paton BL, Novitsky YW, Zerey M, Harrell AG, Norton HJ, Asbun H, Kercher KW & 2291 
Heniford BT. Outcomes of adrenal cortical carcinoma in the United States. Surgery 2006 140 2292 
914–920; discussion 919–920. (https://doi.org/10.1016/j.surg.2006.07.035) 2293 
77 Pennanen M, Heiskanen I, Sane T, Remes S, Mustonen H, Haglund C & Arola J. 2294 
Helsinki score-a novel model for prediction of metastases in adrenocortical carcinomas. 2295 
Human Pathology 2015 46 404–410. (https://doi.org/10.1016/j.humpath.2014.11.015) 2296 
78 Schulick RD & Brennan MF. Long-term survival after complete resection and repeat 2297 
resection in patients with adrenocortical carcinoma. Annals of Surgical Oncology 1999 6 719-2298 
726. (https://doi. org/10.1007/s10434-999-0719-7) 2299 
79 Tran TB, Postlewait LM, Maithel SK, Prescott JD, Wang TS, Glenn J, Phay JE, 2300 
Keplinger K, Fields RC, Jin LDX et al. Actual 10-year survivors following resection of 2301 
adrenocortical carcinoma. Journal of Surgical Oncology 2016 114 971–976. 2302 
(https://doi.org/10.1002/ jso.24439) 2303 
80 Xiao WJ, Zhu Y, Dai B, Zhang HL, Shi GH, Shen YJ, Zhu YP & Ye DW. Conditional 2304 
survival among patients with adrenal cortical carcinoma determined using a national 2305 
population-based surveillance, epidemiology, and end results registry. Oncotarget 2015 6 2306 
44955–44962. 2307 
81 Zini L, Capitanio U, Jeldres C, Lughezzani G, Sun M, Shariat SF, Isbarn H, Arjane P, 2308 
Widmer H, Perrotte P et al. External validation of a nomogram predicting mortality in patients 2309 
with adrenocortical carcinoma. BJU International 2009 104 1661–1667. (https://doi. 2310 
org/10.1111/j.1464-410X.2009.08660.x) 2311 
82 Ronchi CL, Sbiera S, Leich E, Tissier F, Steinhauer S, Deutschbein T, Fassnacht M & 2312 
Allolio B. Low SGK1 expression in human adrenocortical tumors is associated with ACTH-2313 
independent glucocorticoid secretion and poor prognosis. Journal of Clinical Endocrinology 2314 
and Metabolism 2012 97 E2251–E2260. (https://doi. org/10.1210/jc.2012-2669) 2315 
63 
 
83 Macfarlane DA. Cancer of the adrenal cortex; the natural history, prognosis and 2316 
treatment in a study of fifty-five cases. Annals of the Royal College of Surgeons of England 2317 
1958 23 155–186. 2318 
84 Sullivan M, Boileau M & Hodges CV. Adrenal cortical carcinoma. Journal of Urology 2319 
1978 120 660–665. (https://doi.org/10.1016/S0022-5347(17)57317-6) 2320 
85 Lee JE, Berger DH, el-Naggar AK, Hickey RC, Vassilopoulou-Sellin R, Gagel RF, 2321 
Burgess MA & Evans DB. Surgical management, DNA content, and patient survival in 2322 
adrenal cortical carcinoma. Surgery 1995 118 1090–1098. (https://doi.org/10.1016/S0039-2323 
6060(05)80119-9) 2324 
86 DeLellis RA, Lloyd RV, Heitz PU & Eng C. World Health Organization classification of 2325 
tumours. Pathology and Genetics of Tumours of Endocrine Organs 2004 136. 2326 
87 Miller BS, Gauger PG, Hammer GD, Giordano TJ & Doherty GM. Proposal for 2327 
modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade. 2328 
Langenbecks Archives of Surgery 2010 395 955–961. (https://doi.org/10.1007/s00423-010-2329 
0698-y) 2330 
88 Lughezzani G, Sun M, Perrotte P, Jeldres C, Alasker A, Isbarn H, Budaus L, Shariat 2331 
SF, Guazzoni G, Montorsi F et al. The European Network for the Study of Adrenal Tumors 2332 
staging system is prognostically superior to the international union against cancer- staging 2333 
system: a North American validation. European Journal of Cancer 2010 46 713–719. 2334 
(https://doi.org/10.1016/j.ejca.2009.12.007) 2335 
89 Lam AK. Update on adrenal tumours in 2017 World Health Organization (WHO) of 2336 
endocrine tumours. Endocrine Pathology 2017 28 213–227. (https://doi.org/10.1007/s12022-2337 
017-9484-5) 2338 
90 Berruti A, Grisanti S, Pulzer A, Claps M, Daffara F, Loli P, Mannelli M, Boscaro M, 2339 
Arvat E, Tiberio G et al. Long-term outcomes of adjuvant mitotane therapy in patients with 2340 
radically resected adrenocortical carcinoma. Journal of Clinical Endocrinology and 2341 
Metabolism 2017 102 1358–1365. (https://doi.org/10.1210/jc.2016-2894) 2342 
91 Else T, Williams AR, Sabolch A, Jolly S, Miller BS & Hammer GD. Adjuvant therapies 2343 
and patient and tumor characteristics associated with survival of adult patients with 2344 
adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism 2014 99 455–2345 
461. (https:// doi.org/10.1210/jc.2013-2856) 2346 
92 Grubbs EG, Callender GG, Xing Y, Perrier ND, Evans DB, Phan AT & Lee JE. 2347 
Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve 2348 
results equal to surgery plus mitotane. Annals of Surgical Oncology 2010 17 263–270. 2349 
(https://doi. org/10.1245/s10434-009-0716-x) 2350 
93 Postlewait LM, Ethun CG, Tran TB, Prescott JD, Pawlik TM, Wang TS, Glenn J, 2351 
Hatzaras I, Shenoy R, Phay JE et al. Outcomes of adjuvant mitotane after resection of 2352 
adrenocortical carcinoma: a 13-institution study by the US Adrenocortical Carcinoma Group. 2353 
Journal of the American College of Surgeons 2016 222 480–490. (https://doi. 2354 
org/10.1016/j.jamcollsurg.2015.12.013) 2355 
94 Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto 2356 
R, Buci L, Sperone P, Grossrubatscher E et al. Adjuvant mitotane treatment for 2357 
adrenocortical carcinoma. New England Journal of Medicine 2007 356 2372–2380. 2358 
(https://doi. org/10.1056/NEJMoa063360) 2359 
64 
 
95 Bosco JL, Silliman RA, Thwin SS, Geiger AM, Buist DS, Prout MN, Yood MU, Haque 2360 
R, Wei F & Lash TL. A most stubborn bias: no adjustment method fully resolves confounding 2361 
by indication in observational studies. Journal of Clinical Epidemiology 2010 63 64–74. 2362 
(https://doi.org/10.1016/j.jclinepi.2009.03.001) 2363 
96 Hernan MA & Robins JM. Instruments for causal inference: an epidemiologist’s 2364 
dream? Epidemiology 2006 17 360–372. (https://doi. 2365 
org/10.1097/01.ede.0000222409.00878.37) 2366 
97 Suissa S. Immortal time bias in pharmaco-epidemiology. American Journal of 2367 
Epidemiology 2008 167 492–499. (https://doi.org/10.1093/ aje/kwm324) 2368 
98 Fassnacht M, Hahner S, Polat B, Koschker AC, Kenn W, Flentje M & Allolio B. 2369 
Efficacy of adjuvant radiotherapy of the tumor bed  on local recurrence of adrenocortical 2370 
carcinoma. Journal of Clinical Endocrinology and Metabolism 2006 91 4501–4504. 2371 
99 Habra MA, Ejaz S, Feng L, Das P, Deniz F, Grubbs EG, Phan AT, Waguespack S, 2372 
Montserrat AR, Jimenez C et al. A Retrospective Cohort Analysis of the Efficacy of Adjuvant 2373 
Radiotherapy after Primary Surgical Resection in Patients with Adrenocortical Carcinoma. 2374 
Journal of Clinical Endocrinology and Metabolism 2013 98 192–197. 2375 
(https://doi.org/10.1210/jc.2012-2367)   2376 
100 Sabolch A, Else T, Griffith KA, Ben-Josef E, Williams A, Miller BS, Worden F, 2377 
Hammer GD & Jolly S. Adjuvant radiation therapy improves local control after surgical 2378 
resection in patients with localized adrenocortical carcinoma. International Journal of 2379 
Radiation Oncology, Biology, Physics 2015 92 252–259. (https://doi. 2380 
org/10.1016/j.ijrobp.2015.01.007) 2381 
101 Berruti A, Terzolo M, Sperone P, Pia A, Della Casa S, Gross DJ, Carnaghi C, Casali 2382 
P, Porpiglia F, Mantero F et al. Etoposide, doxorubicin and cisplatin plus mitotane in the 2383 
treatment of  advanced adrenocortical carcinoma: a large prospective phase II trial. 2384 
Endocrine-Related Cancer 2005 12 657–666. (https://doi.org/10.1677/ erc.1.01025) 2385 
102 Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, Kroiss M, Quinn 2386 
DI, Hesseltine E, Ronchi CL et al. Linsitinib (OSI- 906) versus placebo for patients with 2387 
locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 2388 
3 study. Lancet Oncology 2015 16 426–435. (https://doi.org/10.1016/ S1470-2045(15)70081-2389 
1) 2390 
103 Hermsen IG, Fassnacht M, Terzolo M, Houterman S, den Hartigh J, Leboulleux S, 2391 
Daffara F, Berruti A, Chadarevian R, Schlumberger M et al. Concentrations of o,p′ DDD, o,p′ 2392 
DDA, and o,p′ DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: 2393 
results of a retrospective ENS@T multicenter study. Journal of Clinical Endocrinology and 2394 
Metabolism 2011 96 1844–1851. 2395 
104 Sperone P, Ferrero A, Daffara F, Priola A, Zaggia B, Volante M, Santini D, Vincenzi 2396 
B, Badalamenti G, Intrivici C et al. Gemcitabine plus metronomic 5-fluorouracil or 2397 
capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a 2398 
multicenter phase II study. Endocrine-Related Cancer 2010 17 445–453. 2399 
(https://doi.org/10.1677/ERC-09-0281) 2400 
105 Abraham J, Bakke S, Rutt A, Meadows B, Merino M, Alexander R, Schrump D, 2401 
Bartlett D, Choyke P, Robey R et al. A phase II trial of combination chemotherapy and 2402 
surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous 2403 
infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein 2404 
antagonist. Cancer 2002 94 2333–2343. (https://doi. org/10.1002/cncr.10487) 2405 
65 
 
106 Baudin E, Docao C, Gicquel C, Vassal G, Bachelot A, Penfornis A & Schlumberger 2406 
M. Use of a topoisomerase I inhibitor (irinotecan, CPT-11) in metastatic adrenocortical 2407 
carcinoma. Annals of Oncology 2002 13 1806–1809. 2408 
(https://doi.org/10.1093/annonc/mdf291)  2409 
107 Baudin E, Pellegriti G, Bonnay M, Penfornis A, Laplanche A, Vassal G & Schlumberger 2410 
M. Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p′ DDD) levels on the 2411 
treatment of patients with adrenocortical carcinoma. Cancer 2001 92 1385–1392. 2412 
(https://doi.org/10.1002/1097- 0142(20010915)92:6<1385::AID-CNCR1461>3.0.CO;2-2) 2413 
108 Berruti A, Sperone P, Ferrero A, Germano A, Ardito A, Priola AM, De Francia S, 2414 
Volante M, Daffara F, Generali D et al. Phase II study of weekly paclitaxel and sorafenib as 2415 
second/third-line therapy in patients with adrenocortical carcinoma. European Journal of 2416 
Endocrinology 2012 166 451–458. (https://doi.org/10.1530/EJE-11-0918) 2417 
109 Bonacci R, Gigliotti A, Baudin E, Wion-Barbot N, Emy P, Bonnay M, Cailleux AF, 2418 
Nakib I & Schlumberger M. Cytotoxic therapy with etoposide and cisplatin in advanced 2419 
adrenocortical carcinoma. British Journal of Cancer 1998 78 546–549. 2420 
(https://doi.org/10.1038/ bjc.1998.530) 2421 
110 Bukowski RM, Wolfe M, Levine HS, Crawford DE, Stephens RL, Gaynor E & Harker 2422 
WG. Phase II trial of mitotane and cisplatin  in patients with adrenal carcinoma: a Southwest 2423 
Oncology Group study. Journal of Clinical Oncology 1993 11 161–165. (https://doi. 2424 
org/10.1200/JCO.1993.11.1.161) 2425 
111 Decker RA, Elson P, Hogan TF, Citrin DL, Westring DW, Banerjee TK, Gilchrist KW & 2426 
Horton J. Eastern-Cooperative-Oncology-Group Study 1879 – mitotane and adriamycin in 2427 
patients with advanced adrenocortical carcinoma. Surgery 1991 110 1006–1013. 2428 
112 Haak HR, Hermans J, van de Velde CJ, Lentjes EG, Goslings BM, Fleuren GJ & 2429 
Krans HM. Optimal treatment of adrenocortical carcinoma with mitotane: results in a 2430 
consecutive series of 96 patients. British Journal of Cancer 1994 69 947–951. (https://doi. 2431 
org/10.1038/bjc.1994.183) 2432 
113 Haluska P, Worden F, Olmos D, Yin D, Schteingart D, Batzel GN, Paccagnella ML, 2433 
de Bono JS, Gualberto A & Hammer GD. Safety, tolerability, and pharmacokinetics of the 2434 
anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical 2435 
carcinoma. Cancer Chemotherapy and Pharmacology 2010 65 765–773. 2436 
(https://doi.org/10.1007/s00280-009-1083-9) 2437 
114 Khan TS, Sundin A, Juhlin C, Wilander E, Oberg K & Eriksson B. Vincristine, 2438 
cisplatin, teniposide, and cyclophosphamide combination in the treatment of recurrent or 2439 
metastatic adrenocortical cancer. Medical Oncology 2004 21 167–177. (https:// 2440 
doi.org/10.1385/MO:21:2:167) 2441 
115 Kroiss M, Deutschbein T, Schlotelburg W, Ronchi CL, Neu B, Muller HH, Quinkler M, 2442 
Hahner S, Heidemeier A & Fassnacht M. Salvage treatment of adrenocortical carcinoma with 2443 
trofosfamide. Hormones and Cancer 2016 7 211–218. (https://doi.org/10.1007/ s12672-016-2444 
0260-7) 2445 
116 Kroiss M, Quinkler M, Johanssen S, van Erp NP, Lankheet N, Pollinger A, Laubner K, 2446 
Strasburger CJ, Hahner S, Muller HH et al. Sunitinib in refractory adrenocortical carcinoma: a 2447 
phase II, single- arm, open-label trial. Journal of Clinical Endocrinology and Metabolism 2012 2448 
97 3495–3503. (https://doi.org/10.1210/jc.2012-1419) 2449 
66 
 
117 Naing A, LoRusso P, Fu S, Hong D, Chen HX, Doyle LA, Phan AT, Habra MA & 2450 
Kurzrock R. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with 2451 
the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. British 2452 
Journal of Cancer 2013 108 826–830. (https://doi.org/10.1038/ bjc.2013.46) 2453 
118 O’Sullivan C, Edgerly M, Velarde M, Wilkerson J, Venkatesan AM, Pittaluga S, Yang 2454 
SX, Nguyen D, Balasubramaniam S & Fojo T. The VEGF inhibitor axitinib has limited 2455 
effectiveness as a therapy for adrenocortical cancer. Journal of Clinical Endocrinology and 2456 
Metabolism 2014 99 1291–1297. 2457 
119 Quinkler M, Hahner S, Wortmann S, Johanssen S, Adam P, Ritter C, Strasburger C, 2458 
Allolio B & Fassnacht M. Treatment of advanced adrenocortical carcinoma with erlotinib plus 2459 
gemcitabine. Journal of Clinical Endocrinology and Metabolism 2008 93 2057–2062. (https:// 2460 
doi.org/10.1210/jc.2007-2564) 2461 
120 Schlumberger M, Brugieres L, Gicquel C, Travagli JP, Droz JP & Parmentier C. 5-2462 
Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal-cortical carcinoma. Cancer 2463 
1991 67 2997–3000. (https://doi.org/10.1002/1097-0142(19910615)67:12<2997::AID- 2464 
CNCR2820671211>3.0.CO;2-#) 2465 
121 Urup T, Pawlak WZ, Petersen PM, Pappot H, Rorth M & Daugaard G. Treatment with 2466 
docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study. British 2467 
Journal of Cancer 2013 108 1994–1997. (https://doi.org/10.1038/bjc.2013.229) 2468 
122 Williamson SK, Lew D, Miller GJ, Balcerzak SP, Baker LH & Crawford ED. Phase II 2469 
evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients 2470 
with locally advanced or metastatic adrenocortical carcinoma – a Southwest Oncology Group 2471 
study. Cancer 2000 88 1159–1165. (https://doi.org/10.1002/ (SICI)1097-2472 
0142(20000301)88:5<1159::AID-CNCR28>3.0.CO;2-R) 2473 
123 Wortmann S, Quinkler M, Ritter C, Kroiss M, Johanssen S, Hahner S, Allolio B & 2474 
Fassnacht M. Bevacizumab plus capecitabine as a salvage therapy in advanced 2475 
adrenocortical carcinoma. European Journal of Endocrinology 2010 162 349–356. 2476 
(https://doi.org/10.1530/EJE-09-0804) 2477 
124 Henning JEK, Deutschbein T, Altieri B, Steinhauer S, Kircher S, Sbiera S, Wild V, 2478 
Schlotelburg W, Kroiss M, Perotti P et al. Gemcitabine-based chemotherapy in 2479 
adrenocortical carcinoma: a multicenter study of efficacy and predictive factors. Journal of 2480 
Clinical Endocrinology and Metabolism 2017 102 4323–4332. (https://doi. 2481 
org/10.1210/jc.2017-01624) 2482 
125 Lerario AM, Worden FP, Ramm CA, Hesseltine EA, Stadler WM, Else T, Shah MH, 2483 
Agamah E, Rao K & Hammer GD. The combination of insulin-like growth factor receptor 1 2484 
(IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with 2485 
recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial. 2486 
Hormones and Cancer 2014 5 232–239. (https:// doi.org/10.1007/s12672-014-0182-1) 2487 
126 Datrice NM, Langan RC, Ripley RT, Kemp CD, Steinberg SM, Wood BJ, Libutti SK, 2488 
Fojo T, Schrump DS & Avital I. Operative management for recurrent and metastatic 2489 
adrenocortical carcinoma. Journal of Surgical Oncology 2012 105 709–713. (https://doi. 2490 
org/10.1002/jso.23015) 2491 
127 Gaujoux S, Al-Ahmadie H, Allen PJ, Gonen M, Shia J, D’Angelica M, Dematteo R, 2492 
Fong Y, Blumgart L & Jarnagin WR. Resection of adrenocortical carcinoma liver metastasis: 2493 
is it justified? Annals of Surgical Oncology 2012 19 2643–2651. (https://doi.org/10.1245/ 2494 
s10434-012-2358-7) 2495 
67 
 
128 Kemp CD, Ripley RT, Mathur A, Steinberg SM, Nguyen DM, Fojo T & Schrump DS. 2496 
Pulmonary resection for metastatic adrenocortical carcinoma: the National Cancer Institute 2497 
experience. Annals of Thoracic Surgery 2011 92 1195–1200. (https://doi.org/10.1016/j. 2498 
athoracsur.2011.05.013) 2499 
129 Kwauk S & Burt M. Pulmonary metastases from adrenal cortical carcinoma: results of 2500 
resection. Journal of Surgical Oncology 1993 53 243–246. 2501 
(https://doi.org/10.1002/jso.2930530411) 2502 
130 op den Winkel J, Pfannschmidt J, Muley T, Grunewald C, Dienemann H, Fassnacht M 2503 
& Allolio B. Metastatic adrenocortical carcinoma: results of 56 pulmonary metastasectomies 2504 
in 24  patients. Annals of Thoracic Surgery 2011 92 1965–1970. (https://doi. 2505 
org/10.1016/j.athoracsur.2011.07.088) 2506 
131 Ripley RT, Kemp CD, Davis JL, Langan RC, Royal RE, Libutti SK, Steinberg SM, 2507 
Wood BJ, Kammula US, Fojo T et al. Liver resection and ablation for metastatic 2508 
adrenocortical carcinoma. Annals of Surgical Oncology 2011 18 1972–1979. 2509 
(https://doi.org/10.1245/ s10434-011-1564-z) 2510 
132 Bellantone R, Ferrante A, Boscherini M, Lombardi CP, Crucitti P, Crucitti F, Favia G, 2511 
Borrelli D, Boffi L, Capussotti L et al. Role of reoperation in recurrence of adrenal cortical 2512 
carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal 2513 
Cortical Carcinoma. Surgery 1997 122 1212–1218. (https://doi. org/10.1016/S0039-2514 
6060(97)90229-4) 2515 
133 Crucitti F, Bellantone R, Ferrante A, Boscherini M, Crucitti P, Carbone G, Casaccia 2516 
M, Campisi C, Cavallaro A, Sapienza P et al. The Italian registry for adrenal cortical 2517 
carcinoma: analysis of a multiinstitutional series of 129 patients. Surgery 1996 119 161–170. 2518 
(https://doi.org/10.1016/S0039-6060(96)80164-4) 2519 
134 Dy BM, Wise KB, Richards ML, Young WE, Grant CS, Bible KC, Rosedahl J, 2520 
Harmsen WS, Farley DR & Thompson GB. Operative intervention for recurrent 2521 
adrenocortical cancer. Surgery 2013 154 1292–1299. 2522 
(https://doi.org/10.1016/j.surg.2013.06.033) 2523 
135 Jensen JC, Pass HI, Sindelar WF & Norton JA. Recurrent or metastatic disease in 2524 
select patients with adrenocortical carcinoma – aggressive resection vs chemotherapy. 2525 
Archives of Surgery 1991 126 457–461. 2526 
(https://doi.org/10.1001/archsurg.1991.01410280059008) 2527 
136 Simon G, Pattou F, Mirallie E, Lifante JC, Nomine C, Arnault V, de Calan L, Gaillard 2528 
C, Carnaille B, Brunaud L et al. Surgery for recurrent adrenocortical carcinoma: a multicenter 2529 
retrospective study. Surgery 2017 161 249–255. (https://doi.org/10.1016/j. surg.2016.08.058) 2530 
137 Tran TB, Liou D, Menon VG & Nissen NN. Surgical management of advanced 2531 
adrenocortical carcinoma: a 21-year population-based analysis. American Surgeon 2013 79 2532 
1115–1118.  2533 
138 Dy BM, Strajina V, Cayo AK, Richards ML, Farley DR, Grant CS, Harmsen WS, 2534 
Evans DB, Grubbs EG, Bible KC et al. Surgical resection of synchronously metastatic 2535 
adrenocortical cancer. Annals of Surgical Oncology 2015 22 146–151. 2536 
(https://doi.org/10.1245/s10434-014-3944-7) 2537 
139 Hahner S, Kreissl MC, Fassnacht M, Haenscheid H, Knoedler P, Lang K, Buck AK, 2538 
Reiners C, Allolio B & Schirbel A. [131I] Iodometomidate for targeted radionuclide therapy of 2539 
68 
 
advanced adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism 2012 2540 
97 914–922. (https://doi.org/10.1210/jc.2011-2765)  2541 
140 Cazejust J, De Baere T, Auperin A, Deschamps F, Hechelhammer L, Abdel-Rehim M, 2542 
Schlumberger M, Leboulleux S & Baudin E. Transcatheter arterial chemoembolization for 2543 
liver metastases in patients with adrenocortical carcinoma. Journal of Vascular and 2544 
Interventional Radiology 2010 21 1527–1532. 2545 
141 Wood BJ, Abraham J, Hvizda JL, Alexander HR & Fojo T. Radiofrequency ablation of 2546 
adrenal tumors and adrenocortical carcinoma metastases. Cancer 2003 97 554–560. 2547 
(https://doi. org/10.1002/cncr.11084) 2548 
142 Ho J, Turkbey B, Edgerly M, Alimchandani M, Quezado M, Camphausen K, Fojo T & 2549 
Kaushal A. Role of radiotherapy in adrenocortical carcinoma. Cancer Journal 2013 19 288–2550 
294. (https:// doi.org/10.1097/PPO.0b013e31829e3221) 2551 
143 Hahner S & Fassnacht M. Mitotane for adrenocortical carcinoma treatment. Current 2552 
Opinion in Investigational Drugs 2005 6 386–394. 2553 
144 Stell A & Sinnott R. The ENSAT registry: a digital repository supporting adrenal 2554 
cancer research. Studies in Health Technology and Informatics 2012 178 207–212. 2555 
145 Fassnacht M, Kenn W & Allolio B. Adrenal tumors: how to establish malignancy? 2556 
Journal of Endocrinological Investigation 2004 27 387–399. 2557 
(https://doi.org/10.1007/BF03351068) 2558 
146 Allolio B & Fassnacht M. Clinical review: adrenocortical carcinoma: clinical update. 2559 
Journal of Clinical Endocrinology and Metabolism 2006 91 2027–2037. 2560 
(https://doi.org/10.1210/jc.2005-2639) 2561 
147 Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, Stewart PM & 2562 
Montori VM. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice 2563 
Guideline. Journal of Clinical Endocrinology and Metabolism 2008 93 1526–1540. 2564 
(https://doi. org/10.1210/jc.2008-0125) 2565 
148 Libe R, Fratticci A & Bertherat J. Adrenocortical cancer: pathophysiology and clinical 2566 
management. Endocrine-Related Cancer 2007 14 13–28. 2567 
(https://doi.org/10.1677/erc.1.01130) 2568 
149 Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R & Welt 2569 
CK. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical 2570 
practice guideline. Journal of Clinical Endocrinology and Metabolism 2013 98 4565–4592. 2571 
(https:// doi.org/10.1210/jc.2013-2350) 2572 
150 Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M & 2573 
Young WF Jr. The management of primary aldosteronism: case detection, diagnosis, and 2574 
treatment: an Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology 2575 
and Metabolism 2016 101 1889–1916. (https://doi. org/10.1210/jc.2015-4061) 2576 
151 Dinnes J, Bancos I, Ferrante di Ruffano L, Chortis V, Davenport C, Bayliss S, Sahdev 2577 
A, Guest P, Fassnacht M, Deeks JJ et al. MANAGEMENT OF ENDOCRINE DISEASE: 2578 
Imaging for the diagnosis of malignancy in incidentally discovered adrenal masses: a 2579 
systematic review and meta-analysis. European Journal of Endocrinology 2016 175 R51–2580 
R64. (https://doi.org/10.1530/EJE-16-0461) 2581 
69 
 
152 Peppercorn PD, Grossman AB & Reznek RH. Imaging of incidentally discovered 2582 
adrenal masses. Clinical Endocrinology 1998 48 379–388. (https://doi.org/10.1046/j.1365-2583 
2265.1998.00475.x) 2584 
153 Caoili EM, Korobkin M, Francis IR, Cohan RH, Platt JF, Dunnick NR & Raghupathi KI. 2585 
Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. 2586 
Radiology 2002 222 629–633. (https://doi.org/10.1148/radiol.2223010766)  2587 
154 Blake MA, Kalra MK, Sweeney AT, Lucey BC, Maher MM, Sahani DV, Halpern EF, 2588 
Mueller PR, Hahn PF & Boland GW. Distinguishing benign from malignant adrenal masses: 2589 
multi-detector row CT protocol with 10-minute delay. Radiology 2006 238 578–585. (https:// 2590 
doi.org/10.1148/radiol.2382041514) 2591 
155 Ilias I, Sahdev A, Reznek RH, Grossman AB & Pacak K. The optimal imaging of 2592 
adrenal tumours: a comparison of different methods. Endocrine-Related Cancer 2007 14 2593 
587–599. (https://doi.org/10.1677/ ERC-07-0045) 2594 
156 Mackie GC, Shulkin BL, Ribeiro RC, Worden FP, Gauger PG, Mody RJ, Connolly LP, 2595 
Kunter G, Rodriguez-Galindo C, Wallis JW et al. Use of [18F]fluorodeoxyglucose positron 2596 
emission tomography in evaluating locally recurrent and metastatic adrenocortical 2597 
carcinoma. Journal of Clinical Endocrinology and Metabolism 2006 91 2665–2671. 2598 
(https://doi.org/10.1210/jc.2005-2612) 2599 
157 Groussin L, Bonardel G, Silvera S, Tissier F, Coste J, Abiven G, Libe R, Bienvenu M, 2600 
Alberini JL, Salenave S et al. 18F-Fluorodeoxyglucose positron emission tomography for the 2601 
diagnosis of adrenocortical tumors: a prospective study in 77 operated patients. Journal of 2602 
Clinical Endocrinology and Metabolism 2009 94 1713–1722. (https:// 2603 
doi.org/10.1210/jc.2008-2302) 2604 
158 Deandreis D, Leboulleux S, Caramella C, Schlumberger M & Baudin E. FDG PET in 2605 
the management of patients with adrenal masses and adrenocortical carcinoma. Hormones 2606 
and Cancer 2011 2 354–362. (https://doi.org/10.1007/s12672-011-0091-5) 2607 
159 Cistaro A, Niccoli Asabella A, Coppolino P, Quartuccio N, Altini C, Cucinotta M, 2608 
Alongi P, Balma M, Sanfilippo S, Buschiazzo A et al. Diagnostic and prognostic value of 18F-2609 
FDG PET/CT in comparison with morphological imaging in primary adrenal gland 2610 
malignancies – a multicenter experience. Hellenic Journal of Nuclear Medicine 2015 18 97–2611 
102. 2612 
160 Altinmakas E, Hobbs BP, Ye H, Grubbs EG, Perrier ND, Prieto VG, Lee JE & Ng CS. 2613 
Diagnostic performance of (18-)F-FDG-PET-CT     in adrenal lesions using histopathology as 2614 
reference standard. Abdominal Radiology 2017 42 577–584. (https://doi.org/10.1007/ 2615 
s00261-016-0915-4) 2616 
161 Ciftci E, Turgut B, Cakmakcilar A & Erturk SA. Diagnostic importance of 18F-FDG 2617 
PET/CT parameters and total lesion glycolysis in differentiating between benign and 2618 
malignant adrenal lesions. Nuclear Medicine Communications 2017 38 788–794. (https://doi. 2619 
org/10.1097/MNM.0000000000000712) 2620 
162 Bluemel C, Hahner S, Heinze B, Fassnacht M, Kroiss M, Bley TA, Wester HJ, Kropf 2621 
S, Lapa C, Schirbel A et al. Investigating the chemokine receptor 4 as potential theranostic 2622 
target in adrenocortical cancer patients. Clinical Nuclear Medicine 2017 42 e29–e34. 2623 
(https://doi.org/10.1097/RLU.0000000000001435) 2624 
163 Werner RA, Kroiss M, Nakajo M, Mugge DO, Hahner S, Fassnacht M, Schirbel A, 2625 
Bluemel C, Higuchi T, Papp L et al. Assessment of tumor heterogeneity in treatment-naive 2626 
70 
 
adrenocortical cancer patients using 18F-FDG positron emission tomography. Endocrine 2627 
2016 53 791–800. (https://doi.org/10.1007/s12020-016-0970-1) 2628 
164 Wu YW & Tan CH. Determination of a cutoff attenuation value on single-phase 2629 
contrast-enhanced CT for characterizing adrenal nodules via chemical shift MRI. Abdominal 2630 
Radiology 2016 41 1170–1177. (https://doi.org/10.1007/s00261-016-0654-6) 2631 
165 Nakajo M, Jinguji M, Shinaji T, Nakabeppu Y, Fukukura Y & Yoshiura T. Texture 2632 
analysis of FDG PET/CT for differentiating between FDG-avid benign and metastatic adrenal 2633 
tumors: efficacy of combining SUV and texture parameters. Abdominal Radiology 2017 42 2634 
2882–2889. (https://doi.org/10.1007/s00261-017-1207-3) 2635 
166 Guerin C, Pattou F, Brunaud L, Lifante JC, Mirallie E, Haissaguerre M, Huglo D, 2636 
Olivier P, Houzard C, Ansquer C et al. Performance of 18F- FDG PET/CT in the 2637 
characterization of adrenal masses in noncancer patients: a prospective study. Journal of 2638 
Clinical Endocrinology and Metabolism 2017 102 2465–2472. 2639 
(https://doi.org/10.1210/jc.2017-00254) 2640 
167 Marty M, Gaye D, Perez P, Auder C, Nunes ML, Ferriere A, Haissaguerre M & 2641 
Tabarin A. Diagnostic accuracy of computed tomography to identify adenomas among 2642 
adrenal incidentalomas in an endocrinological population. European Journal of 2643 
Endocrinology 2018 178 439–446. (https://doi.org/10.1530/EJE-17-1056) 2644 
168 Kim SJ, Lee SW, Pak K, Kim IJ & Kim K. Diagnostic accuracy of (18) F-FDG PET or 2645 
PET/CT for the characterization of adrenal masses: a systematic review and meta-analysis. 2646 
British Journal of Radiology 2018 91 20170520. (https://doi.org/10.1259/bjr.20170520) 2647 
169 Delivanis DA, Bancos I, Atwell TD, Schmit GD, Eiken PW, Natt N, Erickson D, 2648 
Maraka S, Young WF & Nathan MA. Diagnostic performance of unenhanced computed 2649 
tomography and (18) F-fluorodeoxyglucose positron emission tomography in indeterminate 2650 
adrenal tumours. Clinical Endocrinology 2018 88 30–36. (https://doi.org/10.1111/cen.13448) 2651 
170 Romeo V, Maurea S, Cuocolo R, Petretta M, Mainenti PP, Verde F, Coppola M, 2652 
Dell’Aversana S & Brunetti A. Characterization of adrenal lesions on unenhanced MRI using 2653 
texture analysis: a machine-learning approach. Journal of Magnetic Resonance Imaging 2654 
2018 48 198–204. (https://doi.org/10.1002/jmri.25954) 2655 
171 Thomas AJ, Habra MA, Bhosale PR, Qayyum AA, Ahmed K, Vicens R & Elsayes KM. 2656 
Interobserver agreement in distinguishing large adrenal adenomas and adrenocortical 2657 
carcinomas on computed tomography. Abdominal Radiology 2018 Epub. (https://doi. 2658 
org/10.1007/s00261-018-1603-3) 2659 
172 Ng CS, Altinmakas E, Wei W, Ghosh P, Li X, Grubbs EG, Perrier NA, Prieto VG, Lee 2660 
JE & Hobbs BP. Combining washout and noncontrast data from adrenal protocol CT: 2661 
improving diagnostic performance. Academic Radiology 2018 25 861–868. 2662 
(https://doi.org/10.1016/j. acra.2017.12.005) 2663 
173 Petersenn S, Richter PA, Broemel T, Ritter CO, Deutschbein T, Beil FU, Allolio B & 2664 
Fassnacht M. Computed tomography criteria for discrimination of adrenal adenomas and 2665 
adrenocortical carcinomas: analysis of the German ACC registry. European Journal of 2666 
Endocrinology 2015 172 415–422. (https://doi.org/10.1530/EJE-14-0916) 2667 
174 Bancos I, Tamhane S, Shah M, Delivanis DA, Alahdab F, Arlt W, Fassnacht M & 2668 
Murad MH. DIAGNOSIS OF ENDOCRINE DISEASE: The diagnostic performance of adrenal 2669 
biopsy: a systematic review and meta-analysis. European Journal of Endocrinology 2016 175 2670 
R65–R80. (https://doi.org/10.1530/EJE-16-0297) 2671 
71 
 
175 Williams AR, Hammer GD & Else T. Transcutaneous biopsy of adrenocortical 2672 
carcinoma is rarely helpful in diagnosis, potentially harmful, but does not affect patient 2673 
outcome. European Journal of Endocrinology 2014 170 829–835. 2674 
(https://doi.org/10.1530/EJE-13-1033) 2675 
176 Palazzo F, Dickinson A, Phillips B, Sahdev A, Bliss R, Rasheed A, Krukowski Z & 2676 
Newell-Price J. Adrenal surgery in England: better outcomes in high-volume practices. 2677 
Clinical Endocrinology 2016 85 17–20. (https://doi.org/10.1111/cen.13021) 2678 
177 Park HS, Roman SA & Sosa JA. Outcomes from 3144 adrenalectomies in the United 2679 
States: which matters more, surgeon volume or specialty? Archives of Surgery 2009 144 2680 
1060–1067. (https://doi. org/10.1001/archsurg.2009.191) 2681 
178 Lindeman B, Hashimoto DA, Bababekov YJ, Stapleton SM, Chang DC, Hodin RA & 2682 
Phitayakorn R. Fifteen years of adrenalectomies: impact of specialty training and operative 2683 
volume. Surgery 2018 163 150–156. (https://doi.org/10.1016/j. surg.2017.05.024) 2684 
179 Villar JM, Moreno P, Ortega J, Bollo E, Ramirez CP, Munoz N, Martinez C, 2685 
Dominguez-Adame E, Sancho J, Del Pino JM et al. Results of adrenal surgery. Data of a 2686 
Spanish National Survey. Langenbecks Archives of Surgery 2010 395 837–843. 2687 
(https://doi.org/10.1007/ s00423-010-0697-z) 2688 
180 Gallagher SF, Wahi M, Haines KL, Baksh K, Enriquez J, Lee TM, Murr MM & Fabri 2689 
PJ. Trends in adrenalectomy rates, indications, and physician volume: a statewide analysis 2690 
of 1816 adrenalectomies. Surgery 2007 142 1011–1021; discussion 1011–1021. (https://doi. 2691 
org/10.1016/j.surg.2007.09.024) 2692 
181 Lombardi CP, Raffaelli M, Boniardi M, De Toma G, Marzano LA, Miccoli P, Minni F, 2693 
Morino M, Pelizzo MR, Pietrabissa A et al. Adrenocortical carcinoma: effect of hospital 2694 
volume on patient outcome. Langenbecks Archives of Surgery 2012 397 201–207. (https:// 2695 
doi.org/10.1007/s00423-011-0866-8) 2696 
182 Gratian L, Pura J, Dinan M, Reed S, Scheri R, Roman S & Sosa JA. Treatment 2697 
patterns and outcomes for patients with adrenocortical carcinoma associated with hospital 2698 
case volume in the United States. Annals of Surgical Oncology 2014 21 3509–3514. 2699 
(https://doi. org/10.1245/s10434-014-3931-z) 2700 
183 Hermsen IG, Kerkhofs TM, den Butter G, Kievit J, van Eijck CH, Nieveen van Dijkum 2701 
EJ & Haak HR. Surgery in adrenocortical carcinoma: Importance of national cooperation and 2702 
centralized surgery. Surgery 2012 152 50–56. (https://doi.org/10.1016/j. surg.2012.02.005) 2703 
184 Kerkhofs TM, Verhoeven RH, Bonjer HJ, van Dijkum EJ, Vriens MR, De Vries J, Van 2704 
Eijck CH, Bonsing BA, Van de Poll-Franse LV & Haak HR. Surgery for adrenocortical 2705 
carcinoma in The Netherlands: analysis of the national cancer registry data. European 2706 
Journal of Endocrinology 2013 169 83–89. (https://doi.org/10.1530/EJE-13-0142) 2707 
185 Gaujoux S & Mihai R. European Society of Endocrine Surgeons (ESES) and 2708 
European Network for the Study of Adrenal Tumours (ENSAT) recommendations for the 2709 
surgical management of adrenocortical carcinoma. British Journal of Surgery 2017 104 358–2710 
376. (https://doi. org/10.1002/bjs.10414) 2711 
186 Gaujoux S & Brennan MF. Recommendation for standardized surgical management 2712 
of primary adrenocortical carcinoma. Surgery 2012 152 123–132. 2713 
(https://doi.org/10.1016/j.surg.2011.09.030) 2714 
187 Porpiglia F, Fiori C, Daffara FC, Zaggia B, Ardito A, Scarpa RM, Papotti M, Berruti A, 2715 
Scagliotti GV & Terzolo M. Does nephrectomy during radical adrenalectomy for stage II 2716 
72 
 
adrenocortical cancer affect patient outcome? Journal of Endocrinological Investigation 2016 2717 
39 465–471. (https://doi.org/10.1007/s40618-015-0422-4) 2718 
188 Donatini G, Caiazzo R, Do Cao C, Aubert S, Zerrweck C, El-Kathib Z, Gauthier T, 2719 
Leteurtre E, Wemeau JL, Vantyghem MC et al. Long-term survival after adrenalectomy for 2720 
stage I/II adrenocortical carcinoma (ACC): a retrospective comparative cohort study of 2721 
laparoscopic versus open approach. Annals of Surgical Oncology 2014 21 284–291. 2722 
(https://doi.org/10.1245/s10434-013-3164-6) 2723 
189 Sgourakis G, Lanitis S, Kouloura A, Zaphiriadou P, Karkoulias K, Raptis D, 2724 
Anagnostara A & Caraliotas C. Laparoscopic versus open adrenalectomy for stage I/II 2725 
adrenocortical carcinoma: meta-analysis of outcomes. Journal of Investigative Surgery 2015 2726 
28 145–152. (https://doi.org/10.3109/08941939.2014.987886) 2727 
190 Autorino R, Bove P, De Sio M, Miano R, Micali S, Cindolo L, Greco F, Nicholas J, 2728 
Fiori C, Bianchi G et al. Open versus laparoscopic adrenalectomy for adrenocortical 2729 
carcinoma: a meta-analysis of surgical and oncological outcomes. Annals of Surgical 2730 
Oncology 2016 23 1195–1202. (https://doi.org/10.1245/s10434-015-4900-x) 2731 
191 Langenhuijsen J, Birtle A, Klatte T, Porpiglia F & Timsit MO. Surgical management of 2732 
adrenocortical carcinoma: impact of laparoscopic approach, lymphadenectomy, and surgical 2733 
volume on outcomes-a systematic review and meta-analysis of the current literature. 2734 
European Urology Focus 2016 1 241–250. (https://doi.org/10.1016/j. euf.2015.12.001) 2735 
192 Lee CW, Salem AI, Schneider DF, Leverson GE, Tran TB, Poultsides GA, Postlewait 2736 
LM, Maithel SK, Wang TS, Hatzaras I et al. Minimally invasive resection of adrenocortical 2737 
carcinoma: a multi- institutional study of 201 patients. Journal of Gastrointestinal Surgery 2738 
2017 21 352–362. (https://doi.org/10.1007/s11605-016-3262-4) 2739 
193 Zheng GY, Li HZ, Deng JH, Zhang XB & Wu XC. Open adrenalectomy versus 2740 
laparoscopic adrenalectomy for adrenocortical carcinoma: a retrospective comparative study 2741 
on short-term oncologic prognosis. OncoTargets and Therapy 2018 11 1625–1632. 2742 
(https://doi.org/10.2147/OTT.S157518) 2743 
194 Mpaili E, Moris D, Tsilimigras DI, Oikonomou D, Pawlik TM, Schizas D, Papalampros 2744 
A, Felekouras E & Dimitroulis D. Laparoscopic versus open adrenalectomy for 2745 
localized/locally advanced primary adrenocortical carcinoma (ENSAT I-III) in adults: is 2746 
margin-free resection the key surgical factor that dictates outcome? A review of the literature. 2747 
Journal of Laparoendoscopic and Advanced Surgical Techniques Part A 2018 28 408–414. 2748 
(https://doi.org/10.1089/ lap.2017.0546) 2749 
195 Huynh KT, Lee DY, Lau BJ, Flaherty DC, Lee J & Goldfarb M. Impact of laparoscopic 2750 
adrenalectomy on overall survival in patients with nonmetastatic adrenocortical carcinoma. 2751 
Journal of the American College of Surgeons 2016 223 485–492. (https://doi.org/10.1016/j. 2752 
jamcollsurg.2016.05.015) 2753 
196 Barczynski M, Konturek A, Golkowski F, Cichon S, Huszno B, Peitgen K & Walz MK. 2754 
Posterior retroperitoneoscopic adrenalectomy: a comparison between the initial experience 2755 
in the invention phase and introductory phase of the new surgical technique. World Journal 2756 
of Surgery 2007 31 65–71. (https://doi.org/10.1007/s00268-006-0083-8) 2757 
197 Schreinemakers JM, Kiela GJ, Valk GD, Vriens MR & Rinkes IH. Retroperitoneal 2758 
endoscopic adrenalectomy is safe and effective. British Journal of Surgery 2010 97 1667–2759 
1672. (https://doi. org/10.1002/bjs.7191) 2760 
73 
 
198 Nilubol N, Patel D & Kebebew E. Does lymphadenectomy improve survival in patients 2761 
with adrenocortical carcinoma? A population- based study. World Journal of Surgery 2016 40 2762 
697–705. (https://doi. org/10.1007/s00268-015-3283-2) 2763 
199 Saade N, Sadler C & Goldfarb M. Impact of regional lymph node dissection on 2764 
disease specific survival in adrenal cortical carcinoma. Hormone and Metabolic Research 2765 
2015 47 820–825. (https://doi. org/10.1055/s-0035-1549877) 2766 
200 Harrison LE, Gaudin PB & Brennan MF. Pathologic features of prognostic 2767 
significance for adrenocortical carcinoma after curative resection. Archives of Surgery 1999 2768 
134 181–185. (https://doi. org/10.1001/archsurg.134.2.181) 2769 
201 Panjwani S, Moore MD, Gray KD, Finnerty BM, Beninato T, Brunaud L, Fahey TJ 3rd 2770 
& Zarnegar R. The impact of nodal dissection on staging in adrenocortical carcinoma. Annals 2771 
of Surgical Oncology 2017 24 3617–3623. (https://doi.org/10.1245/s10434-017-6064-3) 2772 
202 Gerry JM, Tran TB, Postlewait LM, Maithel SK, Prescott JD, Wang TS, Glenn JA, 2773 
Phay JE, Keplinger K, Fields RC et al. Lymphadenectomy for adrenocortical carcinoma: is 2774 
there a therapeutic benefit? Annals of Surgical Oncology 2016 23 708–713. 2775 
(https://doi.org/10.1245/s10434-016-5536-1) 2776 
203 Reibetanz J, Jurowich C, Erdogan I, Nies C, Rayes N, Dralle H, Behrend M, Allolio B 2777 
& Fassnacht M. Impact of lymphadenectomy on the oncologic outcome of patients with 2778 
adrenocortical carcinoma. Annals of Surgery 2012 255 363–369. (https://doi.org/10.1097/ 2779 
SLA.0b013e3182367ac3) 2780 
204 Chiche L, Dousset B, Kieffer E & Chapuis Y. Adrenocortical carcinoma extending into 2781 
the inferior vena cava: presentation of a 15-patient series and review of the literature. 2782 
Surgery 2006 139 15–27. (https://doi.org/10.1016/j.surg.2005.05.014) 2783 
205 Turbendian HK, Strong VE, Hsu M, Ghossein RA & Fahey TJ. Adrenocortical 2784 
carcinoma: the influence of large vessel extension. Surgery 2010 148 1057–1064. 2785 
(https://doi.org/10.1016/j. surg.2010.09.024) 2786 
206 Mihai R, Iacobone M, Makay O, Moreno P, Frilling A, Kraimps JL, Soriano A, Villar del 2787 
Moral J, Barczynski M, Duran MC et al. Outcome of operation in patients with adrenocortical 2788 
cancer invading the inferior vena cava – a European Society of Endocrine Surgeons (ESES) 2789 
survey. Langenbecks Archives of Surgery 2012 397 225–231. (https:// 2790 
doi.org/10.1007/s00423-011-0876-6)  2791 
207 Eller-Vainicher C, Morelli V, Salcuni AS, Battista C, Torlontano M, Coletti F, Iorio L, 2792 
Cairoli E, Beck-Peccoz P, Arosio M et al. Accuracy of several parameters of hypothalamic-2793 
pituitary-adrenal axis activity in predicting before surgery the metabolic effects of the removal 2794 
of an adrenal incidentaloma. European Journal of Endocrinology 2010 163 925–935. 2795 
(https://doi.org/10.1530/EJE-10-0602) 2796 
208 Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A, Hammer GD, Husebye 2797 
ES, Merke DP, Murad MH, Stratakis CA et al. Diagnosis and treatment of primary adrenal 2798 
insufficiency: an Endocrine Society Clinical Practice Guideline. Journal of Clinical 2799 
Endocrinology and Metabolism 2016 101 364–389. (https://doi. org/10.1210/jc.2015-1710) 2800 
209 Duregon E, Volante M, Bollito E, Goia M, Buttigliero C, Zaggia B, Berruti A, Scagliotti 2801 
GV & Papotti M. Pitfalls in the diagnosis of adrenocortical tumors: a lesson from 300 2802 
consultation cases. Human Pathology 2015 46 1799–1807. (https://doi.org/10.1016/j. 2803 
humpath.2015.08.012) 2804 
74 
 
210 Sangoi AR, Fujiwara M, West RB, Montgomery KD, Bonventre JV, Higgins JP, Rouse 2805 
RV, Gokden N & McKenney JK. Immunohistochemical distinction of primary adrenal cortical 2806 
lesions from metastatic clear cell renal cell carcinoma: a study of 248 cases. American 2807 
Journal of Surgical Pathology 2011 35 678–686. (https://doi. 2808 
org/10.1097/PAS.0b013e3182152629) 2809 
211 Weissferdt A, Phan A, Suster S & Moran CA. Adrenocortical carcinoma: a 2810 
comprehensive immunohistochemical study of 40 cases. Applied Immunohistochemistry and 2811 
Molecular Morphology 2014 22 24–30. (https://doi.org/10.1097/PAI.0b013e31828a96cf) 2812 
212 Tissier F, Aubert S, Leteurtre E, Alghuzlan A, Patey M, Decaussin M, Dousset L, 2813 
Gobet F, Hoang C, Mazerolles C et al. Adrenocortical tumors (ACT): evaluation and 2814 
harmonization of the reading of the Weiss system criteria at the French level. Laboratory 2815 
Investigation 2010 90 133A. 2816 
213 Tissier F, Aubert S, Leteurtre E, Al Ghuzlan A, Patey M, Decaussin M, Doucet L, 2817 
Gobet F, Hoang C, Mazerolles C et al. Adrenocortical tumors: improving the practice of the 2818 
weiss system through virtual microscopy a national program of the French Network INCa- 2819 
COMETE. American Journal of Surgical Pathology 2012 36 1194–1201. 2820 
(https://doi.org/10.1097/PAS.0b013e31825a6308) 2821 
214 Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing 2822 
adrenocortical tumors. American Journal of Surgical Pathology 1984 8 163–169. 2823 
(https://doi.org/10.1097/00000478-198403000-00001) 2824 
215 Weiss LM, Medeiros LJ & Vickery AL Jr. Pathologic features of prognostic 2825 
significance in adrenocortical carcinoma. American Journal of Surgical Pathology 1989 13 2826 
202–206. (https://doi. org/10.1097/00000478-198903000-00004) 2827 
216 van Slooten H, Schaberg A, Smeenk D & Moolenaar AJ. Morphologic characteristics 2828 
of benign and malignant adrenocortical tumors. Cancer 1985 55 766–773. 2829 
(https://doi.org/10.1002/1097- 0142(19850215)55:4<766::AID-CNCR2820550414>3.0.CO;2-2830 
7) 2831 
217 Duregon E, Fassina A, Volante M, Nesi G, Santi R, Gatti G, Cappellesso R, Dalino 2832 
Ciaramella P, Ventura L, Gambacorta M et al. The reticulin algorithm for adrenocortical tumor 2833 
diagnosis: a multicentric validation study on 245 unpublished cases. American Journal of 2834 
Surgical Pathology 2013 37 1433–1440. (https://doi.org/10.1097/ PAS.0b013e31828d387b) 2835 
218 Bisceglia M, Ludovico O, Di Mattia A, Ben-Dor D, Sandbank J, Pasquinelli G, Lau SK 2836 
& Weiss LM. Adrenocortical oncocytic tumors: report of 10 cases and review of the literature. 2837 
International Journal of Surgical Pathology 2004 12 231–243. (https://doi. 2838 
org/10.1177/106689690401200304) 2839 
219 Duregon E, Volante M, Cappia S, Cuccurullo A, Bisceglia M, Wong DD, Spagnolo 2840 
DV, Szpak-Ulczok S, Bollito E, Daffara F et al. Oncocytic adrenocortical tumors: diagnostic 2841 
algorithm and mitochondrial DNA profile in 27 cases. American Journal of Surgical Pathology 2842 
2011 35 1882–1893. (https://doi.org/10.1097/ PAS.0b013e31822da401) 2843 
220 Wong DD, Spagnolo DV, Bisceglia M, Havlat M, McCallum D & Platten MA. 2844 
Oncocytic adrenocortical neoplasms – a clinicopathologic study of 13 new cases 2845 
emphasizing the importance of their recognition. Human Pathology 2011 42 489–499. 2846 
(https://doi. org/10.1016/j.humpath.2010.08.010) 2847 
75 
 
221 Fuhrman SA, Lasky LC & Limas C. Prognostic significance of morphologic 2848 
parameters in renal cell carcinoma. American Journal of Surgical Pathology 1982 6 655–663. 2849 
(https://doi. org/10.1097/00000478-198210000-00007) 2850 
222 Lu H, Papathomas TG, van Zessen D, Palli I, de Krijger RR, van der Spek PJ, 2851 
Dinjens WN & Stubbs AP. Automated Selection of Hotspots (ASH): enhanced automated 2852 
segmentation and adaptive step finding for Ki67 hotspot detection in adrenal cortical cancer. 2853 
Diagnostic Pathology 2014 9 216. (https://doi.org/10.1186/s13000-014-0216-6) 2854 
223 Papathomas TG, Pucci E, Giordano TJ, Lu H, Duregon E, Volante M, Papotti M, 2855 
Lloyd RV, Tischler AS, van Nederveen FH et al. An international Ki67 reproducibility study in 2856 
adrenal cortical carcinoma. American Journal of Surgical Pathology 2016 40 569–576. 2857 
(https://doi.org/10.1097/PAS.0000000000000574) 2858 
224 Morimoto R, Satoh F, Murakami O, Suzuki T, Abe T, Tanemoto M, Abe M, Uruno A, 2859 
Ishidoya S, Arai Y et al. Immunohistochemistry of a proliferation marker Ki67/MIB1 in 2860 
adrenocortical carcinomas: Ki67/ MIB1 labeling index is a predictor for recurrence of 2861 
adrenocortical carcinomas. Endocrine Journal 2008 55 49–55. (https://doi. 2862 
org/10.1507/endocrj.K07-079) 2863 
225 Abiven G, Coste J, Groussin L, Anract P, Tissier F, Legmann P, Dousset B, Bertagna 2864 
X & Bertherat J. Clinical and biological features in the prognosis of adrenocortical cancer: 2865 
poor outcome of cortisol- secreting tumors in a series of 202 consecutive patients. Journal of 2866 
Clinical Endocrinology and Metabolism 2006 91 2650–2655. 2867 
226 Burotto M, Tageja N, Rosenberg A, Mahalingam S, Quezado M, Velarde M, Edgerly 2868 
M & Fojo T. Brain metastasis in patients with adrenocortical carcinoma: a clinical series. 2869 
Journal of Clinical Endocrinology and Metabolism 2015 100 331–336. (https://doi. 2870 
org/10.1210/jc.2014-2650) 2871 
227 Leboulleux S, Dromain C, Bonniaud G, Auperin A, Caillou B, Lumbroso J, Sigal R, 2872 
Baudin E & Schlumberger M. Diagnostic and prognostic value of 18-fluorodeoxyglucose 2873 
positron emission tomography in adrenocortical carcinoma: a prospective comparison with 2874 
computed tomography. Journal of Clinical Endocrinology and Metabolism 2006 91 920–925. 2875 
228 Ardito A, Massaglia C, Pelosi E, Zaggia B, Basile V, Brambilla R, Vigna-Taglianti F, 2876 
Duregon E, Arena V, Perotti P et al. 18F-FDG PET/ CT in the post-operative monitoring of 2877 
patients with adrenocortical carcinoma. European Journal of Endocrinology 2015 173 749–2878 
756. (https://doi.org/10.1530/EJE-15-0707) 2879 
229 Berruti A, Fassnacht M, Baudin E, Hammer G, Haak H, Leboulleux S, Skogseid B, 2880 
Allolio B & Terzolo M. Adjuvant therapy in patients with adrenocortical carcinoma: a position 2881 
of an international panel. Journal of Clinical Oncology 2010 28 e401–e402; author reply 2882 
e403. (https://doi.org/10.1200/JCO.2009.27.5958) 2883 
230 Megerle F, Herrmann W, Schloetelburg W, Ronchi CL, Pulzer A, Quinkler M, 2884 
Beuschlein F, Hahner S, Kroiss M & Fassnacht M. Mitotane monotherapy in patients with 2885 
advanced adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism 2018 2886 
103 1686–1695. (https://doi.org/10.1210/jc.2017-02591) 2887 
231 Volante M, Terzolo M, Fassnacht M, Rapa I, Germano A, Sbiera S, Daffara F, 2888 
Sperone P, Scagliotti G, Allolio B et al. Ribonucleotide reductase large subunit (RRM1) gene 2889 
expression may predict efficacy of adjuvant mitotane in adrenocortical cancer. Clinical 2890 
Cancer Research 2012 18 3452–3461. (https://doi.org/10.1158/1078-0432. CCR-11-2692) 2891 
76 
 
232 Ronchi CL, Sbiera S, Volante M, Steinhauer S, Scott-Wild V, Altieri B, Kroiss M, Bala 2892 
M, Papotti M, Deutschbein T et al. CYP2W1 is highly expressed in adrenal glands and is 2893 
positively associated with the response to mitotane in adrenocortical carcinoma. PLoS ONE 2894 
2014 9 e105855. (https://doi.org/10.1371/journal.pone.0105855) 2895 
233 Terzolo M, Baudin AE, Ardito A, Kroiss M, Leboulleux S, Daffara F, Perotti P, 2896 
Feelders RA, deVries JH, Zaggia B et al. Mitotane levels predict the outcome of patients with 2897 
adrenocortical carcinoma treated adjuvantly following radical resection. European Journal of 2898 
Endocrinology 2013 169 263–270. (https://doi.org/10.1530/EJE-13-0242) 2899 
234 Terzolo M, Daffara F, Ardito A, Zaggia B, Basile V, Ferrari L & Berruti A. Management 2900 
of adrenal cancer: a 2013 update. Journal of Endocrinological Investigation 2014 37 207–2901 
217. (https://doi. org/10.1007/s40618-013-0049-2) 2902 
235 Huang H & Fojo T. Adjuvant mitotane for adrenocortical cancer – a recurring 2903 
controversy. Journal of Clinical Endocrinology and Metabolism 2008 93 3730–3732. 2904 
(https://doi.org/10.1210/jc.2008-0579) 2905 
236 Terzolo M, Fassnacht M, Ciccone G, Allolio B & Berruti A. Adjuvant mitotane for 2906 
adrenocortical cancer – working through uncertainty. Journal of Clinical Endocrinology and 2907 
Metabolism 2009 94 1879–1880. (https://doi.org/10.1210/jc.2009-0120) 2908 
237 Polat B, Fassnacht M, Pfreundner L, Guckenberger M, Bratengeier K, Johanssen S, 2909 
Kenn W, Hahner S, Allolio B & Flentje M. Radiotherapy in adrenocortical carcinoma. Cancer 2910 
2009 115 2816–2823. (https:// doi.org/10.1002/cncr.24331) 2911 
238 Sabolch A, Else T, Jackson W, Williams A, Miller BS, Worden F, Hammer GD & Jolly 2912 
S. Improved local control with adjuvant radiation therapy in localized adrenocortical 2913 
carcinoma: a case- matched retrospective study. International Journal of Radiation Oncology 2914 
Biology Physics 2013 1 S84. (https://doi.org/10.1016/j. ijrobp.2013.06.219) 2915 
239 Nelson DW, Chang SC, Bandera BC, Fischer TD, Wollman R & Goldfarb M. Adjuvant 2916 
radiation is associated with improved survival for select patients with non-metastatic 2917 
adrenocortical carcinoma. Annals of Surgical Oncology 2018 25 2060–2066. (https://doi. 2918 
org/10.1245/s10434-018-6510-x) 2919 
240 Cerquetti L, Bucci B, Marchese R, Misiti S, De Paula U, Miceli R, Muleti A, Amendola 2920 
D, Piergrossi P, Brunetti E et al. Mitotane increases the radiotherapy inhibitory effect and 2921 
induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines. 2922 
Endocrine-Related Cancer 2008 15 623–634. (https://doi. org/10.1677/erc.1.1315) 2923 
241 Cerquetti L, Sampaoli C, Amendola D, Bucci B, Misiti S, Raza G, De Paula U, 2924 
Marchese R, Brunetti E, Toscano V et al. Mitotane sensitizes adrenocortical cancer cells to 2925 
ionizing radiations by involvement of the cyclin B1/CDK complex in G2 arrest and mismatch 2926 
repair enzymes modulation. International Journal of Oncology 2010 37 493–501. 2927 
242 Khan TS, Imam H, Juhlin C, Skogseid B, Grondal S, Tibblin S, Wilander E, Oberg K & 2928 
Eriksson B. Streptozocin and o,p′DDD in the treatment of adrenocortical cancer patients: 2929 
long-term survival in its adjuvant use. Annals of Oncology 2000 11 1281–1287. (https://doi. 2930 
org/10.1023/A:1008377915129) 2931 
243 Hermsen IGC, Gelderblom H, Kievit J, Romijn JA & Haak HR. Extremely long survival 2932 
in six patients despite recurrent and metastatic adrenal carcinoma. European Journal of 2933 
Endocrinology 2008 158 911–919. (https://doi.org/10.1530/EJE-07-0723) 2934 
244 Bednarski BK, Habra MA, Phan A, Milton DR, Wood C, Vauthey N, Evans DB, Katz 2935 
MH, Ng CS, Perrier ND et al. Borderline resectable adrenal cortical carcinoma: a potential 2936 
77 
 
role for preoperative chemotherapy. World Journal of Surgery 2014 38 1318–1327. (https:// 2937 
doi.org/10.1007/s00268-014-2484-4) 2938 
245 Wangberg B, Khorram-Manesh A, Jansson S, Nilsson B, Nilsson O, Jakobsson CE, 2939 
Lindstedt S, Oden A & Ahlman H. The long-term survival in adrenocortical carcinoma with 2940 
active surgical management and use of monitored mitotane. Endocrine-Related Cancer 2010 2941 
17 265–272. (https://doi.org/10.1677/ERC-09-0190) 2942 
246 Rangel C, Scattolin G, Pais-Costa SR, Vieira E & Gaio E. Neoadjuvant chemotherapy 2943 
and salvage surgery for an aldosterone-producing adrenal carcinoma with inferior vena cava 2944 
thrombus: case report and literature review. Asian Journal of Surgery 2013 36 134–136. 2945 
(https://doi.org/10.1016/j.asjsur.2012.08.008) 2946 
247 Ronchi CL, Sbiera S, Kraus L, Wortmann S, Johanssen S, Adam P, Willenberg HS, 2947 
Hahner S, Allolio B & Fassnacht M. Expression of excision repair cross complementing 2948 
group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based 2949 
chemotherapy. Endocrine-Related Cancer 2009 16 907–918. (https:// doi.org/10.1677/ERC-2950 
08-0224) 2951 
248 Malandrino P, Al Ghuzlan A, Castaing M, Young J, Caillou B, Travagli JP, Elias D, de 2952 
Baere T, Dromain C, Paci A et al. Prognostic markers of survival after combined mitotane- 2953 
and platinum-based chemotherapy in metastatic adrenocortical carcinoma. Endocrine- 2954 
Related Cancer 2010 17 797–807. (https://doi.org/10.1677/ERC-09-0341) 2955 
249 Roca E, Berruti A, Sbiera S, Rapa I, Oneda E, Sperone P, Ronchi CL, Ferrari L, 2956 
Grisanti S, Germano A et al. Topoisomerase2alpha and thymidylate synthase expression in 2957 
adrenocortical cancer. Endocrine- Related Cancer 2017 24 299–307. 2958 
(https://doi.org/10.1530/ERC-17-0095) 2959 
250 Laufs V, Altieri B, Sbiera S, Kircher S, Steinhauer S, Beuschlein F, Quinkler M, 2960 
Willenberg HS, Rosenwald A, Fassnacht M et al. ERCC1 as predictive biomarker to 2961 
platinum-based chemotherapy in adrenocortical carcinomas. European Journal of 2962 
Endocrinology 2018 178 183–190. (https://doi.org/10.1530/EJE-17-0788) 2963 
251 Bates SE, Shieh CY, Mickley LA, Dichek HL, Gazdar A, Loriaux DL & Fojo AT. 2964 
Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug 2965 
resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical 2966 
carcinomas. Journal of Clinical Endocrinology and Metabolism 1991 73 18–29. (https://doi. 2967 
org/10.1210/jcem-73-1-18) 2968 
252 Almeida MQ, Fragoso MC, Lotfi CF, Santos MG, Nishi MY, Costa MH, Lerario AM, 2969 
Maciel CC, Mattos GE, Jorge AA et al. Expression of IGF-II and its receptor in pediatric and 2970 
adult adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism 2008 93 2971 
3524–3531. (https://doi.org/10.1210/jc.2008-0065) 2972 
253 Boulle N, Logie A, Gicquel C, Perin L & Le Bouc Y. Increased levels of insulin-like 2973 
growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic 2974 
adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism 1998 83 1713–2975 
1720. 2976 
254 Gicquel C, Bertagna X, Schneid H, Francillard-Leblond M, Luton JP, Girard F & Le 2977 
Bouc Y. Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-2978 
II gene in sporadic adrenocortical tumors. Journal of Clinical Endocrinology and Metabolism 2979 
1994 78 1444–1453. 2980 
78 
 
255 Giordano TJ, Thomas DG, Kuick R, Lizyness M, Misek DE, Smith AL, Sanders D, 2981 
Aljundi RT, Gauger PG, Thompson NW et al. Distinct transcriptional profiles of adrenocortical 2982 
tumors uncovered by DNA microarray analysis. American Journal of Pathology 2003 162 2983 
521–531. (https://doi.org/10.1016/S0002-9440(10)63846-1) 2984 
256 Weber MM, Fottner C & Wolf E. The role of the insulin-like growth factor system in 2985 
adrenocortical tumourigenesis. European Journal of Clinical Investigation 2000 30 2986 
(Supplement 3) 69–75. (https://doi. org/10.1046/j.1365-2362.2000.0300s3069.x) 2987 
257 Jones RL, Kim ES, Nava-Parada P, Alam S, Johnson FM, Stephens AW, Simantov 2988 
R, Poondru S, Gedrich R, Lippman SM et al. Phase I study of intermittent oral dosing of the 2989 
insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced 2990 
solid tumors. Clinical Cancer Research 2015 21 693–700. (https://doi. org/10.1158/1078-2991 
0432.CCR-14-0265) 2992 
258 Naing A, Kurzrock R, Burger A, Gupta S, Lei X, Busaidy N, Hong D, Chen HX, Doyle 2993 
LA, Heilbrun LK et al. Phase I trial of cixutumumab combined with temsirolimus in patients 2994 
with advanced cancer. Clinical Cancer Research 2011 17 6052–6060. (https://doi. 2995 
org/10.1158/1078-0432.CCR-10-2979) 2996 
259 Vezzosi D, Do Cao C, Hescot S, Bertherat J, Haissaguerre M, Bongard V, Drui D, De 2997 
La Fouchardiere C, Illouz F, Borson-Chazot F et al. Time until partial response in metastatic 2998 
adrenocortical carcinoma long-term survivors. Hormones and Cancer 2018 9 62–69. 2999 
(https://doi.org/10.1007/s12672-017-0313-6) 3000 
260 Kroiss M, Quinkler M, Lutz WK, Allolio B & Fassnacht M. Drug interactions with 3001 
mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical 3002 
carcinoma. Clinical Endocrinology 2011 75 585–591. (https://doi.org/10.1111/j.1365- 3003 
2265.2011.04214.x) 3004 
261 Faggiano A, Leboulleux S, Young J, Schlumberger M & Baudin E. Rapidly 3005 
progressing high o,p′DDD doses shorten the time required to reach the therapeutic threshold 3006 
with an acceptable tolerance: preliminary results. Clinical Endocrinology 2006 64 110–113. 3007 
(https:// doi.org/10.1111/j.1365-2265.2005.02403.x) 3008 
262 Mauclere-Denost S, Leboulleux S, Borget I, Paci A, Young J, Al Ghuzlan A, 3009 
Deandreis D, Drouard L, Tabarin A, Chanson P et al. High-dose mitotane strategy in 3010 
adrenocortical carcinoma (ACC): prospective analysis of plasma mitotane measurement 3011 
during the first three months of follow-up. European Journal of Endocrinology 2011 166 261–3012 
268. (https://doi.org/10.1530/EJE-11-0557) 3013 
263 Terzolo M, Pia A, Berruti A, Osella G, Ali A, Carbone V, Testa E, Dogliotti L & Angeli 3014 
A. Low-dose monitored mitotane treatment achieves the therapeutic range with manageable 3015 
side effects in patients with adrenocortical cancer. Journal of Clinical Endocrinology and 3016 
Metabolism 2000 85 2234–2238. 3017 
264 Terzolo M & Berruti A. Adjunctive treatment of adrenocortical carcinoma. Current 3018 
Opinion in Endocrinology, Diabetes and Obesity 2008 15 221–226. 3019 
(https://doi.org/10.1097/MED.0b013e3282fdf4c0) 3020 
265 Kerkhofs TM, Baudin E, Terzolo M, Allolio B, Chadarevian R, Mueller HH, Skogseid 3021 
B, Leboulleux S, Mantero F, Haak HR et al. Comparison of two mitotane starting dose 3022 
regimens in patients with advanced adrenocortical carcinoma. Journal of Clinical 3023 
Endocrinology and Metabolism 2013 98 4759–4767. (https://doi.org/10.1210/ jc.2013-2281) 3024 
79 
 
266 Moolenaar AJ, van Slooten H, van Seters AP & Smeenk D. Blood levels of o,p′-DDD 3025 
following administration in various vehicles after a single dose and during long-term 3026 
treatment. Cancer Chemotherapy and Pharmacology 1981 7 51–54. (https://doi.org/10.1007/ 3027 
BF00258213) 3028 
267 Kerkhofs TM, Derijks LJ, Ettaieb MH, Eekhoff EM, Neef C, Gelderblom H, den Hartigh 3029 
J, Guchelaar HJ & Haak HR. Short-term variation in plasma mitotane levels confirms the 3030 
importance of trough level monitoring. European Journal of Endocrinology 2014 171 677–3031 
683. (https://doi.org/10.1530/EJE-14-0388) 3032 
268 Daffara F, De Francia S, Reimondo G, Zaggia B, Aroasio E, Porpiglia F, Volante M, 3033 
Termine A, Di Carlo F, Dogliotti L et al. Prospective evaluation of mitotane toxicity in 3034 
adrenocortical cancer patients treated adjuvantly. Endocrine-Related Cancer 2008 15 1043–3035 
1053. (https://doi.org/10.1677/ERC-08-0103) 3036 
269 van Slooten H, Moolenaar AJ, van Seters AP & Smeenk D. The treatment of 3037 
adrenocortical carcinoma with o,p′-DDD: prognostic implications of serum level monitoring. 3038 
European Journal of Cancer and Clinical Oncology 1984 20 47–53. 3039 
(https://doi.org/10.1016/0277-5379(84)90033-6) 3040 
270 Chortis V, Taylor AE, Schneider P, Tomlinson JW, Hughes BA, O’Neil DM, Libé R, 3041 
Allolio B, Bertagna X, Bertherat J et al. Mitotane therapy in adrenocortical cancer induces 3042 
CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and 3043 
androgen replacement. Journal of Clinical Endocrinology and Metabolism 2013 98 161–171. 3044 
(https://doi.org/10.1210/jc.2012-2851) 3045 
271 Reimondo G, Puglisi S, Zaggia B, Basile V, Saba L, Perotti P, De Francia S, Volante 3046 
M, Zatelli MC, Cannavo S et al. Effects of mitotane on the hypothalamic-pituitary-adrenal axis 3047 
in patients with adrenocortical carcinoma. European Journal of Endocrinology 2017 177 361–3048 
367. (https://doi.org/10.1530/EJE-17-0452) 3049 
272 Kerkhofs TM, Derijks LJ, Ettaieb H, den Hartigh J, Neef K, Gelderblom H, Guchelaar 3050 
HJ & Haak HR. Development of a pharmacokinetic model of mitotane: toward personalized 3051 
dosing in adrenocortical carcinoma. Therapeutic Drug Monitoring 2015 37 58–65. 3052 
(https://doi.org/10.1097/FTD.0000000000000102) 3053 
273 Alexandraki KI, Kaltsas GA, le Roux CW, Fassnacht M, Ajodha S, Christ-Crain M, 3054 
Akker SA, Drake WM, WM, Edwards R, Allolio B et al. Assessment of serum-free cortisol 3055 
levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study. Clinical 3056 
Endocrinology 2010 72 305–311. (https://doi.org/10.1111/ j.1365-2265.2009.03631.x) 3057 
274 Russo M, Scollo C, Pellegriti G, Cotta OR, Squatrito S, Frasca F, Cannavo S & Gullo 3058 
D. Mitotane treatment in patients with adrenocortical cancer causes central hypothyroidism. 3059 
Clinical Endocrinology 2016 84 614–619. (https://doi.org/10.1111/cen.12868) 3060 
275 Tada H, Nohara A, Kawashiri MA, Inazu A, Mabuchi H & Yamagishi M. Marked 3061 
transient hypercholesterolemia caused by low-dose mitotane as adjuvant chemotherapy for 3062 
adrenocortical carcinoma. Journal of Atherosclerosis and Thrombosis 2014 21 1326–1329. 3063 
(https://doi.org/10.5551/jat.27557) 3064 
276 Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO & Tabarin 3065 
A. Treatment of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. 3066 
Journal of Clinical Endocrinology and Metabolism 2015 100 2807–2831. (https://doi. 3067 
org/10.1210/jc.2015-1818) 3068 
80 
 
277 Claps M, Cerri S, Grisanti S, Lazzari B, Ferrari V, Roca E, Perotti P, Terzolo M, 3069 
Sigala S & Berruti A. Adding metyrapone to chemotherapy plus mitotane for Cushing’s 3070 
syndrome due to advanced adrenocortical carcinoma. Endocrine 2017 61 169–172. 3071 
(https://doi. org/10.1007/s12020-017-1428-9) 3072 
278 Castinetti F, Fassnacht M, Johanssen S, Terzolo M, Bouchard P, Chanson P, Do Cao 3073 
C, Morange I, Pico A, Ouzounian S et al. Merits and pitfalls of mifepristone in Cushing’s 3074 
syndrome. European Journal of Endocrinology 2009 160 1003–1010. 3075 
(https://doi.org/10.1530/EJE-09-0098) 3076 
279 Chow E, Hoskin P, Mitera G, Zeng L, Lutz S, Roos D, Hahn C, van der Linden Y, 3077 
Hartsell W & Kumar E. Update of the international consensus on palliative radiotherapy 3078 
endpoints for future clinical trials in bone metastases. International Journal of Radiation 3079 
Oncology, Biology, Physics 2012 82 1730–1737. (https://doi.org/10.1016/j. 3080 
ijrobp.2011.02.008) 3081 
280 Pin Y, Paix A, Le Fevre C, Antoni D, Blondet C & Noel G. A systematic review of 3082 
palliative bone radiotherapy based on pain relief and retreatment rates. Critical Reviews in 3083 
Oncology/ Hematology 2018 123 132–137. (https://doi.org/10.1016/j. critrevonc.2018.01.006) 3084 
281 Ferrell BR, Temel JS, Temin S, Alesi ER, Balboni TA, Basch EM, Firn JI, Paice JA, 3085 
Peppercorn JM, Phillips T et al. Integration of palliative care into standard oncology care: 3086 
American Society of Clinical Oncology Clinical Practice Guideline update. Journal of Clinical 3087 
Oncology 2017 35 96–112. (https://doi.org/10.1200/JCO.2016.70.1474) 3088 
282 Herrmann LJ, Heinze B, Fassnacht M, Willenberg HS, Quinkler M, Reisch N, Zink M, 3089 
Allolio B & Hahner S. TP53 germline mutations in adult patients with adrenocortical 3090 
carcinoma. Journal of Clinical Endocrinology and Metabolism 2012 97 E476–E485. 3091 
(https://doi. org/10.1210/jc.2011-1982) 3092 
283 Raymond VM, Else T, Everett JN, Long JM, Gruber SB & Hammer GD. Prevalence of 3093 
germline TP53 mutations in a prospective series of unselected patients with adrenocortical 3094 
carcinoma. Journal of Clinical Endocrinology and Metabolism 2013 98 E119–E125. 3095 
(https://doi. org/10.1210/jc.2012-2198) 3096 
284 Waldmann J, Patsalis N, Fendrich V, Langer P, Saeger W, Chaloupka B, 3097 
Ramaswamy A, Fassnacht M, Bartsch DK & Slater EP. Clinical impact of TP53 alterations in 3098 
adrenocortical carcinomas. Langenbecks Archives of Surgery 2012 397 209–216. 3099 
(https://doi. org/10.1007/s00423-011-0868-6) 3100 
285 Raymond VM, Everett JN, Furtado LV, Gustafson SL, Jungbluth CR, Gruber SB, 3101 
Hammer GD, Stoffel EM, Greenson JK, Giordano TJ et al. Adrenocortical carcinoma is a 3102 
lynch syndrome-associated cancer. Journal of Clinical Oncology 2013 31 3012–3018. 3103 
(https://doi. org/10.1200/JCO.2012.48.0988) 3104 
286 Stoffel EM, Mangu PB, Gruber SB, Hamilton SR, Kalady MF, Lau MW, Lu KH, Roach 3105 
N & Limburg PJ. Hereditary colorectal cancer syndromes: American Society of Clinical 3106 
Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: 3107 
European Society for Medical Oncology Clinical Practice Guidelines. Journal of Clinical 3108 
Oncology 2015 33 209–217. (https://doi. org/10.1200/JCO.2014.58.1322) 3109 
287 Daly MB, Pilarski R, Berry M, Buys SS, Farmer M, Friedman S, Garber JE, Kauff ND, 3110 
Khan S, Klein C et al. NCCN Guidelines Insights: genetic/familial high-risk assessment: 3111 
breast and ovarian, version 2.2017. Journal of the National Comprehensive Cancer Network 3112 
2017 15 9–20. (https://doi.org/10.6004/jnccn.2017.0003) 3113 
81 
 
288 Kratz CP, Achatz MI, Brugieres L, Frebourg T, Garber JE, Greer MC, Hansford JR, 3114 
Janeway KA, Kohlmann WK, McGee R et al. Cancer screening recommendations for 3115 
individuals with Li-Fraumeni syndrome. Clinical Cancer Research 2017 23 e38–e45. 3116 
(https://doi. org/10.1158/1078-0432.CCR-17-0408) 3117 
289 Ballinger ML, Best A, Mai PL, Khincha PP, Loud JT, Peters JA, Achatz MI, Chojniak 3118 
R, Balieiro da Costa A, Santiago KM et al. Baseline surveillance in Li-Fraumeni syndrome 3119 
using whole-body magnetic resonance imaging: a meta-analysis. JAMA Oncology 2017 3 3120 
1634–1639. (https://doi.org/10.1001/jamaoncol.2017.1968) 3121 
290 Gupta S, Provenzale D, Regenbogen SE, Hampel H, Slavin TP Jr, Hall MJ, Llor X, 3122 
Chung DC, Ahnen DJ, Bray T et al. NCCN guidelines insights: genetic/familial high-risk 3123 
assessment: colorectal, version 3.2017. Journal of the National Comprehensive Cancer 3124 
Network 2017 15 1465–1475. (https://doi.org/10.6004/jnccn.2017.0176) 3125 
291 Stoffel EM, Mangu PB & Limburg PJ. Hereditary colorectal cancer syndromes: 3126 
American Society of Clinical Oncology clinical practice guideline endorsement of the familial 3127 
risk-colorectal cancer: European Society for Medical Oncology clinical practice guidelines. 3128 
Journal of Oncology Practice 2015 11 e437–e441. (https://doi. 3129 
org/10.1200/JOP.2015.003665) 3130 
292 Else T. Association of adrenocortical carcinoma with familial cancer susceptibility 3131 
syndromes. Molecular and Cellular Endocrinology 2012 351 66–70. 3132 
(https://doi.org/10.1016/j.mce.2011.12.008) 3133 
293 McDonnell CM & Zacharin MR. Adrenal cortical tumours: 25 years’ experience at the 3134 
Royal Children’s Hospital, Melbourne. Journal of Paediatrics and Child Health 2003 39 682–3135 
685. (https://doi. org/10.1046/j.1440-1754.2003.00268.x) 3136 
294 Custodio G, Parise GA, Kiesel Filho N, Komechen H, Sabbaga CC, Rosati R, Grisa L, 3137 
Parise IZ, Pianovski MA, Fiori CM et al. Impact of neonatal screening and surveillance for the 3138 
TP53 R337H mutation on early detection of childhood adrenocortical tumors. Journal of 3139 
Clinical Oncology 2013 31 2619–2626. (https://doi.org/10.1200/ JCO.2012.46.3711) 3140 
295 Wasserman JD, Novokmet A, Eichler-Jonsson C, Ribeiro RC, Rodriguez-Galindo C, 3141 
Zambetti GP & Malkin D. Prevalence and functional consequence of TP53 mutations in 3142 
pediatric adrenocortical carcinoma: a children’s oncology group study. Journal of Clinical 3143 
Oncology 2015 33 602–609. (https://doi.org/10.1200/ JCO.2013.52.6863) 3144 
296 Eschler DC, Kogekar N & Pessah-Pollack R. Management of adrenal tumors in 3145 
pregnancy. Endocrinology Metabolism Clinics of North America 2015 44 381–397. 3146 
(https://doi.org/10.1016/j. ecl.2015.02.006) 3147 
297 Abiven-Lepage G, Coste J, Tissier F, Groussin L, Billaud L, Dousset B, Goffinet F, 3148 
Bertagna X, Bertherat J & Raffin-Sanson ML. Adrenocortical carcinoma and pregnancy: 3149 
clinical and biologicalfeatures and prognosis. European Journal of Endocrinology 2010 163 3150 
793–800. (https://doi.org/10.1530/EJE-10-0412) 3151 
298 Sirianni R, Zolea F, Chimento A, Ruggiero C, Cerquetti L, Fallo F, Pilon C, Arnaldi G, 3152 
Carpinelli G, Stigliano A et al. Targeting estrogen receptor-alpha reduces adrenocortical 3153 
cancer (ACC) cell growth in vitro and in vivo: potential therapeutic role of selective estrogen 3154 
receptor modulators (SERMs) for ACC treatment. Journal of Clinical Endocrinology and 3155 
Metabolism 2012 97 E2238–E2250. (https://doi. org/10.1210/jc.2012-2374) 3156 
82 
 
299 Tripto-Shkolnik L, Blumenfeld Z, Bronshtein M, Salmon A & Jaffe A. Pregnancy in a 3157 
patient with adrenal carcinoma treated with mitotane: a case report and review of literature. 3158 
Journal of Clinical Endocrinology and Metabolism 2013 98 443–447. 3159 
300 de Corbiere P, Ritzel K, Cazabat L, Ropers J, Schott M, Libe R, Koschker AC, 3160 
Leboulleux S, Deutschbein T, Do Cao C et al. Pregnancy in women previously treated for an 3161 
adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism 2015 100 4604–3162 
4611. (https://doi.org/10.1210/jc.2015-2341) 3163 
301 Hescot S, Seck A, Guerin M, Cockenpot F, Huby T, Broutin S, Young J, Paci A, 3164 
Baudin E & Lombes M. Lipoprotein-free mitotane exerts high cytotoxic activity in 3165 
adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism 2015 100 2890–3166 
2898. (https://doi. org/10.1210/JC.2015-2080) 3167 
302 Hescot S, Slama A, Lombes A, Paci A, Remy H, Leboulleux S, Chadarevian R, 3168 
Trabado S, Amazit L, Young J et al. Mitotane alters mitochondrial respiratory chain activity by 3169 
inducing cytochrome c oxidase defect in human adrenocortical cells. Endocrine-Related 3170 
Cancer 2013 20 371–381. (https://doi.org/10.1530/ERC-12-0368) 3171 
303 Sbiera S, Leich E, Liebisch G, Sbiera I, Schirbel A, Wiemer L, Matysik S, Eckhardt C, 3172 
Gardill F, Gehl A et al. Mitotane inhibits sterol-O-acyl transferase 1 triggering lipid-mediated 3173 
endoplasmic reticulum stress and apoptosis in adrenocortical carcinoma cells. Endocrinology 3174 
2015 156 3895–3908. (https://doi.org/10.1210/en.2015-1367) 3175 
304 Hescot S, Amazit L, Lhomme M, Travers S, DuBow A, Battini S, Boulate G, Namer IJ, 3176 
Lombes A, Kontush A et al. Identifying mitotane-induced mitochondria-associated 3177 
membranes dysfunctions: metabolomic and lipidomic approaches. Oncotarget 2017 8 3178 
109924–109940. 3179 
305 Arlt W, Biehl M, Taylor AE, Hahner S, Libe R, Hughes BA, Schneider P, Smith DJ, 3180 
Stiekema H, Krone N et al. Urine steroid metabolomics as a biomarker tool for detecting 3181 
malignancy in adrenal tumors. Journal of Clinical Endocrinology and Metabolism 2011 96 3182 
3775–3784. (https:// doi.org/10.1210/jc.2011-1565) 3183 
306 Kerkhofs TM, Kerstens MN, Kema IP, Willems TP & Haak HR. Diagnostic value of 3184 
urinary steroid profiling in the evaluation of adrenal tumors. Hormones and Cancer 2015 6 3185 
168–175. (https://doi. org/10.1007/s12672-015-0224-3) 3186 
307 Taylor DR, Ghataore L, Couchman L, Vincent RP, Whitelaw B, Lewis D, Diaz-Cano 3187 
S, Galata G, Schulte KM, Aylwin S et al. A 13-steroid serum panel based on LC-MS/MS: use 3188 
in detection of adrenocortical carcinoma. Cliniccal Chemistry 2017 63 1836–1846. 3189 
(https://doi.org/10.1373/clinchem.2017.277624) 3190 
308 Hines JM, Bancos I, Bancos C, Singh RD, Avula AV, Young WF, Grebe SK & Singh 3191 
RJ. High-resolution, accurate-mass (HRAM) mass spectrometry urine steroid profiling in the 3192 
diagnosis of adrenal disorders. Clinical Chemistry 2017 63 1824–1835. (https://doi. 3193 
org/10.1373/clinchem.2017.271106) 3194 
309 Pinzani P, Scatena C, Salvianti F, Corsini E, Canu L, Poli G, Paglierani M, Piccini V, 3195 
Pazzagli M, Nesi G et al. Detection of circulating tumor cells in patients with adrenocortical 3196 
carcinoma: a monocentric preliminary study. Journal of Clinical Endocrinology and 3197 
Metabolism 2013 98 3731–3738. (https://doi.org/10.1210/jc.2013-1396) 3198 
310 Chabre O, Libe R, Assie G, Barreau O, Bertherat J, Bertagna X, Feige JJ & Cherradi 3199 
N. Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer 3200 
patients. Endocrine-Related Cancer 2013 20 579–594. 3201 
83 
 
311 Szabo DR, Luconi M, Szabo PM, Toth M, Szucs N, Horanyi J, Nagy Z, Mannelli M, 3202 
Patocs A, Racz K et al. Analysis of circulating microRNAs in adrenocortical tumors. 3203 
Laboratory Investigation 2014 94 331–339. (https://doi.org/10.1038/labinvest.2013.148) 3204 
312 Perge P, Butz H, Pezzani R, Bancos I, Nagy Z, Paloczi K, Nyiro G, Decmann A, Pap 3205 
E, Luconi M et al. Evaluation and diagnostic potential of circulating extracellular vesicle-3206 
associated microRNAs in adrenocortical tumors. Scientific Reports 2017 7 5474. (https://doi. 3207 
org/10.1038/s41598-017-05777-0) 3208 
313 Creemers SG, Korpershoek E, Atmodimedjo PN, Dinjens WNM, van Koetsveld PM, 3209 
Feelders RA & Hofland LJ. Identification of mutations in cell-free circulating tumor DNA in 3210 
adrenocortical carcinoma: a case series. Journal of Clinical Endocrinology and Metabolism 3211 
2017 102 3611–3615. (https://doi.org/10.1210/jc.2017-00174) 3212 
314 Garinet S, Nectoux J, Neou M, Pasmant E, Jouinot A, Sibony M, Orhant L, Pipoli da 3213 
Fonseca J, Perlemoine K, Bricaire L et al. Detection and monitoring of circulating tumor DNA 3214 
in adrenocortical carcinoma. Endocrine-Related Cancer 2018 25 L13–L17. 3215 
(https://doi.org/10.1530/ERC-17-0467) 3216 
 3217 
